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THE ROLE OF PERIVASCULAR FIBROSIS IN POST-STROKE GLYMPHATIC 
IMPAIRMENT AND CEREBRAL AMYLOID ANGIOPATHY 
 
Matthew David Howe, B.S. 
Advisory Professor: Louise McCullough, M.D., Ph.D. 
 
In healthy brain tissue, toxic amyloid-β (Aβ) proteins are transported by the pulsatile 
flow of cerebrospinal fluid (CSF) along perivascular drainage pathways.  Ischemic stroke 
may disrupt this process, leading to a perivascular build-up of Aβ, termed cerebral amyloid 
angiopathy (CAA).  I hypothesize that an abnormal pattern of extracellular matrix deposition 
within the vascular basement membrane, termed fibrosis, impairs Aβ drainage from the aged 
brain after stroke.  I further hypothesize that inhibition of astrocytic transforming growth 
factor-β (TGF-β) signaling can reverse these phenotypes.  Finally, I also hypothesize that 
serum biomarkers of perivascular fibrosis can be used to diagnose CAA following 
intracerebral hemorrhage (ICH).  To test these hypotheses, I first performed experimental 
stroke in young and aged wild-type mice, then measured basement membrane fibrosis and 
CSF flow using a variety of biochemical and physiological techniques. I also evaluated the 
contribution of astrocytes to these phenotypes using a primary cell culture model.  Then, I 
treated aged mice with a TGF-β antagonist, and measured the impact on fibrosis and CSF 
flow.  Finally, I explored the relevance of these findings to humans by measuring serum 
biomarkers of fibrosis after ICH, and correlating them to CAA etiology, injury severity and 
functional outcomes.  Overall, my findings support a role for fibrosis in impairing 
perivascular Aβ drainage after stroke, which could lead to CAA and progressive cognitive 
decline in stroke survivors. 
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CHAPTER 1 
 Background and Significance 
 
1.1: Stroke is a major risk factor for cognitive decline in the elderly.   
Ischemic stroke occurs when a blood clot acutely reduces blood flow to a region of 
brain tissue, leading to acute infarction of the affected area.1 This type of stroke affects 
approximately 800,000 people every year within the U.S.,1,2 and is a leading cause of 
acquired disability.3 With approximately 7 million stroke survivors currently alive in the 
U.S.,2 there is a desperate need to better understand the long-term cognitive consequences of 
stroke and to develop tailored strategies to address the unique clinical challenges in this 
vulnerable population. 
The most common type of stroke is a large vessel occlusion of the middle cerebral 
artery (MCA).  During the acute phase of injury, this type of stroke typically damages the 
cortex and basal ganglia.4 Following blockage by a thrombus or embolus, acute ischemia in 
these brain regions produces confusion and hemiparesis, as well as different cortical signs 
depending on which side of the brain is affected.4  Tissue plasminogen activator (tPA) 
represents the only available pharmacologic treatment for acute stroke, and must be used 
within hours of stroke onset to be efficacious in reducing injury severity.5 However, even 
when properly treated, stroke frequently leads to long-term disability, including chronic 
motor, sensory and cognitive impairment.3  Recent studies in the clinical literature suggest 
that in addition to acute deficits in cognitive function, stroke commonly leads to a slowly 
progressive form of cognitive decline, termed ‘vascular’ dementia.6  However, this disease 
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has proven challenging to model in mice, and the underlying mechanisms leading to this 
phenotype are a subject of intense debate.   
There is significant evidence in the clinical literature that stroke is an independent 
risk factor for progressive cognitive decline.  The Framingham heart study found that stroke 
doubles the risk of cognitive decline, with 35% of stroke survivors progressing to dementia 
within ten years of the initial insult.7  Furthermore, the Rotterdam study confirmed that stroke 
doubles the risk of dementia, and that this occurs independently of pre-stroke cognitive 
function and, importantly, in the absence of recurrent stroke.8  More recent work has shown 
that in addition to an acute loss of cognitive function, stroke also accelerates the trajectory of 
underlying progressive cognitive decline, suggesting a synergistic relationship between 
chronic neurodegenerative disease and acute injury.9 Overall, these data from multiple, large 
clinical studies indicate that stroke is a major, yet largely unrecognized independent risk 
factor for progressive cognitive decline.  However, the lack of a coherent disease mechanism 
presents a major roadblock to developing potential treatments for post-stroke dementia.6  
Stroke may induce acute cognitive impairment due to the initial loss of brain tissue 
associated with the primary injury.4  However, this progressive impairment, described above, 
requires the exploration of additional, more chronic mechanisms.  This has mainly been 
studied with experimental MCA occlusion (MCAO) models in mice.6  One plausible 
hypothesis is that stroke initiates a neuroinflammatory cascade, which contributes to 
widespread neuronal loss and dementia by autoimmune mechanisms.10  For example, one 
previous study showed that young mice subjected to a small, cortical stroke developed 
progressive cognitive decline over seven weeks after injury, due to a neuroinflammatory 
response involving B cell activation.11 Similarly, previous work by our lab has shown that 
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aging exacerbates chronic T cell responses to stroke,12 which could also impair cognitive 
function.  Others have shown that sterile inflammation, modeled by lipopolysaccharide (LPS) 
stimulation, impairs cognitive function in mice.13  Furthermore, this can be abolished by 
treatment with anti-inflammatory drugs at the time of LPS exposure, indicating a detrimental 
effect of immune activation on cognition.13 However, based on the fact that cognitive 
impairment continues to progress years after the peak of inflammation has subsided, there 
could be other, non-immune mechanisms at play that have not been adequately explored in 
animal models. 
Alzheimer’s disease (AD) provides a relatively well-understood alternative prototype 
for progressive cognitive decline, which serves as a useful starting point to explore additional 
potential mechanisms of post-stroke dementia.  In classic AD-type dementia patients, a toxic 
protein called amyloid-β (Aβ) accumulates and forms plaques in the hippocampus, which is 
associated with progressive impairment of cognitive function.14  Similarly, when humanized 
amyloid protein is overexpressed in the brains of mice, they also begin to develop 
progressive cognitive decline with aging,15 further supporting the so-called ‘amyloid cascade 
hypothesis’ of neurodegeneration in AD.16,17   As hippocampal amyloid pathology forms 
early in the disease course, AD patients develop deficits in hippocampal dependent tasks, 
such as short-term and working memory.  Additionally, in most AD patients, Aβ deposits in 
the walls of cortical vessels, which can lead to a loss of vessel integrity and recurrent 
microhemorrhage.18–20  This special type of vascular pathology is termed cerebral amyloid 
angiopathy (CAA).19  The appearance of microhemorrhage is often associated with 
impairment in multiple other ‘extra-hippocampal’ cognitive domains, including executive 
function, language and facial recognition; although some patients are cognitively normal 
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until late stage disease.21 While the literature supports that Aβ accumulation plays a major 
role in AD pathogenesis,17 it is not known if CAA contributes to post-stroke dementia.6   
 Stroke patients tend to exhibit early problems with ‘cortical’ domains of cognitive 
function.9,21  In particular, compared to AD, a marked loss of executive function occurs early 
in post-stroke dementia, suggesting damage to the frontal cortex or white matter.22 
Additionally, patients with post-stroke dementia often follow a stepwise loss of cognitive 
function, suffering repeated vascular insults, including microhemorrhage and microinfarction 
throughout the cortex, in a similar distribution to that seen in AD-associated CAA.9 
Therefore, it stands to reason that CAA could play a major, early role in driving the 
progression of post-stroke dementia.  It is not known how stroke induces conditions that 
could favor the formation of CAA deposits,17 but understanding this process could shed light 
on the pathogenesis of both post-stroke dementia and lead to new disease-modifying 
treatments. 
In summary, ischemic stroke is a leading cause of dementia in the elderly, however, 
the mechanism driving cognitive decline in these patients is not known.  Both AD and post-
stroke dementia may involve the accumulation of Aβ, however, differences in the disease 
course and impact on specific domains in cognitive function suggest that this accumulation 
occurs in different locations; therefore, they likely occur by distinct pathophysiological 
mechanisms.  In particular, the cognitive symptoms and clinical course of post-stroke 
dementia suggest a pattern of cortical vascular amyloid deposition that is consistent with 
CAA.23   
In the remainder of this chapter, the evidence that stroke induces CAA pathology in 
human patients will be extensively explored.  Additionally, the multiple mechanisms by 
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which Aβ deposition induces vessel damage and cognitive decline will also be reviewed in 
detail.  Finally, a new potential mechanism by which stroke induces vascular Aβ deposition 
in the cerebrovascular basement membrane will be introduced.  A better understanding of 
these mechanisms may lead to new diagnostic tools and therapeutic avenues for stroke 
survivors at risk of cognitive decline. 
 
1.2: CAA drives cognitive decline in aging and after stroke.   
CAA is pathologically defined as the appearance of amyloid (“sugar-like”) deposits 
in vessels accompanied by vessel wall hypertrophy, fibrinoid necrosis and/or hemorrhage.19 
These amyloid deposits form in the brain extracellular perivascular space (PVS) and are 
primarily composed of amyloid-β (Aβ), a 4 kD peptide with a unique biochemical profile.20 
Importantly, the majority of dementia patients suffer from mixed brain pathologies, and have 
histological evidence of both macroscopic infarction, caused by prior stroke, and 
Alzheimer’s disease (amyloid deposition) at autopsy.18,24,25 This association between stroke 
and CAA is clearly evidenced in the clinical literature by both histopathological and imaging 
studies.   
First, several postmortem histopathological studies of human patients support an 
association between ischemic stroke and CAA.  One study found that cerebral infarction and 
amyloid pathology synergize to worsen cognitive impairment in elderly individuals.24 
Importantly, this association also occurs in patients with mild-cognitive impairment (MCI), 
indicating that vascular and amyloid pathologies co-exist even in the earliest stages of 
dementia.18 CAA pathology is associated with executive dysfunction in MCI patients, further 
supporting the notion that vascular amyloid pathology impairs specific domains of cognitive 
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function.26 Overall, these studies show that stroke and amyloid pathology frequently co-
occur, and are associated with both early and late stages of disease.  
Further supporting the relationship between stroke and CAA, data from positron 
emission tomography (PET) studies support a relationship between ischemia and amyloid 
deposition using the Pittsburgh compound B (PiB) retention ratio.27  Ischemic stroke patients 
exhibit significantly higher amyloid burden in the area of infarction during the subacute 
phase of injury,28 which correlates with both magnetic resonance imaging (MRI) biomarkers 
of CAA, and dementia, in elderly stroke patients.29  Furthermore, stroke patients with high 
amyloid burden are also more likely to develop hemorrhagic transformation, suggesting that 
these post-stroke amyloid deposits are associated with underlying small vessel disease.30   
Finally, MRI studies also support a relationship between stroke and small vessel 
disease phenotypes that are characteristic of CAA.  MRI can be used to meet a probable 
diagnosis of CAA by measuring several types of secondary brain injuries, termed the ‘Boston 
criteria,’ including the presence of cerebral microbleeds, lacunar infarction (small ischemic 
strokes), leukoairaiosis (white matter hyperintensity), superficial siderosis, cortical atrophy 
and enlarged PVS.31,32 Stroke survivors with imaging biomarkers of CAA have worse 
functional outcomes 3 months after stroke.33 They exhibit higher levels of leukoairiosis, 
which positively correlates with cognitive decline after stroke.34,35 Additionally, stroke 
survivors commonly develop enlarged visible PVS.32,33,36 Overall, these studies demonstrate 
(1) that stroke patients are at a high risk of developing the secondary injuries associated with 
CAA, and (2) that stroke patients with more severe CAA exhibit increased rates of cognitive 
impairment after stroke.   
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While these findings clearly support a relationship between stroke and CAA, this may 
be complicated by the fact that stroke and AD share several major risk factors.37  Sporadic 
AD and stroke share genetic risk factors, including apolipoprotein E ε4 genotype,38 
methylenetetrahydrofolate reductase polymorphisms39 as well as regulators of C-reactive 
protein and plasma lipids.40 In addition, the two diseases also share several modifiable risk 
factors, including hypertension,41 hypercholesterolemia,42 diabetes mellitus,43 obesity,44 
sedentary lifestyle45 and smoking.46 All of these shared factors could confound even the best-
designed retrospective study, and highlight the need for more prospective studies with 
baseline imaging and cognitive testing.  While these shared risk factors between AD and 
stroke may confound the clinical literature, they also raise the question as to how the 
underlying pathophysiology of stroke and CAA are related. 
In theory, the causative relationship between stroke and CAA would be best 
illustrated by studies in the animal literature, because they avoid many of the confounding 
variables of shared risk factors, described above, by the use of littermate controls.  A few 
interesting studies using wild-type rats have shown that stroke increases the levels of soluble 
Aβ within the thalamus after MCAO, which may be a result of secondary injury.47–51 These 
studies support the notion that stroke independently increases amyloid burden, but do not 
perfectly mimic the findings seen in stroke patients involving CAA pathology and amyloid 
plaque deposition in the area of infarction.  However, these papers provide consistent support 
for a causative relationship between stroke and amyloid deposition.   
 Overall, data from diverse studies using histopathology as well as MRI and PET 
imaging strongly support an association between ischemic stroke, CAA and cognitive 
decline.  However, the causative nature of stroke on CAA progression is difficult to infer in 
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these clinical studies, due to both unavoidable shortcomings in study design, as well as the 
significant overlap of risk factors for AD and stroke.  Additional studies of long-term 
histological and cognitive outcomes in transgenic AD mice with experimental stroke are 
needed to confirm the directionality of the relationship between stroke and CAA, as well as 
to better understand the potential mechanism of CAA induction after stroke. 
 
1.3: Increased vascular Aβ deposition mediates vascular pathology in CAA.  
CAA is associated with maladaptive vascular phenotypes that could contribute to 
cognitive decline in stroke survivors by negatively affecting neurons and other brain cells 
that rely on affected vessels for perfusion.  Based on a review of the existing literature, it is 
clear that the vascular phenotypes and cognitive loss observed in CAA are, in large part, a 
direct consequence of Aβ deposition into cerebral blood vessels.  Therefore, therapies that 
reduce the production, aggregation or deposition, or conversely, enhance the clearance of Aβ 
from the PVS, could slow the progression of CAA.   
The Aβ peptide is a metabolic product that is derived from the much larger amyloid 
precursor protein (APP), which is an 87 kD integral membrane-spanning protein.52 In the 
healthy brain, APP plays an important role in synapse formation,53 synaptic plasticity54 and 
iron metabolism.55  Importantly, APP is degraded during the course of normal 
neurotransmission, and Aβ is produced and released into the extracellular space, where it 
undergoes two sequential cleavage steps by two enzymes: β-secretase and γ-secretase.56 The 
major Aβ isoforms that are associated with CAA and Alzheimer’s disease are Aβ peptides 
containing the amino acid residues numbered 1-40 and 1-42 (denoted as Aβ1-40 and Aβ1-42, 
respectively).  Both isoforms exhibit extensive beta sheet structure, which causes monomeric 
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Aβ particles to assemble into dimers, oligomers and eventually large insoluble aggregates, 
which are found as abnormal deposits within the vascular basement membrane.17  Aβ1-40 is 
most commonly associated with CAA plaques,57 potentially due to its improved solubility 
compared to the longer Aβ1-42 isoform,58  which could allow for it to travel further from the 
synapse and associate with the vasculature.  
While there is a strong association between CAA and dementia, there is historical 
debate as to whether Aβ1-40 represents a cause or a consequence of the underlying small 
vessel pathology.  The most direct evidence that Aβ is causally related to small vessel disease 
comes from studies of early-onset, genetic forms of CAA.  For example, patients with Downs 
syndrome (Trisomy 21) exhibit overexpression of APP and develop AD pathology and CAA 
at increased rates.59 Additionally, in familial AD, activating mutations in γ-secretase 
(presenilin-1 [PS1]) increase the generation of Aβ from APP,56,60,61  leading to extensive Aβ 
plaques and early-onset cognitive decline,62 and certain PS1 mutations induce vascular 
amyloid deposition and multiple hemorrhage.63–65 Finally, rare cases of familial CAA, caused 
by specific mutations in the Aβ coding region of the APP gene, comprise a small group of 
diseases termed hereditary cerebral hemorrhage with amyloidosis.66–69 While total APP 
expression is unaffected, altered cleavage by γ-secretase leads to relative increases in Aβ1-40 
compared to Aβ1-42.70,71  While the causative nature of Aβ overproduction is clearly linked to 
early-onset familial CAA, the mechanism driving late-onset sporadic CAA is not as clear in 
the literature.    
These genetic mutations are such powerful drivers of disease, that simply inducing 
their expression in mice is sufficient to recapitulate many of the nuances of CAA.  For 
example, one of the most widely used models of AD is the Tg2576 mutant mouse, which 
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possess the APP(KM670, 671NL [Swedish]) mutation.72  This strain exhibits slowly 
progressive, age-associated cognitive impairments, and begins to develop more widespread 
parenchymal and vascular pathology by 9 – 10 months of age.72  In contrast, another strain, 
termed APP/PS1, harbors two mutant alleles: mutant-APP(KM670N, 671NL [Swedish]), as 
well as PS1(L166P).73  Due to the additional genetic manipulation, these mice develop 
parenchymal amyloid pathology much earlier in life, leading to neuronal loss, astrogliosis 
and cognitive impairment by 6 – 8 months of age.73  This particular mutation induces very 
high production of Aβ1-42 compared to Aβ1-40, which likely explains the apparent lack of 
CAA until very advanced age in this model.73   
On the other end of the disease spectrum, another strain, termed TgSwDI, exhibits 
CAA-like pathology very early in life.74  These animals possess three disease-associated 
transgenes: APP(KM670N, 671NL [Swedish]), APP(E693Q [Dutch]) and APP(D694N 
[Iowa]).74  The Dutch and Iowa ‘vasculotropic’ APP mutations were isolated from families 
with hereditary cerebral hemorrhage with amyloidosis.66,75  As such, these animals develop 
early elevations in Aβ1-40 and widespread vascular amyloid pathology from 3 – 6 months of 
age.74  They also develop some of the earliest cognitive impairment of any AD model, 
performing worse than their wild-type counterparts on cognitive tasks by 3 months of age.76  
Overall, these transgenic models of familial disease support increases in Aβ1-40 as a major 
driver of small vessel disease and cognitive decline in CAA. 
In contrast with familial cases, the epidemiology of late-onset CAA points to 
disruption of Aβ1-40 clearance as a potential driver of so-called ‘sporadic’ disease.  In contrast 
to genetic forms of CAA, the vast majority of CAA patients develop the sporadic form of the 
disease in old age, with mild CAA pathology present in approximately half of elderly brains, 
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and in 80 - 90% of Alzheimer’s disease brains.77,78 While less common, even moderate to 
severe CAA is present in 8% of patients aged 75 to 84, and grows to 12.1% of patients over 
the age of 85 years.20 This is likely to become even higher in the future as our population 
continues to age, as preclinical studies have shown that aging impairs the clearance of 
soluble Aβ1-40 from the brain.79–82 Further work in mouse models indicate that other CAA 
risk factors can further impair Aβ1-40 clearance and accelerate amyloid deposition, including 
hypertension,83 hyperlipidemia,84 diabetes/obesity,85 apolipoprotein E ε4 (APOE ε4) 
genotype78,86 and sedentary lifestyle.87  Overall, impaired Aβ1-40 clearance is a plausible 
mechanism of sporadic CAA, which could also occur after stroke. 
Taken together, this review of the literature indicates that Aβ1-40 directly contributes 
to cognitive decline in both familial and sporadic forms of CAA.  While overproduction of 
Aβ1-40 is the major cause of early-onset CAA, impaired clearance of Aβ1-40 represents an 
alternative, additional driver of sporadic CAA, and is implicated in nearly all of the known 
risk factors that are common in elderly CAA patients.  Therefore, stroke likely also disrupts 
the process of Aβ1-40 transport and clearance from the vasculature.  However, further work is 
needed to confirm that this occurs in animal models of stroke, which will aid in determining 
which specific Aβ1-40 clearance mechanisms fail in stroke patients. 
 
1.4: The basement membrane is the initial site of Aβ1-40 deposition in CAA.   
It is clear from the existing literature that increases in Aβ1-40, whether from increased 
production or reduced clearance, lead to small vessel disease and cognitive decline in CAA.  
However, the impact of Aβ1-40 on vessel function remains understudied.  Cerebral arteries 
penetrate from the surface of the cortex and branch into descending arterioles, which further 
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split to form capillary beds, where nutrients and waste products are exchanged with the brain 
parenchyma.88,89 Cerebral capillaries are comprised of a monolayer of endothelial cells 
surrounded by a unique extracellular structure called the vascular basement membrane,90 
which also contains pericytes and astrocytic endfeet.90 Together, these structures coordinate 
cerebral blood flow and neuronal activity to optimize cognitive function, in a synergy termed 
the ‘neurovascular unit’ (NVU), which becomes impaired in CAA.91  The current literature 
suggests that CAA begins within the basement membrane, and leads to cognitive decline due 
to repetitive brain injury as well as impaired NVU regulation. 
 In early CAA, Aβ1-40 preferentially deposits within distinct regions of the 
cerebrovascular tree.92  CAA is predominantly observed within the cerebral cortex and 
cerebellum, and generally spares the deeper nuclei of the cerebrum and brainstem, as well as 
the white matter.77  Within these affected brain areas, CAA first spreads through the 
leptomeningeal and superficial cortical vessels, and later involves the majority of small 
arteries, arterioles and capillaries within the cortex.93  The initial deposits associated with 
CAA form along the outer layer of basement membrane, providing a ‘seed’ for the eventual 
growth of CAA plaques.94  However, it is not known why certain individuals develop these 
initial basement membrane deposits. 
In advanced CAA, Aβ1-40 deposits invade the deeper layers of the vessel wall.  In 
particular, the walls of small arteries, arterioles and capillaries are often replaced entirely by 
amyloid deposits, while sparing the inner endothelial lining.77,95  During this process, 
astrocytes aggregate and become dystrophic around large capillary plaques, indicating 
potential involvement of these perivascular glial cells in modulating CAA pathology.94  
Finally, advanced CAA induces several pathognomonic vasculopathies, including duplication 
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of the vessel lumen, destruction of the vessel wall, hyalinosis, formation of microaneurysms 
as well as fibrinoid necrosis.19,95,96  Taken together, these findings indicate that CAA begins 
within the basement membrane of cortical vessels, and involves perivascular astrocytes as 
well as invasion of deeper portions of the vessel wall, leading to severe and widespread 
vasculopathy throughout the affected brain structures. 
 CAA vasculopathies can be broadly separated into changes favoring both 
hemorrhagic and ischemic injury, which both contribute to impaired cognitive function via 
progressive loss of brain tissue.  In hemorrhagic injury, CAA reduces vessel wall integrity 
and leads to the formation of microaneurysms, which can spontaneously rupture and lead to 
both microbleeds95 and intracerebral hemorrhage (ICH).97  Additionally, small ischemic 
injuries, termed ‘microinfarctions’ can also occur during CAA,98,99 and results from invasion 
of the small vessel lumen by vascular amyloid deposits, leading to occlusive disease and 
leukoairiosis on imaging.100,101 Together, both microbleeds and microinfarction contribute to 
loss of cognitive function via impairing white matter connectivity,102–104 inducing cortical 
atrophy,105 as well as promoting local inflammatory responses.106,107  Overall, induction of 
ischemic and hemorrhagic brain injury occur via different mechanisms, but similarly 
contribute to cognitive decline in CAA patients. 
 In addition to focal brain injury, there is also significant evidence that CAA induces 
chronic disruption of the NVU.  Preclinical studies have shown that Aβ1-40 inhibits cerebral 
autoregulation, leading to vasoconstriction of cerebral arteries in isolated preparations and 
intact cortex.108  In advanced CAA, vascular amyloid deposits impair vasomotor function in a 
dose-dependent manner.109  In addition, Aβ1-40 can also induce direct damage to the cells of 
the NVU due to increased free radical formation.110  Specifically, Aβ1-40 damages 
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neurons,111,112 vascular smooth muscle cells,113 pericytes114 and endothelial cells.115  These 
changes impair NVU function which may disrupt neurotransmission along axons.116  The net 
results of NVU disruption in human CAA patients include impaired perfusion of small vessel 
beds,117,118 reduced vessel integrity 119–121 as well as reduced neurovascular coupling 122–124.  
In conclusion, while CAA is a major cause of focal brain injury, Aβ1-40 also contributes to 
progressive cognitive decline via altered autoregulatory responses as well as direct 
cytotoxicity to cellular components of the NVU. 
 In summary, Aβ1-40 deposition is initiated at the cerebrovascular basement membrane 
and then spreads to invade the vessel wall.  This deposition leads to microhemorrhages as 
well as microinfarction, which both contribute to stepwise cognitive decline in CAA patients.  
Additionally, Aβ1-40  impairs cerebrovascular reactivity and induces cytotoxicity, causing 
dysfunction of the NVU and contributing to progressive cognitive decline.  Therefore, a 
better understanding of the molecular, cellular and physiological processes that contribute to 
the initial deposition of Aβ1-40 within the basement membrane is critical to formulating 
therapies to slow CAA progression.  Furthermore, successful prevention of basement 
membrane Aβ1-40 deposition deposition could prevent amyloid-induced vasculopathy and 
improve cognitive function in stroke survivors.  In theory, this could be accomplished by 
targeting the various transport mechanisms that are involved in depositing and removing Aβ1-
40 from the PVS. 
 
1.5: Cerebrospinal fluid is a potential source of perivascular Aβ1-40 deposits in CAA.   
 Previous work has shown that the vascular basement membrane is the initial site of 
amyloid pathology in CAA.  However, the physiological route of Aβ1-40 deposition is not 
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known.  This deposition may occur due to alterations in the perivascular transport of 
cerebrospinal fluid (CSF), which acts as a ‘lymphatic’ fluid that is pumped through the 
cerebrovascular basement membrane.  This process is key for removing waste products from 
the PVS in healthy individuals.125  However, this function may become impaired, or even 
maladaptive, in aging and stroke, potentially favoring the deposition of CSF-derived Aβ 
within the basement membrane.  Therefore, I hypothesize that the CSF is a major potential 
source of Aβ1-40 that becomes deposited within the basement membranes of CAA patients.  I 
further hypothesize that aging and stroke reduce the flow rate of CSF, further contributing to 
impaired transport of Aβ1-40 through the basement membrane.   
CSF is produced within the choroid plexus (CP), a cuboidal epithelial monolayer that 
lines the brain ventricles.126  This unique epithelial layer displays a high degree of polarity, 
with a basement membrane on its basolateral surface, and apical microvilli with ciliary 
projections extending into the ventricle lumen.127 The CP secretes approximately 600 mL of 
CSF per day in healthy individuals,128,129 which is supported by several factors including 
dense vascularization,127 high rates of blood flow,130 enriched mitochondrial content127 and 
the presence of high surface area secretory microvilli.127 In healthy individuals, the CP 
provides a barrier between the plasma and CSF.126 Together, these qualities allow for rapid 
turnover of CSF, while still maintaining the blood-CSF barrier. 
Importantly, the transport of water within the CP takes place by distinct transcellular 
and paracellular pathways.  In both cases, these processes are driven by favorable ion 
gradients that are primarily driven by the continuous activity of Na-K-ATPase, which enable 
the osmotic transport of water.131,132 Transcellular diffusion occurs through the epithelial 
cells, and is enabled by the membrane expression of aquaporin-1 (AQP1).133–137 In contrast, 
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in paracellular transport, claudin-2 allows for the movement of water moves through 
selectively permeable extracellular pores.138,139 This continuous production of CSF provides 
a driving force for the bulk flow of CSF through the brain ventricular system, displacing the 
existing fluid from the ventricular system to the subarachnoid space surrounding the brain.140  
Upon exiting the ventricular system, CSF then flows along the surface of the brain 
through the cisterns, which are a series of hollow chambers that generally contain the major 
arteries within the subarachnoid space.  The majority of the CSF drains into the bloodstream 
via the subarachnoid granulations,141,142 dural lymphatic vessels,143,144 the nasal cribriform 
plate145 and along cranial/spinal nerve sheaths.146 This process of CSF drainage allows for 
homeostatic waste clearance to occur.147 The relative contribution of these various pathways, 
and how they may be modulated by aging, stroke and neurodegenerative disease remain an 
area of highly active investigation.148 The CSF contains a variety of waste products, 
including Aβ1-40, which are derived from its function in clearing waste products from the 
brain parenchyma.  Previous work has shown that, in patients with AD and CAA, this 
homeostatic balance abnormally shifts over the course of disease, leading to predictable 
fluctuations in CSF Aβ1-40 concentration.149  Most importantly, increases in CSF Aβ1-40 are a 
pathological hallmark of early CAA,150 and may actively contribute to disease by crossing a 
critical threshold to favor the aggregation and deposition within the cerebrovascular 
basement membrane. 
While it is clear that CSF Aβ1-40 levels rise during the early stages of CAA, it is not 
clear whether this is simply a biomarker of disease, or if this increase contributes to the 
formation of the initial basement membrane amyloid deposits.  The precise perivascular 
routes, and the potential regulators of this process are not known.  In addition to changes in 
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the total amount of CSF Aβ1-40, increased affinity of the basement membrane for circulating 
CSF Aβ1-40 could further accelerate the formation of CAA plaques in aging and after stroke. 
 
1.6: Basement membrane fibronectin may promote the formation of CAA pathology. 
In healthy adults, the vascular basement membrane is predominantly comprised of 
heparan sulfate proteoglycans (HSPGs), collagen, laminin and integrins.151 Together, these 
proteins create a porous, flexible structure that permits the flow of CSF in the healthy brain.  
However, aging and stroke-induced basement membrane fibrosis could sequester Aβ1-40 and 
lead to CAA.  Therefore, I hypothesize that stroke abnormally increases basement membrane 
fibronectin expression, which worsens with aging and contributes to the development of 
CAA pathology. 
Fibronectin is a modular glycoprotein that is composed of two 230 kD – 270 kD 
subunits.152 It plays a central role in organizing the molecular structure of the basement 
membrane during development, anchoring cellular components to the HSPG matrix, and is 
also upregulated during the response to injury.90,153–155  Fibronectin is a highly modular 
protein that is predominantly composed of three different repeats, termed Type I – III.156 The 
Type I region is involved in the polymerization of fibronectin into large insoluble aggregates, 
a process called fibrillogenesis, which occurs during wound repair.156  The Type II region 
binds collagen, and the Type III region binds integrins and HSPGs.156  Together, each of 
these domains plays an important role in linking the protein components of the basement 
membrane to each other, as well as anchoring the cellular components via integrin receptors. 
Fibronectin plays an important role in organizing the HSPG matrix within the 
basement membrane.  HSPGs are very large (> 1000 kD) proteoglycans that are formed by 
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numerous, negatively charged heparan-sulfated glycosaminoglycans (GAG) side-chains that 
surround a relatively small, positively charged protein core.157  HSPGs are the major 
component of the cerebrovascular basement membrane, which expresses several subtypes, 
including perlecan,158 agrin,159–161 collagen XVIII162 and syndecan-4.163  In particular, 
syndecan-4 binds fibronectin with high affinity via the Type III domain.164  In addition to 
providing structural integrity, HSPGs are involved in a number of processes, including 
support of vascular development, maintenance of blood-brain barrier (BBB) integrity, and 
angiogenic responses to focal injuries, such as stroke.157,165 They also may be important in 
maintaining CSF flow in the healthy brain.  
Integrins are a family of cell membrane receptors which contain both α and β 
subunits, and play a major role in anchoring cells to the basement membrane and enabling 
cell motility.  Different classes of β1 integrin are expressed by endothelial cells (α1β1, α3β, 
α6β1, αvβ1),166–169 pericytes (α4β1)170 and astrocytes (α1β1, α5β1, α6β1).169 Importantly, the 
major receptor for fibronectin in the brain is α5β1 integrin, which is expressed on the outer 
surface of astrocytic endfeet.171–173 The β1 subunit contains a binding site for fibronectin, 
while the α5 subunit plays a role in modulating the binding affinity.174–177  Integrins also 
provide the major anchor points for attaching the astrocytic endfeet to the endothelium via 
binding to β-dystrophoglycan, another protein expressed within the basement 
membrane.178,179 This anchoring to the basement membrane creates the ‘double-barreled’ 
structure of the PVS, which supports normal CSF transport.  
CAA is associated with major changes in the basement membrane, including a 
‘thickened’ morphology as well as well as altered protein composition.   Studies of AD 
patients have found that the outer basement membrane layer, which is normally produced by 
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astrocytes, is selectively thickened.180  Further studies found that these alterations occur in 
areas with increased amyloid pathology,181,182 and that these changes can occur prior to 
development of amyloid pathology.183   Specific basement membrane proteins, including 
collagen IV, laminins and nidogen are downregulated in amyloid plaques and have been 
shown to prevent amyloid deposition in the healthy brain.184,185 However, both fibronectin 
and perlecan increase in mouse models of AD.181,182,186 While both perlecan and fibronectin 
have been shown to bind Aβ aggregates in vitro,187 the physiological relevance of this 
phenomenon has never been examined in vivo.  Overall, a better understanding of how 
alterations in basement membrane composition contribute to the development of CAA is 
needed, and may help to better understand how aging and stroke induce the formation of 
CAA plaque pathology. 
There is limited data available on the impact of aging on basement membrane 
morphology and composition.  Aging induces thinning of the basement membrane in the 
cortex, hippocampus and thalamus, but not the striatum.181  Additionally, aging reduces 
collagen IV, laminin and nidogen 2 expression, but upregulates fibronectin and perlecan 
expression in the cortex.181  While similar increases in total fibronectin expression is 
observed in other brain regions, this is not associated with reductions in other basement 
membrane proteins, suggesting that the relative amount of fibronectin may be most important 
in determining the cortical location of sporadic CAA pathology.181   
In contrast with normal aging, stroke induces a ‘biphasic’ effect on basement 
membrane thickness and composition.  During the acute phase of injury, stroke increases 
BBB permeability, allowing for the influx of serum and cellular factors into the brain 
parenchyma that degrade the basement membrane via increased exposure to proteases and 
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inflammatory cytokines.188–191   In particular, upregulation of matrix metalloproteinases 
(MMP’s) leads to a general loss of basement membrane proteins during the acute phases of 
ischemia, including reductions in collagen IV, laminin, agrin, perlecan and fibronectin.188,191–
193  However, few studies have examined the chronic effects of stroke on the basement 
membrane.  It is known that newly forming vessels upregulate both fibronectin and perlecan 
during the chronic angiogenic response after stroke.165,194  These changes are similar to what 
is seen in the aging brain at baseline, and may further exacerbate age-related changes in 
basement membrane proteins.  However, it is not known whether these changes accelerate 
the formation of CAA pathology. 
In conclusion, it is clear from the literature that CAA is associated with changes in 
basement membrane composition, which are similar to what has been observed in both 
normal aging and the chronic phase of stroke.  Pathological upregulation of basement 
membrane proteins, including various integrin receptors or fibronectin could favor the 
development of CAA.  This may occur by altering the transport of CSF-derived Aβ1-40 
through the basement membrane, which could favor the initial formation of CAA pathology 
in elderly stroke patients. 
 
1.7: CSF bulk flow transports Aβ1-40 through the vascular basement membrane.  
The cortical distribution of CAA pathology gives clues to its pathophysiological 
mechanism.  As described in earlier sections, CAA is initiated in the leptomeningeal arteries, 
and ‘descends’ along cerebral arteries, arterioles and eventually capillary beds, sparing the 
venous system almost entirely.  Previous studies have shown that CSF Aβ1-40 levels rise in 
the early stages of CAA,149,150 providing a potential source for the ‘outside to inside’ 
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distribution of CAA pathology within the surface cortex.19 Both classical studies of 
perivascular anatomy, and the physiology of perivascular flow of CSF explain how and why 
amyloid pathology spreads through the cortex in this distinctive pattern.  Therefore, I 
hypothesize that the transport of CSF Aβ1-40 along perivascular routes is a major driver of 
CAA pathology in aging and after stroke. 
Importantly, both the macroscopic and microscopic anatomy of the Virchow-Robin 
space allow for a route of CSF flow along perivascular routes.195 A merging of the innermost 
meningeal membrane (pia mater) with the outermost layer of cortex (glia limitans) produces 
this small, but important anatomical space, allowing for the subarachnoid space to involute 
and extend into the brain alongside each individual penetrating artery.196 Distal to this region 
of pial involution, the glia limitans then fully envelopes each penetrating artery in a 
monolayer of astrocytic endfeet.197 Components of the vessel wall, primarily smooth muscle 
cells in the arteries, and eventually endothelial cells and pericytes in the capillary beds 
secrete a glycosylated matrix of proteins, termed the ‘inner’ basement membrane.81,151 
Similarly, the astrocytic endfeet also secrete their own distinct ‘outer’ basement membrane 
along their edges.196 Therefore, as the Virchow-Robin space narrows, the astrocytic endfeet 
and vessel wall are brought closer together, and eventually merge to form a single basement 
membrane with 2 - 4 layers.196 This multilayered, largely acellular basement membrane 
structure provides a unique avenue for CSF, and the solutes contained therein, to flow into 
the brain with minimal resistance.  This may allow for efficient CSF-ISF exchange.125,196  
In addition to this anatomical evidence, numerous studies of brain solute exchange, 
diffusion and bulk flow provide physiological evidence for the existence of a perivascular 
circulation of CSF.  Beginning in the 1970s, pioneering work showed that when various sized 
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tracers, including polyethylene glycol and albumin, were infused into the brains of rats, they 
all cleared from the interstitial fluid (ISF) at the same rate, regardless of molecular 
weight.198–201  These findings suggest that solute movement within the PVS is primarily 
driven by convective bulk flow, rather than purely by osmotic diffusion, which would predict 
that solutes of different sizes would clear from the brain at different rates.202  Additional 
work showed that the ISF moves at a rate of 10.5 µm/min, and that this ISF is a major source 
of ‘extra-choroidal’ CSF.203  Interestingly, Rennels et al. (1985) subsequently found that 
proteins infused into the cisterna magna, a major CSF compartment on the surface of the 
brain, rapidly penetrated into the brain within minutes.204  Taken together, these studies 
indicate that bulk flow is the major transport mechanism of CSF flow, completing the 
physiologic ‘circuit’ for perivascular solute transport.   
Nearly 30 years later, this perivascular exchange was later ‘re-discovered’ using two-
photon microscopy, and shown to be important for the clearance of Aβ1-40 in a process 
termed glial-lymphatic (‘glymphatic’) flow.  Since then, the importance of glymphatic flow 
has been further supported by a series of recent papers, confirming that CSF drives the bulk 
flow of ISF within the PVS.82,125,205–209  In this initial model, the arterial beds act as a positive 
‘source’ of bulk influx of CSF, and the venous system acting as a negative ‘sink’ for the bulk 
clearance of ISF.  Further work newly showed that aquaporin-4 (AQP4), expressed on 
astrocytic endfeet, provides a semipermeable barrier for the exchange of CSF and ISF, which 
is required for the clearance of intraparenchymally injected Aβ1-40.125  More recent studies 
have updated this model, and have subsequently found that the perivascular influx of CSF 
occurs within the outer basement membrane (associated with the glia limitans astrocyes), and 
that the clearance of ISF can simultaneously occur in the opposite direction along the inner 
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basement membrane of cerebral arteries.196  However, more work is needed to clarify how 
CSF and ISF are exchanged within the perivascular microenvironment, and the role of the 
basement membrane in regulating this process in health and disease.  
Overall, given that (1) high levels of CSF Aβ1-40 predispose individuals to the 
development of CAA, (2) CSF is in continuous contact with the basement membrane, (3) that 
CSF drives the clearance of Aβ1-40 from the brain, and (4) the basement membrane is the 
initial site of amyloid pathology in CAA, it is highly likely that this physiological route is 
involved in the early stages of CAA development.  However, the specific molecular and 
cellular factors within the basement membrane that regulate CSF flow, and Aβ1-40 deposition, 
have yet to be identified.  A better understanding of how aging and stroke impact the 
molecular composition of the basement membrane could shed important light on the 
pathogenesis of CAA.  Furthermore, this work could help to identify novel molecular targets 
that could help to shield the basement membrane from Aβ1-40 deposition, allowing for new 
disease-modifying therapies to be developed.  
 
1.8: Theoretical considerations for CSF Aβ1-40 distribution in the basement membrane. 
The vascular basement membrane is essential to maintaining the structural 
organization of the PVS.  In addition to providing structural integrity, disease-associated 
basement membrane proteins, like fibronectin, may induce the deposition of CSF Aβ1-40 by 
impairing the free diffusion of molecules.  As CSF solutes are delivered to the PVS by bulk 
flow, solutes must diffuse through the basement membrane, which could modulate regional 
transport of solutes.  Diffusion within the PVS is thermodynamically governed by Brownian 
movement, which is described by the Stokes-Einstein equation, given as: 
	   24 
𝐷 = 𝑘!𝑇3𝜋𝜂(𝑑!)   ×  10!" 
 Where D = free diffusion coefficient (cm2/s), kB = Boltzmann’s constant (1.38065 x 10-23), η 
= viscosity (Pa x S) and dH = hydrodynamic diameter of the molecule (nm).202  This equation 
indicates that the rate that a molecule diffuses through the PVS is directly related to 
temperature, and inversely related to the diameter of the molecule and viscosity of the 
diffusing medium (in this case, CSF within the basement membrane).  For a given molecule 
under physiological conditions (37°C), this equation predicts that the major determinant of 
solute diffusion will be the viscosity (or “stickiness”) of the basement membrane, as well as 
the hydrodynamic radius of the diffusing molecule. 
Several basement membrane properties may impair the diffusion of CSF solutes 
following injury.  These include increased geometric path length around cells, increased dead 
spaces between cells, alterations in the electrical charge of the basement membrane, general 
increases in viscosity due to weak interactions, as well as upregulation of specific receptors 
for the diffusing molecule of interest.202 The simplest way to describe impairment of 
diffusion in biological systems, such as the basement membrane, is an experimentally 
defined measurement called tortuosity (λ).  Using tortuosity, it is possible to describe the 
relative diffusion rate of molecules between two different experimental conditions (such as 
aging or ischemia), making it a simple, yet powerful tool to get an overall picture of diffusion 
rates within living brain tissue.  Tortuosity is given by the following equation: 
𝜆 =   𝜆!× 𝜆!𝜆! × 𝜆!𝜆!…    𝜆𝜆!   = 𝐷𝐷! ×𝐷!𝐷! ×𝐷!𝐷!…   𝐷!𝐷∗   =      𝐷𝐷∗ 
Where λ = tortuosity, D = diffusion in the control condition, and D* = diffusion in the 
experimental condition.202  In this equation, the subscripts denote the contribution of 
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individual factors.  For example, λg and Dg would correspond to the tortuosity and rate of 
diffusion attributable to geometric path length, respectively, with other numbers representing 
the contribution of other hypothetical factors.  However, the individual factors can be 
“cancelled out” by measuring the diffusion rate as a whole, dramatically simplifying 
quantification under experimental settings.  Diffusion can be experimentally measured in 
several ways, including tetramethylammonium (TMA) iontophoresis, radioligand injection as 
well as the tracking of fluorophores.202  Regardless of the technique that is used, tortuosity 
can be determined simply by comparing the rate of diffusion between two states. 
As a final point, tortuosity is also related to the volume fraction (α) of the 
extracellular space (ECS), given by the following equation: 
𝛼 = 𝑉!"#𝑉!"##$% 
Where α = volume fraction, VECS = volume of the ECS, and Vtissue = total volume of tissue.202  
While tortuosity and volume fraction intuitively should co-vary (all things being equal, 
increased free space for diffusion should result in faster diffusion, measured as reduced 
tortuosity), they do not always correlate well under biological conditions.  This is most likely 
due to the contribution of some of the other factors outlined in the preceding paragraphs, 
which are all taken into account by the tortuosity equation. 
Both human and murine cortex exhibit relatively high tortuosity, with diffusion 
occuring approximately ~2.5 times more slowly than what is observed in a free medium.210–
212  In pathological states, changes in basement membrane composition may further increase 
tortuosity, restricting diffusion and favoring the deposition of CSF Aβ1-40.  There is limited 
data available that suggests both aging and ischemia further increase the tortuosity of whole 
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brain tissue,213,214 however, more specific studies are needed to determine the impact of aging 
on tortuosity of the vascular basement membrane, specifically. 
While the in vivo impact of focal stroke on brain parenchymal tortuosity and volume 
fraction is not known, the acute impacts of global hypoxia or ischemia on these parameters of 
brain diffusion are well described, largely using in vitro slice physiology.  One study found 
that hypoxia dramatically reduced volume fraction and increased tortuosity in adult rat 
cortex,215 with an additional study finding that hypoxia alone induced more modest increases 
in tortuosity in adult rat cortex.216 While this work supports the notion that aging and hypoxia 
may broadly reduce the diffusion of solutes through the extracellular space, one major caveat 
is that these techniques do not specifically assess basement membrane tortuosity, rather, they 
rely on measurements of whole brain slices in an ex vivo setting. 
In my experimental setting, increased fibronectin expression may be a major driver of 
increased tortuosity of the basement membrane after stroke, which could have major 
consequences in vivo.  This could occur due to its activity as a nonspecific ‘obstacle’ to 
diffusion, as it may increase the viscosity and complexity of the structure for molecules to 
diffuse through.  Additionally, fibronectin may have selective effects on the diffusion of Aβ1-
40, as one study found that fibronectin binds amyloid aggregates via the type I domain.217  
However, it is not known if fibronectin can bind soluble Aβ1-40 within the perivascular 
microenvironment.   Increased expression of basement membrane fibronectin could lead to 
the specific trapping of CSF Aβ1-40 within the PVS, in addition to the nonspecific reductions 
in diffusibility due to changes in basement membrane composition or structure. 
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1.9: Astrocytic TGF-β signaling may mediate basement membrane fibrosis and CAA.  
 Previous work indicates that transforming growth factor-β (TGF-β) levels are 
elevated in mouse models of CAA,218 and that overexpression of TGF-β in wild-type mice 
leads to astrogliosis, fibronectin expression and microvascular damage.219,220  However, it is 
not known whether TGF-β mediates post-stroke basement membrane fibrosis.  This section 
will first review the potential TGF-β signaling mechanisms involved in post-stroke 
fibronectin expression.  Then, the impact of aging and stroke on TGF-β expression and 
astrocyte phenotypes will be examined.   
TGF-β is a member of the TGF-β cytokine superfamily, which also contains glial 
derived neurotrophic factor, activin, 8-vinyl reductase (DVR), and growth differentiation 
factor subfamilies.221  The TGF-β subfamily contains 3 different isoforms: TGF-β1, TGF-β2 
and TGF-β3, which are differentially expressed during development of the central nervous 
system (CNS), and nearly absent from the adult brain under homeostatic conditions.222  
However, following stroke, activated microglia secrete high levels of TGF-β1 during the 
acute phase of injury.223   Previous work has shown that TGF-β activates TGF-β receptor-1 
and receptor-2 (TGF-βR1/R2), which dimerize upon TGF-β binding within the cell 
membrane.224  Following dimerization, TGF-βR1 phosphorylates Smad proteins, including 
Smad2 and Smad3, which then complex with other Smad proteins and translocate to the 
nucleus.225  These complexes subsequently influence gene expression by binding to 
enhancer/repressor sites within the genome, influencing cell differentiation and the 
expression of ECM proteins in astrocytes during development and after brain injury.226  
TGF-β signaling after stroke has several beneficial pro-survival effects, including 
expression of anti-apoptotic proteins Bcl-2 and Bcl-x1, leading to reduced neuronal death 
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during the acute phase of injury.227  These early beneficial effects, which have only been 
studied in young animals, have led to TGF-β being labeled as an anti-inflammatory molecule 
in the context of acute brain injury.228,229  However, TGF-β is a highly pleiotropic cytokine, 
and also induces astrogliosis and ECM deposition, which have well-documented detrimental 
impacts, including inhibition of axonal regrowth230,231 and angiogenesis232 due to the 
abnormal production of ECM proteins.  Furthermore, other work has shown that TGF-β 
expression is disproportionately increased in aged animals after stroke, which may increase 
the likelihood of detrimental affects in the chronic phase of injury.223  Along these lines, 
previous studies by our laboratory have shown that aged animals exhibit increased glial 
scarring in the ischemic penumbra after MCAO, which is associated with delayed behavioral 
recovery.233  Even in young animals, inhibition of TGF-β signaling may reduce astrogliosis 
within the glial scar, however, the impact of this treatment on long-term cognitive function is 
not known.229  Overall, the role of TGF-β during brain injury remains controversial, and the 
few studies performed in aged animals suggest a detrimental effect of TGF-β signaling on 
functional recovery, which could be due to abnormally high levels of astrogliosis. 
 Astrocytes are a major type of glial cell in the brain that, under normal conditions, 
perform numerous homeostatic functions including support of BBB integrity,234 
metabolism234 and waste clearance.125  Astrocytes interface with the perivascular niche via 
numerous small endfeet, and regulate the composition of the outermost basement membrane 
layer, which is involved early in the pathogenesis of CAA.181,196  Furthermore, reactive 
astrocytes are associated with impaired CSF flow during normal aging,235 multiple 
microinfarction,236,237 traumatic brain injury235  and Alzheimer’s disease.209,238  However, the 
role of reactive astrocytes in basement membrane remodeling is understudied, and it is not 
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known whether inhibiting TGF-β signaling in astrocytes can restore CSF flow under 
pathological conditions. 
Recent work has shown that reactive astrocytes generally exhibit two major 
phenotypes, defined by their gene expression pattern – A1 (modeled by peripheral 
stimulation with LPS) and A2 (modeled by MCAO).239  While A1 astrocytes have been 
recently shown to induce inflammation, downregulate AQP4 and secrete toxic products that 
are detrimental to neuronal survival,240 the functions and phenotypes of A2 astrocytes are not 
known. Furthermore, excess TGF-β signaling, as occurs after stroke in the aged brain,223 
could further impact A2 astrocyte responses to ischemic injury and induce the abnormal 
production of ECM proteins.  If true, astrocytes may hold the key to preventing CAA after 
stroke. 
Overall, previous work has shown that TGF-β increases in aging and stroke, and may 
also contribute to the formation of CAA pathology.  However, it is not known whether TGF-
β mediates basement membrane fibrosis after stroke, or if inhibiting astrocytic TGF-β 
signaling is sufficient to improve CSF flow and prevent the perivascular deposition of CSF 
Aβ1-40 within the basement membrane.  Elucidating the role of TGF-β would significantly 
improve our understanding of the molecular and cellular regulation of basement membrane 
composition in pathological states.  Furthermore, modulating the function of A2 astrocytes 
with TGF-β inhibitors could also lead to new therapeutic targets for post-stroke CAA in aged 
populations. 
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CHAPTER 2 
Specific Aims of Dissertation Research 
 
2.1: Overview.  
CAA may be caused, in part, by a 
failure of Aβ1-40 transport through the vascular 
basement membrane of cerebral blood vessels 
after stroke.  The basement membrane 
transports Aβ1-40 via facilitating CSF flow 
within the PVS.  Therefore, impairment of CSF 
flow may contribute to CAA after stroke.  I 
propose that TGF-β signaling pathologically 
increases the expression of fibronectin within 
the basement membrane, reducing CSF flow 
through the cortex.  I further propose that 
increases in fibronectin selectively favors the 
binding of CSF Aβ1-40 to the basement 
membrane, accelerating the formation of 
amyloid pathology in the proximal regions of 
cortical vessels after stroke (Fig. 2-1).  Therefore, my overall hypothesis is that TGF-β-
driven increases in basement membrane fibronectin leads to increased perivascular 
deposition of Aβ1-40 after stroke, contributing to increased CAA burden and accelerated 
cognitive decline. To test this hypothesis, I propose the following specific aims:  
Figure 2-1: Reactive astrocytes may 
secrete fibronectin and impair the 
perivascular transport of CSF-
derived Aβ1-40 after stroke. 
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2.2: Specific Aims. 
Aim 1. To determine whether aging and stroke induce the deposition of CSF Aβ1-40 
within the vascular basement membrane.  While the clinical literature suggests that focal 
stroke may be a risk factor for CAA, there is a lack of studies examining whether stroke 
induces CAA in mouse models of focal stroke.  Additionally, the potential 
pathophysiological sources of basement membrane Aβ1-40 deposits are not known.  I 
hypothesize that aging and stroke impair perivascular CSF flow and induce the trapping of 
CSF Aβ1-40, which contributes to increased CAA pathology and cognitive decline.  To test 
this hypothesis, I propose the following sub-aims: 
• Sub-Aim 1A: To assess how aging and stroke impact perivascular CSF flow. 
• Sub-Aim 1B: To characterize how aging and stroke modulate the perivascular 
transport of CSF Aβ1-40 through the basement membrane.  
 
Aim 2. To determine if astrocytic TGF-β signaling mediates basement membrane 
fibrosis and Aβ1-40 deposition in aging and after stroke.  While previous work has shown 
that stroke induces basement membrane fibrosis in young animals, characterized by increased 
expression of fibronectin, it is not known whether aging worsens post-stroke basement 
membrane fibrosis.  Furthermore, it is not known whether these changes in protein 
composition mediate the initial trapping of CSF Aβ1-40 or the eventual formation of CAA 
plaques.  Finally, the impact of aging and TGF-β on perivascular astrocyte phenotype and 
function are understudied, or if blocking TGF-β can reduce basement membrane fibrosis 
after stroke.  Therefore, I hypothesize that stroke induces basement membrane fibrosis in a 
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TGF-β-dependent manner, which worsens with aging.  To test this hypothesis, I propose the 
following sub-aims: 
• Sub-Aim 2A: To characterize how aging and stroke impact the structure and 
composition of the cerebrovascular basement membrane. 
• Sub-Aim 2B: To examine whether fibronectin mediates post-stroke Aβ1-40  
deposition, and if this worsens with aging in mice.  
• Sub-Aim 2C: To evaluate whether TGF-β activates A2 astrocytes to produce 
fibronectin using both in vitro and in vivo systems.  
• Sub-Aim 2D: To explore whether blocking TGF-β signaling reduces perivascular 
gliosis and basement membrane fibrosis in young and aged mice with stroke.  
 
Aim 3. To explore whether peripheral markers of small vessel fibrosis predict CAA 
diagnosis and disease progression.  Previous work has shown that CAA can be diagnosed 
using cortical biopsy or a set of imaging guidelines, termed the “Boston criteria.”  However, 
CAA diagnosis and management has been hampered by a lack of blood biomarkers that can 
easily and reliably predict the presence of pathology or correlate with long-term functional 
outcomes.  Therefore, I hypothesize that serum markers of basement membrane fibrosis 
(soluble fibronectin, TGF-β and MMPs) may predict CAA diagnosis and functional recovery 
in human ICH patients.  To test this hypothesis, I propose the following sub-aims: 
• Sub-Aim 3A: To test the clinical utility of biomarkers of fibrosis in diagnosing CAA 
pathology after ICH. 
• Sub-Aim 3B: To evaluate whether biomarkers of fibrosis are predictive of long-term 
functional outcomes after ICH.   
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2.3: Translational statement.   
This research is significant because it impacts our understanding of a new potential 
mechanism by which stroke induces cognitive decline.  Additionally, these findings shed 
light on a new physiological route by which Aβ1-40 becomes deposited in the basement 
membrane of aged mice with stroke, which may have relevance for human stroke patients, as 
well as elderly patients with sporadic CAA.  Fibronectin may be a major mediator of 
perivascular CSF Aβ1-40 deposition in aging and after stroke, which could be secreted by 
astrocytes in response to TGF-β signaling.  Furthermore, blocking TGF-β signaling to 
astrocytes by peripheral pharmacological treatment may reverse basement membrane 
fibrosis, which could lead to new therapies for CAA in stroke survivors.  Finally, this 
preclinical research could be used to develop new biomarkers for CAA in human ICH 
patients, which could be translated to the clinic as a diagnostic panel, potentially improving 
CAA diagnosis and management.   
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CHAPTER 3 
Early Validation of Perivascular CSF Flow 
in the Murine Brain 
 
3.1: Introduction 
3.1.1: Overview.   
Previous studies showed that brain ISF solutes are cleared by bulk flow,200 despite the 
fact that the BBB tight junction proteins preclude significant bulk influx of plasma.241  One 
potential explanation for these disparate findings is that CSF, contained within the cisterns, 
exchanges with brain ISF via the PVS.204  More recent work has shown that this process of 
perivascular CSF flow drives the bulk flow of ISF,125 and is required for the clearance of 
Aβ1-40 via the meningeal lymphatic system.143  This process is thought to be critical to 
maintaining brain homeostasis, and may help to prevent CAA in healthy individuals. 
 
3.1.2: Significance.   
We hypothesized that CSF flow occurs along perivascular routes, and that diffusion 
through the basement membrane is dependent on the size of the injected tracer.  While these 
findings have been previously shown in the literature, given that these techniques are largely 
new to our laboratory, it was important for us to internally validate our techniques.  
Therefore, prior to undertaking our studies in mouse models of stroke, we wished to replicate 
previous physiological studies in our own laboratory using naive young animals.  This also 
afforded us a chance to develop and troubleshoot our own techniques to study CSF flow, 
helping to ensure the success of our future experiments.  While many of our findings were in 
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agreement with the existing literature, we found an interesting phenomenon of size exclusion 
within basement membrane sublayers that deserves further study. 
 
3.1.3:  Experimental design.   
We sought to replicate previous work using intracisternal injection of tracers in 
anesthetized mice, which have been used previously as an experimental model of 
perivascular CSF flow.  To accomplish this, we developed a custom injection apparatus and 
used it to infuse a variety of tracers, starting with Evans blue dye, which is visible to the 
naked eye and allows for quick confirmation of successful injection.  We then progressed to 
using simultaneous injection of dyes into the vasculature and cisterna magna, which allowed 
us to assess the perivascular localization of CSF dye by conventional fluorescence 
microscopy in fixed brain tissue.  Next, we tested multiple dextran particles of different 
molecular weights, and assessed their transport through the basement membrane by in vivo 
two-photon microscopy.  We also confirmed our findings by intracisternal injection of 
radiolabeled 14C-Inulin and 3H2O, which allowed us to easily quantify the amount of tracer 
taken up into the brain ISF and facilitated the creation of optimal time-courses for our later 
experiments.  Finally, we also compared the clearance rate of 125I-Aβ1-40 to 125I-Αlbumin to 
evaluate whether it is removed solely via bulk flow, or if other clearance mechanisms are 
involved. 
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3.2: Methods 
3.2.1: Animals.   
Wild-type young (2 – 3 month-old) male C57BL/6 mice were obtained from Charles 
River. Mice were kept on a 12-hour light-dark cycle, and fed standard dry chow with ad 
libitum access to food and water.  Mice were examined regularly by trained members of the 
lab and the veterinary staff for any signs of illness, as well as gross pathology at the time of 
sacrifice.  Importantly, all studies were carried out in accordance with the recommendations 
in the guide for the Care and Use of Laboratory Animals of the National Institutes of Health. 
The protocols were approved by the UTHealth Institutional Animal Care and Use Committee 
(IACUC) and carried out in a facility approved by the Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC).  Animals were randomized to 
experimental conditions, and investigators were blinded to treatment.  
 
3.2.2: Preparation of fluorescent tracers.  
Artificial CSF (aCSF) containing Na+ (150 mM), K+ (3 mM), Ca2+ (1.4 mM), Mg 
(0.8 mM), P (1.0 mM) and HCO3 (24.1 mM) was freshly prepared in sterile distilled water 
prior to the experiment.  First, on the day of the experiment, a 2% solution of Evans blue dye 
(Sigma) was created in aCSF and mixed 1:1 with aCSF alone or aCSF containing 10% 
bovine serum albumin (BSA, Sigma) in aCSF, then filtered using a molecular-weight cutoff 
filter (MW cutoff = 50 kD) to create 1% working stocks of Evans blue dye (EBD) or Evans 
blue albumin (EBA) conjugate.  Additionally, for subsequent multi-color experiments, 
various lyophilized dextran conjugates were first obtained from Thermo Fisher and then 
reconstituted separately in aCSF.  Then, 4% stock solutions of 2000 kD fluorescein 
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isothiocyanate dextran (FITC-d2000), lysine-fixable 70 kD FITC dextran (FITC-d70) and 
lysine-fixable 3 kD tetramethylrhodamine dextran (TR-d3) were prepared and stored at -
20°C prior to the experiments.  Then, on the day of the experiment, fluorescent tracers were 
then further diluted/combined in aCSF to a working concentration of 1%.  To measure 
fluorescent background signal, aCSF with no tracers was also retained for injection into 
control animals. Tracer mixtures were kept on ice for up to 4 hours prior to use, and vortexed 
for 5 seconds immediately before infusion.   
 
3.2.3: Preparation of 125I-radiolabeled tracers.   
Recombinant human Aβ1-40 (Anaspec, Fremont, CA) or BSA (Sigma) was first 
dissolved to a concentration of 1 µg/µL in sterile, chloride-free 250 mM sodium phosphate 
buffer (pH = 7.4).  Then, peptides were conjugated to Iodine-125 (125I) with chloramine T as 
previously described.242 125I-peptide was separated from free 125I by washing the mixture 
through a Sephadex G-10 column. Successful conjugation was measured by TCA 
precipitation, and fractions retaining > 95% counts per minute (CPM) values in the solid 
phase were then combined and lyophilized overnight for later use.  
 
3.2.4: Preparation of 14C-Inulin/3H2O tracer cocktails.   
14C-Inulin and 3H2O were purchased directly from Perkin-Elmer, and stock solutions 
of 14C-Inulin (Perkin-Elmer, ~2 x 105 disintegrations/minute/microliter [DPM/uL]) and 3H2O 
(Perkin-Elmer, ~2 x 106 DPM/uL) were dissolved in aCSF and radioactivity normalized via 
liquid scintillation counting.  Then, stock solutions were combined to a final concentration of 
1 x 105 DPM/uL 14C-Inulin and 1 x 106 DPM/uL 3H2O in aCSF.   
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3.2.5: Intracisternal injection.   
Mice were deeply anesthetized with an intraperitoneal injection of Ketamine-
Xylazine dissolved in 0.9% saline (120 mg/kg Ketamine, 10 mg/kg Xylazine), then placed in 
a stereotaxic frame.  The hair over the cervical spine was then shaved, and then the skin was 
aseptically prepared and incised.  Following this, a 30 gauge needle attached to catheter 
tubing was inserted through the superficial neck musculature and into the cisterna magna as 
previously described.125 Tracer was slowly infused into the cisterna magna (1 µL/min) over 
10 minutes, after which mice were transferred to a warmed cage.  Then, 15, 30 or 60 minutes 
after the initiation of the injection, mice were sacrificed by Avertin overdose (250 mg/kg), 
followed by transcardial perfusion with phosphate buffered saline (PBS) supplemented with 
0.2% heparin, then 4% paraformaldehyde (PFA) in PBS for histological experiments.  
Tissues (brain and skull) were dissected and stored at 4% PFA for histology, or snap frozen 
and stored at -80°C for radiouptake measurements.   
 
3.2.6: Intravenous injection.   
Mice were deeply anesthetized with an intraperitoneal injection of Ketamine-
Xylazine dissolved in 0.9% saline (120 mg/kg Ketamine, 10 mg/kg Xylazine).  Two minutes 
prior to sacrifice, a 2 cm midline incision was made on the skin covering the ventral neck 
musculature, and the jugular vein visualized.  Then, a 100 µL bolus of 5% EBA was injected 
into the jugular vein, and allowed to circulate for 30 seconds.  Successful injection was 
confirmed via inspection of the mucous membranes for gross darkening.  Mice were 
sacrificed by Avertin overdose (250 mg/kg), followed by cervical dislocation.  Then, tissues 
were dissected and post-fixed in 4% PFA until later use.   
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3.2.7: Intraparenchymal injection.  
Mice were deeply anesthetized with an intraperitoneal injection of Ketamine-
Xylazine dissolved in 0.9% saline (120 mg/kg Ketamine, 10 mg/kg Xylazine), then placed in 
a stereotaxic frame.  A craniotomy was performed and a Hamilton syringe was then 
advanced into the striatum (0.4 mm anterior to Bregma, lateral 2.2 mm, ventral 3.5 mm).  
Then, 2 µL dH2O containing 1 x 106 CPM of reconstituted tracer solution was then infused at 
a rate of 1 µL/min.  To reduce inflammation, the needle was left in place for the duration of 
the experiment.  Mice were sacrificed by Avertin overdose (250 mg/kg) after 60 minutes, and 
successful injections confirmed by inspection of the needle tract.  Finally, brains were snap 
frozen and stored at -80°C prior to gamma counting. 
 
3.2.8: Brain sectioning.   
Following perfusion, brains were extracted and post-fixed for 24 hours in 4% PFA.  
Then, brains were dehydrated in 30% sucrose, frozen to -20°C and sectioned to 24 µm 
(immunohistochemistry [IHC]/cresyl violet staining) or 100 µm (tracer quantification) 
sections. Sections were then mounted onto slides and coverslipped with Fluoromount G or 
Vectashield + DAPI (4',6-diamidino-2-phenylindole, Vector Laboratories).   
 
3.2.9: Fluorescence microscopy.  
Sections were imaged under fluorescence with a Leica DMi8 microscope at 10X 
magnification.  A blinded investigator imaged the lateral cortex (0.38 mm anterior to 
Bregma, 2.5 mm lateral, 1.5 mm deep).  Then, 100 µm Z stack images were obtained, and 
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maximum intensity projections performed with LAS X software. Single-plane mosaic images 
were also obtained at 10X magnification with autofocus. 
 
3.2.10: Two-photon microscopy.  
Mice were deeply anesthetized with an intraperitoneal injection of Ketamine-
Xylazine dissolved in 0.9% saline (120 mg/kg Ketamine, 10 mg/kg Xylazine), then placed in 
a stereotaxic frame.  Immediately following acute installation of a glass coverslipped cranial 
window over the right dorsal forebrain, tracer was infused into the cisterna magna, and cortex 
was imaged through the window.  Briefly, animals were imaged using a custom-built two-
photon microscope (Bruker Nano, WI) with femto-second pulse lasers (Spectra physics).  
Fluorophore was excited at 810 nm and emission of photon was collected by two-channel 
top-mounter GaAsp detectors equipped with dual emission filters (525/70m-2P and 595/50m-
2P). Two-photon image acquisition was performed with a imaging software Prairie View. A 
water immersion objective lens (Nikon CFI 16x/0.80) was used throughout the imaging 
session.   Upon completion of imaging experiments, mice were sacrificed by Avertin 
overdose (250 mg/kg) and then cervically dislocated. 
 
3.2.11: Gamma counting.   
Frozen brain samples were thawed on ice, then manually homogenized in 30% TCA 
in glass test tubes.  Then, whole homogenates were centrifuged at 5000 x g for 15 minutes, 
and the supernatant removed to a separate tube.  Then, the amount of peptide-bound (pellet) 
and free iodine (supernatant) were quantified using a gamma counter (Packard Cobra II), 
courtesy of Dr. Claudio Soto.  
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3.2.12: Liquid scintillation counting.   
Samples were thawed on ice, then placed in 5 mL glass vials and dissolved in 1 mL 
Solvable (Perkin Elmer) overnight at 37°C.  Then, homogenates were vortexed and mixed 
with 4 mL Hionic-Fluor scintillation cocktail (Perkin Elmer).  Following this, β-emissions 
were measured using a Tri-Carb T2900 Liquid Scintillation Counter (LSC) (Perkin Elmer), 
with 3H2O emissions counted at less than 20 keV, and 14C-Inulin measured counted between 
20 and 150 KeV.  Control vials containing aCSF alone, aCSF + 14C-Inulin and aCSF + 3H2O 
were used to account for background radiation, as well as to normalize emission signals from 
samples for subsequent analyses. 
 
3.2.13: Statistics. All data are presented as mean (+/-) SEM, with the number of animals per 
experimental group (n).  Statistically significant changes over time were determined by one-
way analysis of variance (ANOVA).  Statistical significance in total clearance was calculated 
by Student’s t-test. Significance is denoted as *p < 0.05, **p < 0.01, ***p < 0.001. 
 
 
 
 
 
 
 
 
 
	   42 
3.3: Results 
3.3.1: CSF traveled through the brain along perivascular routes.   
 First, to test the hypothesis that CSF solute exchange occurs within the PVS in a size-
dependent manner, I compared the distribution of intracisternally injected Evans blue (EBD, 
~500 Da) to Evans blue albumin (EBA, 70 kD) at 60 minutes post-injection.  Upon gross 
examination, I found that EBD spread from the circle of Willis and diffused bilaterally across 
the dorsal surface of the brain along vascular tracts, including the MCA, as well as the 
posterior cerebral artery (PCA) and the anterior cerebral artery (ACA) (Fig. 3-1A).  The dye 
formed a visible diffusion gradient, appearing to spread from the arterial structure to the 
surrounding parenchymal tissue (Fig. 3-1A).  Unexpectedly, EBA, the larger molecule, was 
more tightly associated with surface vessels than EBD (Fig. 3-1B).  Examination under 
fluorescence revealed that this vascular association continued within the PVS of deep brain 
vessels, and appeared more strongly with EBA injection (Fig. 3-1C).  These studies confirm 
that CSF flow occurs along the surface of the brain, and follows perivascular routes, rather 
than simply diffusing randomly throughout the brain.  They also suggest a size-exclusion 
property of the pial membrane, which allows for the rapid diffusion of EBD, but not EBA, 
away from the major vessels and into surface capillaries and interstitial spaces.   
	   43 
 
 
	   44 
Figure 3-1: Visualization of CSF influx by intracisternal dye injection. (A.) Photograph 
of (i.) dorsolateral and (ii.) ventral mouse brain 30 minutes after intracisternal injection with 
Evans blue dye (EBD, 500 Da). (iii. – vi.) Light micrograph showing intraparenchymal EBD 
distribution within coronal sections. (vii. – viii.) Fluorescent mosaic micrographs from two 
mice showing EBD influx along the superficial surfaces of the brain.  (B.) Photograph of (i.) 
dorsolateral mouse brain 30 minutes after intracisternal injection with Evans blue albumin 
(EBA, 70 kD). (ii. – iii..) Light micrograph showing perivascular EBA distribution within 
coronal sections. (iv.) Representative fluorescent mosaic image showing EBA influx along 
the superficial surfaces of the brain.  (C.) Fluorescent micrographs showing how (ii.) EBA 
exhibits stronger perivascular localization than (i.) EBD.  Scale bar (black, white) = 50 µm. 
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Then, to confirm that CSF influxes into the deeper structures of the brain along penetrating 
arterial beds, I double-labeled CSF and plasma by injecting FITC-dextran (70 kD, FITC-d70) 
into the cisterna magna, and then injecting EBD into the jugular vein immediately prior to 
sacrifice (Fig. 3-2A).  I found that the injected CSF FITC-d70 tracer strongly localized to the 
injected plasma EBD tracer, and distributed along arteries, arterioles and capillary beds, 
extending into the deepest structures of the brain (Fig. 3-2B).  These findings were later 
confirmed with two-photon microscopy, where CSF flow was observed to occur within the 
PVS of young mice in real-time.  When different size tracers were simultaneously injected 
(2000 kD, FITC-d2000; 4 kD, 594-d3), we found that the smaller tracer traveled more 
closely to the vessel wall, while the larger tracer was excluded from this region and diffused 
along the outer surface (Fig. 3-2C).   This intriguing finding suggests that the basement 
membrane layers exhibit size-exclusion properties, potentially filtering larger particles out of 
the inner basement membrane layers.  In addition to being interesting from a biophysical 
perspective, this could have significance for the ability of to efficiently transport smaller 
monomeric vs larger oligomeric amyloid species. 
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Figure 3-2.  CSF influx occurs along perivascular routes. (A.) (i.) Representative 
fluorescent mosaic micrograph showing (ii.) plasma (red) colocalizing with (iii.) CSF.  (iv.) 
Nuclei were counterstained with DAPI. (B.) (i.) High-resolution confocal micrograph 
showing CSF influx along perivascular routes. (ii.) 3-dimensional reconstruction of CSF 
influx showing diffusion away from the perivascular regions.  (C.) Representative in vivo 
two-photon image showing differential distribution of FITC-d2000 and TR-d3.  Scale bar 
(black, white) = 100 µm.  Note: Panel C was used with permission from Dr. Akihiko 
Urayama (unpublished data). 
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Figure 3-3. Kinetics of influx and efflux of injected tracers. (A.) Intracisternally injected 
14C-Inulin levels increase within the brain interstitial fluid over time and equilibrates by 30 
minutes. n = 5 – 8 per time-point. (B.) Intracisternally injected 3H2O reduces and equilibrates 
with the brain by 30 minutes. n = 5 – 8 per time-point. (C.) Intraparenchymally injected 125I-
Albumin (70 kD) clears more slowly from the brain than 125I-Aβ1-40 (4.5 kD) over 60 
minutes. n = 5 per group.  Data are analyzed by Student’s t-test, *** p < 0.001. 
 
3.3.2: CSF solutes rapidly achieve equilibrium with the brain interstitial fluid.  Next, to 
assess the time-course of diffusion of CSF solutes, we performed intracisternal injections of 
14C-Inulin and 3H2O.  14C-Inulin was selected as a marker for extracellular diffusion of CSF, 
due to the fact that it is soluble in water but cannot cross lipid bilayers.  3H2O was used to 
measure the intracellular uptake of CSF, which largely occurs in astrocytes via AQP4.  I 
found that 14C-Inulin levels gradually increased over time (F[3, 34] = 9.87, p < 0.001).  In 
contrast, I found that 3H2O levels rapidly increased, and then plateaued (F[3, 36] = 230.6, p < 
0.001).  These findings indicate that both intracellular and extracellular uptake occur over 
different time courses, and provide support for choosing a 30-minute duration for subsequent 
studies, as injected extracellular tracers will have reached equilibrium. 
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 In a separate experiment, we measured the clearance rate of solutes within the 
interstitial fluid by performing intraparenchymal injection of 125I-Albumin or 125I-Aβ1-40.  
Unlike previous studies that have found that intraparenchymally injected solutes all move at 
the same rate, regardless of molecular weight, I found that 125I-Aβ1-40 (4 kD) cleared much 
more rapidly than 125I-Albumin (70 kD) (t[7] = 14.9, p < 0.001), being removed almost 
entirely from the brain by 60 minutes post-injection.  This may be due to additional clearance 
mechanisms for interstitial Aβ1-40.   
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3.4: Discussion 
Even after 30 years of extensive research,202 the existence of physiologically 
meaningful perivascular CSF flow remains controversial.243,244  However, newer studies with 
two-photon microscopy125 have helped this concept gain wider acceptance within the 
scientific community.  Importantly, our work provides further evidence for the perivascular 
flow of CSF within the healthy brain using multiple types of measurements, including ex vivo 
fluorescence imaging, brain radiouptake measurements as well as in vivo two-photon 
imaging.   
 Unlike previous studies of interstitial clearance,200 we newly found that the influx of 
CSF solutes through the basement membrane is size-dependent, with the transport of large 
solutes (2000 kD) occurring in a separate layer of basement membrane than smaller solutes 
(70 kD).  This may have disease relevance to CAA, as monomeric Aβ1-40 is small (~4.5 kD), 
but can form larger oligomers and eventually enormous, insoluble plaques,245 potentially 
affecting different layers of the basement membrane at different disease stages.  Alterations 
in the composition or communication between these layers could further reduce the transport 
rate of CSF solutes, which could further worsen deposition of Aβ1-40 within the basement 
membrane.  Similar to CSF influx, we additionally found that that intraparenchymally 
injected albumin cleared more slowly from the brain than Aβ1-40 in naïve animals, measured 
at 60 minutes post-striatal injection.  While this could be due to size differences (molecular 
weight of albumin is 70 kD), more likely, our observed differences are due to the existence of 
specific BBB transporters that are involved with the active clearance of Aβ1-40, which could 
increase the rate of Aβ1-40 clearance from the brain compared to other compounds, such as 
albumin.246,247  Further work is needed to determine how aging and stroke alter the ability of 
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these active transport mechanisms in clearing Aβ1-40 across the BBB, which could protect the 
brain from CAA even under conditions that would otherwise favor the deposition of Aβ1-40 
within the basement membrane. 
In summary, these initial studies confirm that CSF flows from the cisterns into the 
brain parenchyma, and that this transport occurs within the PVS.  They further indicate that 
the transport of solutes is segregated by molecular weight, with larger molecules excluded 
from the inner regions of the PVS.  They also suggest that microstructural differences within 
the basement membrane sub-layers, which may produce the size-exclusion properties to 
different CSF solutes, becomes altered with disease and could sensitize the brain to CAA in 
pathological states. 
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CHAPTER 4 
Fibronectin Induces the Perivascular Deposition of  
CSF-derived Aβ in Aging and After Stroke 
 
4.1: Introduction 
4.1.1: Significance.  
While CAA is a pervasive finding in stroke survivors, the pathophysiological 
mechanisms underlying progressive vascular Aβ1-40 accumulation remain understudied.  
Recent studies suggest that the clearance of Aβ1-40 from blood vessels is mediated via a 
perivascular route of CSF flow, termed the glymphatic system.125  During glymphatic flow, 
the pulsation of arteries pushes CSF from the meningeal cisterns along penetrating arterioles 
and eventually capillary beds through the PVS,248 which is bordered on either side by the 
vascular basement membrane and astrocytic endfeet.181,249  Interestingly, Peng et al. (2016) 
showed that in addition to clearing Aβ1-40 from the brain, the glymphatic system can also 
redistribute CSF Aβ1-40 back into the brain along perivascular routes.  This process can be 
exacerbated by brain pathology, as they further showed that CSF-derived Aβ1-40 selectively 
accumulates in the brains of aged APP/PS1 mice, and colocalizes with pre-existing cortical 
Aβ plaques. Taken together with clinical data showing that CSF Aβ1-40 levels fluctuate over 
the course of disease in dementia patients,250 these findings suggest that CSF Aβ1-40 may 
deposit within perivascular regions involved in glymphatic flow.  While increased 
perivascular redistribution of CSF Aβ1-40 could lead to CAA, the molecular and cellular 
factors that induce Aβ1-40 deposition in CAA, especially in the context of ischemic stroke, 
remain understudied. 
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The perivascular flow of CSF may be dependent on the vascular basement membrane 
which consists of a glycosylated protein matrix that can be stained with tomato lectin. This 
protein matrix may act as a filtration path that could restrict, in part, the redistribution of 
solutes dissolved in the CSF.  We postulate that this novel basement membrane function may 
become dysregulated after ischemic stroke, which stimulates the overexpression of 
fibronectin and its receptor, α5β1 integrin.  Cellular fibronectin is a dimeric 440 kD basement 
membrane glycoprotein that links cell membrane integrins to HSPGs.171–173 Importantly, 
fibronectin is also expressed in CAA plaques251 and may exhibit affinity for aggregated 
Aβ.217,252 Therefore, we hypothesize that stroke-induced increases in basement membrane 
fibronectin leads to perivascular deposition of soluble, CSF-derived Aβ1-40 by direct binding.   
 
4.1.2: Experimental Design.  
We show that both aging and focal stroke inhibit the bulk flow of CSF along 
perivascular routes within the brain, which is associated with impairment of cognitive 
function.  Furthermore, we also demonstrate that CSF Aβ1-40 is abnormally deposited within 
the basement membrane after stroke in aged animals, and that this deposition strongly 
correlates with the peri-infarct basement membrane labeled by lectin.  We identified that 
fibronectin and the integrin-α5 receptor subunit are upregulated basement membrane proteins 
in aged animals with stroke, which enhanced the deposition of CSF Aβ1-40.  Based on our 
findings, we propose targeting fibronectin as a strategy to treat age and stroke-related CAA. 
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4.2: Methods 
4.2.1: Animals.   
Wild-type young (2 – 3 month-old) and aged (18 – 20 month-old) male C57BL/6 
mice were obtained from Charles River and the National Institute of Aging, respectively. 
Mice were kept on a 12-hour light-dark cycle, and fed standard dry chow with ad libitum 
access to food and water.  Mice were examined regularly by trained members of the lab and 
the veterinary staff for any signs of illness, as well as gross pathology at the time of sacrifice. 
The protocols were approved by the UTHealth IACUC and carried out in an AAALAC-
approved facility, as described in the preceding chapter.  Animals were randomized to 
experimental conditions, and investigators were blinded to treatment.  
 
4.2.2: Permanent distal middle cerebral artery occlusion.   
Mice were subjected to permanent distal middle cerebral artery occlusion (DMCAO) 
as previously described.253  Briefly, mice under isoflurane anesthesia were placed in a prone 
position inside a sterile surgical field, and body temperature maintained at 37°C.  Following 
this, the right dorsolateral cranium was shaved and aseptically prepared.  Then, local 
anesthetic was injected (Marcaine, 0.05 mL), the skin and underlying temporalis muscle were 
incised, and a 2 mm burr hole was drilled to expose the MCA, which was then cauterized to 
induce ischemia.  After successful cauterization, the burr hole was closed with dental cement, 
the temporalis muscle repaired with Vetbond and the skin incision closed with Vicryl 5-0 
nylon sutures.  Sham surgeries were performed following an identical procedure, except that 
no cauterization was performed.  Ischemia was confirmed by Laser Doppler flow 
measurement immediately following MCA cauterization. 
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4.2.3: Behavioral tests   
• DigiGait.  The impact of aging and stroke on motor function was assessed using 
DigiGait (Mouse Specifics) at 3 and 7 days post-injury (DPI) in a double-blinded 
manner.  Mice were first acclimated to the system, and then the speed was gradually 
increased to 15 centimeters/second.  Gait was recorded for 60 seconds, and the degree 
of left forepaw rotation was measured using automated DigiGait analysis software 
over 10 steps by a separate blinded investigator.  
• Barnes Maze.  Hippocampal-dependent spatial reference memory was assessed at 28 
DPI using a one day training-testing paradigm, modified from previously described 
work 254. Following habituation, mice were trained to find the escape hole in an 
illuminated, elevated Barnes maze (Mouse Specifics).  This training was repeated 4 
times, and then tested 4 hours later in a 3 minute probe trial. The latency to find the 
escape hole, number of errors and total distance moved were quantified using 
EthoVision XT software in a blinded manner. 
• Open Field.  Spontaneous exploratory behavior was assessed at 28 DPI by open field 
testing.  Mice were allowed to explore a 40 cm2 opaque chamber for 5 minutes.  
Absolute distance traveled (centimeters) was recorded and quantified using 
EthoVision XT software in a blinded manner.  
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4.2.4: Preparation of fluorescent tracers.  
aCSF containing Na+ (150 mM), K+ (3 mM), Ca2+ (1.4 mM), Mg (0.8 mM), P (1.0 
mM) and HCO3 (24.1 mM) was prepared in sterile distilled water on the day of the 
experiment.  Stock solutions of lysine-fixable 3 kD cascade blue dextran (CB-d3, 3,000 MW, 
anionic, 4% stock, Thermo Fisher) and 2000 kD FITC dextran (FITC-d2000, 2,000,000 MW, 
anionic, 4% stock, Thermo Fisher) were prepared in aCSF.  Additionally, AlexaFluor-647-
conjugated human amyloid-β1-40 (647-Aβ1-40, 100 µM stock, Anaspec), FITC-conjugated 
recombinant human amyloid-β1-40 (FITC-Aβ1-40, 100 µM stock, Anaspec), and FITC-
conjugated recombinant human amyloid-β1-42 (FITC-Aβ1-42, 100 µM stock, Anaspec) were 
also prepared in aCSF.  Tracers were then combined to a solution 1 (2% CB-d3, 1% FITC-
d2000 and 10 µM 647-Aβ1-40), solution 2 (10 µM FITC-Aβ1-42 and 10 µM 647-Aβ1-40) or 
solution 3 (10 µM FITC-Aβ1-40 alone).  In other experiments, recombinant human fibronectin 
(R&D Systems, cat. 4305-FN) or aCSF was added to the tracer mixture to a concentration of 
500 nM and incubated for 1 hour at room temperature prior to infusion.  Tracer mixtures 
were kept on ice for up to 4 hours prior to use, and vortexed for 5 seconds immediately 
before infusion.  To measure fluorescent background signal, zero control animals received 
aCSF with no tracers.  
 
4.2.5: Tracer injection.   
Mice were deeply anesthetized with an intraperitoneal injection of Ketamine-
Xylazine dissolved in 0.9% NaCl (120 mg/kg Ketamine, 10 mg/kg Xylazine), then placed in 
a stereotaxic frame.  The skin over the cervical spine was then shaved, aseptically prepared 
and incised.  Following this, the needle was inserted through the superficial neck musculature 
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and into the cisterna magna as previously described.125  Tracer was slowly infused into the 
cisterna magna (1 µL/min) over 10 minutes, after which mice were transferred to a warmed 
cage.  Then, 30 minutes after the initiation of the injection, mice were sacrificed by Avertin 
overdose (250 mg/kg), followed by transcardial perfusion with 0.2% heparin-PBS, then 4% 
PFA.  Tissues were dissected and stored in 4% PFA until later use. 
 
4.2.6: Fluorescent microscopy and tracer imaging.   
Following perfusion, brains were extracted and post-fixed for 24 hours in 4% PFA.  
Then, brains were dehydrated in 30% sucrose, frozen to -20°C and sectioned to 24 µm 
(IHC/cresyl violet staining) or 100 µm (tracer quantification) sections. Sections were then 
mounted onto slides and coverslipped.  For experiments involving colocalization with lectin, 
sections were first stained with Lycopersicon esculentum (Tomato) lectin (see 
Immunohistochemistry).  Sections were imaged under fluorescence with a Leica DMi8 
microscope at 10X magnification.  A blinded investigator imaged the lateral cortex (0.38 mm 
anterior to Bregma, 2.5 mm lateral, 1.5 mm deep).  Then, 100 µm Z stack images were 
obtained, and maximum intensity projections performed with LAS X software.  Images were 
then quantified in ImageJ (see Data Analysis).  
 
4.2.7: Immunohistochemistry.   
IHC was performed on fixed brain sections (24 µm) that were mounted onto slides 
and incubated with Lycopersicon esculentum lectin (1:100, λ = 594, Vector Laboratories, cat. 
DL-1177), anti-fibronectin (Rabbit, 1:100, abcam, cat. ab2413), anti-integrin-α5 (Rabbit, 
1:100, abcam, cat. EPR7854) or anti-glial fibrillary acid protein [GFAP]-Cy3 (Mouse, 
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1:1000, Millipore Sigma, cat. C9205,) antibodies.  Then, sections were incubated with 
secondary antibodies (Goat anti-Rabbit (Abcam, Alexa-Fluor, 1:500, λ = 488, 594 or 647 
nm).  Finally, sections were cover-slipped with Vectashield containing DAPI (Vector 
Laboratories, H-1200).   
 
4.2.8: Protein isolation, SDS-PAGE and western blotting.   
The right cortex was perfused with heparinized PBS, homogenized and lysed in 
buffer containing 1% NP-40, 1 mM phenylmethylsulfonyl fluoride (PMSF), cOmplete 
(Roche) and PhosSTOP (Roche).  Following centrifugation, the supernatant was removed 
and diluted to 4 mg/mL in 4x Laemmli Sample Buffer (Bio-Rad, 161-0737) supplemented 
with 4% β-mercaptoethanol, then heated to 95°C for 5 minutes.  Following sample 
preparation, 10 µL of each lysate was run on a 4-15% Criterion TGX 26-well gels (Bio-Rad, 
cat. 5671085), and SDS-Page performed at 120V for 60 minutes in Tris-Glycine-SDS buffer 
(Bio-Rad).  Protein bands were subsequently transferred to a polyvinylidene fluoride (PVDF) 
membrane and probed with anti-fibronectin (Rabbit, 1:1000, abcam, cat. ab2413), anti-α5 
Integrin (Rabbit, 1:1000, abcam, cat. EPR7854) or anti-vinculin antibody (Rabbit, 1:10,000, 
abcam, cat. EPR8185).  Blots were then probed with HRP-conjugated goat anti-rabbit 
secondary antibody (1:10,000, Vector Laboratories, cat. PI-1000) and imaged using a Bio-
Rad ChemiDoc Imager. 
 
4.2.9: Generation of radiolabeled amyloid-β.   
Recombinant human Aβ1-40 (Anaspec, Fremont, CA) was first dissolved to a 
concentration of 1 µg/µL in sterile, chloride-free 250 mM sodium phosphate buffer (pH = 
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7.4).  Then, Aβ1-40 was conjugated to 2 mCi Iodine-125 (125I) with chloramine T (1 µg/µL) as 
previously described.242  The labeling reaction was terminated by adding sodium 
metabisulfate (10 µg/µL) to the reaction.  125I-Aβ1-40 was separated from free 125I by washing 
the mixture through a Sephadex G-10 column. Successful conjugation was measured by TCA 
precipitation ratio, calculated as % precipitation = CPM (pellet) / (CPM [pellet] + 
CPM[supernatant]).  Fractions retaining > 95% CPM values in the solid phase were then 
combined and lyophilized overnight for later use.   
 
4.2.10: Fibronectin-125I-Aβ1-40 binding assay.   
To measure the binding affinity of radiolabeled 125I-Aβ1-40 for fibronectin, an in vitro 
assay was developed that relies on separation of free 125I-Aβ1-40 (4.2 kD) from fibronectin-
125I-Aβ1-40 conjugates (> 220 kD) based on molecular weight.  First, serially diluted 
recombinant human fibronectin (1 x 103 to 1 x 108 ng/ml) (R&D Systems, cat. 4305-FN) was 
incubated with 125I-Aβ1-40 (1 x 105 CPM) at room temperature for 1 hour. Reaction mixtures 
were then centrifuged in a molecular weight cutoff spin column (> 50 kD, Amicon Ultra, 
Millipore-Sigma).  The columns were washed with 400 µL of sterile PBS and centrifuged 3 
times for 5 minutes at 5,000 x g.  Finally, the remaining 125I-Aβ-fibronectin conjugates were 
resuspended in sterile PBS and the amount of fibronectin-bound 125I-Aβ quantified by a 
gamma counter (Packard Cobra II).  See Data Analysis for the calculation of the standard 
curve. 
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4.2.11: Data Analysis. 
• Atrophy quantification.  High resolution images of cresyl violet-stained coronal brain 
sections (24 µm) were obtained (Fig. 4-1).  Then, ventricular volume and hemisphere 
size were quantified as previously described (Harris et al., 2016; Verma et al., 2014).  
Tissue atrophy percentage was calculated by the formula: % tissue loss = 100 - ([total 
ipsilateral tissue/total contralateral tissue] × 100). 
• Tracer intensity.  Tracer influx was quantified by measuring intensity as a function of 
tissue depth using ImageJ (Fig. 4-1).  Then, average intensity values were imported 
into Excel, and integrated into 50 µm bins.  Absolute binned intensity values were 
then plotted as raw intensity (arbitrary units, [A.U.]).  To normalize potential age-
induced differences in background intensity, the relative tracer intensity was 
calculated by subtracting each binned value from intensity values obtained from age-
matched control mice that did not receive tracer injections (Δ Intensity [A.U.]). 
• Immunohistochemical quantification.  IHC images were acquired and quantified in 
a double-blinded manner.  Based on lectin staining, regions of interest (ROI’s) were 
drawn around 3 peri-infarct vessels/image across 3 brain sections for a total of 27 
vessels/brain.  Threshold was held constant between brains, and the area and average 
pixel intensity of fibronectin was measured relative to the ROI.   
• Calculation of 50% Effective Concentration (EC50).  The EC50 was quantified using 
a sigmoidal EMax model by plotting the log [Fibronectin] against the %Aβ binding 
(calculated as CPM [X]/CPM [Max]). A sigmoidal regression line was fit with Prism, 
and the EC50 was interpolated from the curve.  Each measurment at each 
concentration was replicated 3 times. 
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4.2.12: Statistics.   
Data are expressed as mean (+/-) SEM with the number of animals per group (n).  
The physiology data measured at different depths was analyzed by repeated measures two-
way ANOVA, with factors of aging and DMCAO. Repeated measures one-way ANOVA 
was used for repeated measures with only one factor.  For immunohistochemical 
quantification of area or intensity, as well as for analysis of band intensity of western blots, 
two-way ANOVA was used, examining the effects of aging and DMCAO on the dependent 
variable. All of the above analyses were followed by Sidak’s post-hoc test. Scatter plots were 
provided and linear mixed-effects models were used to study the association between the 
dextran intensity and and Aβ1-40 intensity, and between the lectin intensity and the tracer 
intensity.  Statistical significance is denoted as *p < 0.05, **p < 0.01, ***p < 0.001, ns, no 
significance. 
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4.3: Results  
4.3.1: Aging and DMCAO impaired the perivascular flow of CSF.   
Previous work has shown that aging impairs glymphatic flow,235 and that multiple 
microinfarction disrupts CSF flow in middle-aged mice (12 months-old).208  However, it was 
not known whether a single focal stroke, modeled by DMCAO, induces glymphatic 
impairment, or if this would further worsen underlying impairments in aged mice (generally 
considered to be > 18 months of age).  Therefore, to assess the impact of aging and DMCAO 
on overall perivascular CSF flow, we injected fluorescent tracer into the cisterna magna at 30 
days post-DMCAO, and quantified the uptake 30 minutes later (Fig. 4-1, Fig. 4-2).   We 
found that CSF influx, measured as the distribution of dextran-derived fluid space markers, 
occurred along the superficial surfaces of the brain (Fig. 4-2).  Furthermore, we found that 
the distribution of both low (CB-d3, 3 kD) and high (FITC-d2000, 2000 kD) molecular 
weight dextran colocalized with lectin-stained vessels, supporting a perivascular route for 
CSF influx (Fig. 4-1A).  When raw CB-d3 uptake values were examined, we found reduced 
CSF flow occurred in aged animals at baseline (Fig. 4-2D, iii, Main Effect: Age, [F(1, 19) = 
6.2, p = 0.022]). We then measured how CSF influx changed in the injured cortex, relative to 
the contralateral hemisphere, and found the distribution of CB-d3 was inhibited by DMCAO 
in both young and aged animals (Fig. 4-1C, i., [F(1, 18) = 52.3, p < 0.001]). Taken together, 
these data indicate that DMCAO produced a unilateral impairment of bulk CSF influx 
through the lectin-stained basement membrane, even in aged mice, which exhibit baseline 
reductions in CSF flow. 
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Figure 4-1. Aging and DMCAO disrupted the transport of CSF and enhanced Aβ1-40 
distribution in the superficial cortex. (A.) Representative images of tracer uptake (CB-d3, 
647-Aβ1-40, FITC-d2000) and colocalization with lectin+ basement membrane. (B.) (i.) 
Representative 10X magnification images from young sham and DMCAO animals showing 
axis of tracer quantification, (ii.) Comparison of intensity tracings from young sham and 
DMCAO animals. (C.) Quantification of (i.) CB-d3 tracer uptake and (ii.) 647-Aβ1-40 from 
ipsilateral (injured/sham) cortex, 1 – 250 µm depth.  Data are normalized to contralateral 
hemisphere. All experiments, n = 5 – 8 per group. Data are analyzed by two-way ANOVA 
with Sidak’s post-hoc test.  *p < 0.05, **p < 0.01, ***p < 0.001.  Scale bar = 50 µm. 
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Figure 4-2.  Infusion technique, representative images and raw tracer uptake 
values.  (A.) Measurement of glymphatic flow by tracer uptake. (B.) Representative images 
of tracer uptake (CB-d3, FITC-d2000) changes with aging any stroke.  (C.) Representative 
raw tracing of dextran uptake in a tracer infused and non-tracer infused mouse 
brain.  (D.) Aging and stroke both reduced glymphatic flow compared to young sham 
animals in the injured cortex.  Data are analyzed by repeated measures two-way ANOVA 
with Tukey’s post-hoc test. *young sham vs. young stroke, #aged sham vs aged stroke, †young 
sham vs. aged sham, ‡young stroke vs. aged stroke.  *p < 0.05, **p < 0.01, ***p < 
0.001.  Scale bar = 50 µm. 
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4.3.2: DMCAO increased the perivascular distribution of CSF Aβ1-40, which worsens with 
aging.   
Previous work has shown that the glymphatic system provides a perivascular route for 
the deposition of CSF Aβ1-40 in mouse models of Alzheimer’s disease with pre-existing Aβ 
pathology,209 but it was not known whether stroke would induce de novo Aβ1-40 deposition, 
given the absence of pre-existing Aβ plaques in wild-type mice.  Therefore, to determine 
whether stroke selectively induced the ‘trapping’ of CSF Aβ1-40, we first examined whether 
DMCAO increased the total amount of Aβ1-40 deposition within the brains of young and aged 
wild-type mice by quantification of 647-Aβ1-40 distribution.  While we did not observe an 
impact on aged animals at baseline, we found an interesting interaction effect, which showed 
a paradoxical increase in 647-Aβ1-40 distribution in aged animals with DMCAO (Fig. 4-1C, 
ii., F[1, 18] = 21.7, p < 0.001).  Importantly, these differences between young and aged mice 
with DMCAO were not associated with significant differences in tissue atrophy ipsilateral to 
the injury (Fig. 4-3B, p = 0.96]), suggesting that other mechanisms, aside from infarct 
volume, could play an important role in determining the fate of CSF Aβ1-40.  Taken together, 
these data indicate that both aging and DMCAO induced the abnormal deposition of CSF 
Aβ1-40, with a major effect of DMCAO on the injured hemisphere, and a major effect of 
aging on the contralateral hemisphere.   
Then, to determine whether this effect was truly specific to Aβ1-40, we compared the 
distribution of 647-Aβ1-40 to FITC-Aβ1-42 in aged animals with sham and DMCAO in a 
separate cohort (Fig. 4-4A).  This analysis confirmed that 647-Aβ1-40 was increased in aged 
animals with DMCAO (Fig. 4-4B, i., p = 0.015), with no significant impact on FITC-Aβ1-42 
distribution (Fig. 4-4B, ii., p = 0.596).  Normalization of these values confirmed that 647-
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Aβ1-40/ FITC-Aβ1-42 ratio was significantly increased with DMCAO (Fig. 4-4B, iii., p = 
0.045).  Given that the same amount of Aβ1-40 and Aβ1-42 were infused into the brain, and that 
the proteins are similar in molecular weight, these data indicate a specific effect of DMCAO 
on the transport of CSF Aβ1-40 through the aged basement membrane after DMCAO, which 
we next explored by correlation analysis. 
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Figure 4-3.  Comparison of cortical atrophy, motor and cognitive impairments in young 
and aged mice with DMCAO. (A.) Timeline of stroke surgery and behavioral tests.  (B.) (i.) 
Cresyl violet staining of DMCAO brains revealed focal damage to the lateral cortex in both 
young and aged mice at 30 DPI.  (ii.) DMCAO induced similar degrees of atrophy in young 
and aged mice at 30 DPI (Data are analyzed by Student’s t-test, n = 10 per group). (C.) 
DMCAO induced alterations in forepaw rotation at day 3, which recovered by day 7 as 
measured by Digigait.  n = 5 - 12 per group (D.) (i.) Aging and stroke impaired performance 
on the Barnes maze.  (ii.) Aging reduced exploratory behavior on the open field test.  n = 7 – 
8 per group.  Data from panels C and D are analyzed by two-way ANOVA with Sidak’s post-
hoc test. *p < 0.05, **p < 0.01. ns, no significance.  
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Figure 4-4. DMCAO selectively increased the uptake of Aβ1-40 in the injured cortex of 
aged animals.  (A.) Representative images comparing the distribution of 647-Aβ1-40 to 
FITC-Aβ1-42 in aged animals treated with sham or DMCAO at 30 DPI.  (B.) Quantification of 
(i.) 647-Aβ1-40 uptake, (ii.) FITC-Aβ1-42 uptake and (iii.) 647-Aβ1-40/FITC-Aβ1-42 ratio.  All 
data are acquired from 1 – 250 µm depth of superficial cortex, and normalized to the 
contralateral hemisphere.  n = 5 per group.  Data are analyzed by Student’s t-test, *p < 
0.05. 
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4.3.3: Aging decoupled Aβ1-40 transport from CSF flow.  
To examine whether abnormal Aβ1-40 deposition is related to the bulk flow of CSF, 
the average intensity of 647-Aβ1-40 and CB-d3 (CSF fluid space marker) were compared 
within each 50 µm bin for the ipsilateral hemisphere (5 bins/animal) (Fig. 4-5, A-B).   
Comparison of CB-d3 and 647-Aβ1-40 influx curves revealed similar distribution kinetics as a 
function of tissue depth in young sham animals (Fig. 4-5A).  Furthermore, linear regression 
revealed a positive correlation (non-zero slope) of CB-d3 and 647-Aβ1-40 uptake in young 
sham (Fig. 4-5C, i., [t(21) = 5.89, p < 0.001]) and young stroke animals (Fig. 4-5C, ii., [t(25) 
= 3.25, p = 0.003]).  However, CB-d3 uptake did not predict Aβ1-40 uptake in aged sham 
[t(17) = 0.9, p = 0.379] or aged stroke animals [t(17) = 1.89, p = 0.076].  These findings 
indicate that age-induced disruption of bulk CSF influx did not predict the behavior of Aβ1-40, 
implying that other mechanisms, such as altered diffusion of Aβ1-40 through the basement 
membrane, may have played a more important role in determining CSF Aβ1-40 deposition 
with aging, which may be further changed by DMCAO. 
Since bulk flow did not significantly predict CSF Aβ1-40 deposition in disease states, 
we then broadly assessed whether components of the basement membrane are associated 
with CSF Aβ1-40 accumulation in vivo.  To accomplish this, the average intensity of 647-Aβ1-
40 and CB-d3 were each compared to the expression of glycosylated basement membrane 
matrix proteins, measured by the intensity of 594-lectin staining (Fig. 4-6). Interestingly, 
linear regression of 594-lectin vs. 647-Aβ1-40 intensity revealed a highly significant positive 
correlation in all experimental groups (Fig. 4-6C, i. – iv.; young sham, [F(1, 23) = 10.1, p < 0 
.001]; young stroke, [F(1, 27) = 67.91, p < .0001]; aged sham, [F(1, 19) = 26.4, p < 0.001]; 
aged stroke, [F(1, 19) = 17.61, p < 0.001]).  In contrast, linear regression of 594-lectin vs. 
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CB-d3 intensity (used as a fluid space marker and to control for potential non-specific 
trapping within the extracellular space) revealed a positive relationship in young sham 
animals (sham, Fig. 4-6B, i., t(23) = 3.7, p = 0.001], but not in young DMCAO animals (Fig. 
4-6B, ii., [t(27) = 0.4, p = 0.685]).  Additionally, in aged animals, 594-lectin intensity did not 
correlate with CB-d3 intensity in sham (Fig. 4-6B, iii., [t(19) = 0.9, p = 0.384]) or DMCAO 
mice (Fig. 4-6B, iv., [t(19) = 0.5, p = 0.619]).  Overall, these data showed that basement 
membrane proteins were more strongly associated with 647-Aβ1-40 than CB-d3 controls, 
indicating an association of lectin-stained basement membrane proteins on Aβ1-40 levels. This 
difference was further exacerbated by aging and DMCAO. 
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Figure 4-5.  Distribution of dextran did not predict Aβ1-40 distribution in disease 
conditions.  (A.) Distribution of Aβ1-40 and dextran by tissue depth in young sham animals,  
(B.)  Correlation plot of dextran and Aβ40 uptake in all experimental groups. (C.)  (i. - iv.) 
Linear regression of dextran vs. Aβ1-40 uptake. A - C, n = 5 - 7, 5 bins/animal.  Data are 
analyzed by a linear mixed effect model to control for within-subject correlations. 
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Figure 4-6.  Lectin staining predicted Aβ1-40 distribution in all experimental groups. 
(A.)  Correlation plot of lectin staining and Aβ1-40 uptake in all experimental groups. (B.) 
Comparison of lectin-Aβ slopes across experimental groups. (C.)  (i. - iv.) Linear regression 
of  lectin vs. Aβ40 uptake and lectin vs. dextran (3 kD) uptake. A - C, n = 5 - 7. Data are 
analyzed by a linear mixed effect model to control for within-subject correlations. 
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4.3.4: DMCAO increased fibronectin and integrin-α5 expression in young and aged 
animals. 
We next examined how the expression of fibronectin changes in the context of the 
PVS, bordered by astrocytic endfeet and the lectin-stained basement membrane matrix.  IHC 
revealed increases in fibronectin expression at 7 DPI (Fig. 4-7A).  To confirm these findings, 
total protein levels of fibronectin and integrin-α5 were then assessed by western blot of the 
peri-infarct cortex (Fig. 4-7B, Fig. 4-8).  Stroke increased fibronectin expression (Fig. 4-7C, 
i., [F(1, 19) = 63.8, p < 0.001]), with no additional effects of aging [F(1, 19) = 0.06, p = 0.81] 
or interaction [F(1, 19) = 0.1, p = 0.733].  In contrast, integrin-α5 levels were increased by 
both DMCAO (Fig. 4-7C, ii., [F(1, 19) = 34.6, p < 0.001]) and aging [F(1, 19) = 5, p = 
0.038], with no significant interaction effect [F(1, 19) = 1.5, p = 0.232].  These data indicate 
that perivascular fibronectin deposition occurred by 7 DPI, which was also accompanied by 
further increases in integrin-α5 expression in aged animals with DMCAO.  We also observed 
acute reductions in LRP1 following DMCAO in aged animals (Fig. 4-9), which may further 
impair the clearance of Aβ1-40 from the basement membrane across the BBB in the aged 
brain.80   
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Figure 4-7.  DMCAO increased the expression of fibronectin and integrin-α5 at 7 DPI. 
(A.) Representative images of fibronectin expression in young and aged animals, taken at 7 
DPI (40X magnification). (B.) Representative blots and quantification of fibronectin, 
integrin-α5 and vinculin (loading control) expression of these proteins at 7 DPI.  Data are 
analyzed by two-way ANOVA with Sidak’s post-hoc test, n = 5 – 7 per group, *p < 0.05, * 
***p < 0.001.  Scale bar = 50 µm. 
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Figure 4-8. DMCAO upregulated the expression of fibronectin and integrin α5 in young 
and aged mice.  Western blot image showing upregulation of basement membrane proteins 
at 3 and 7 DPI in both young and aged mice.  Gels were run in parallel, cut at 100 kD, then 
transferred to the same PVDF membrane.  Proteins were identified by molecular weight 
using Bio-Rad Precision Plus Dual Color standards. 
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Figure 4-9.  DMCAO reduced LRP1 expression in aged mice.  (A.) Quantification of 
LRP1 expression in young and aged mice at 7 DPI.  (B.) Western blot showing reduced 
expression of LRP1 in aged mice with DMCAO.  n = 5 – 7.  Data are analyzed by two-way 
ANOVA with Sidak’s post-hoc test, *p < 0.05. 
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4.3.5: CSF-derived Aβ1-40 colocalized with fibronectin, the integrin-α5 subunit and lectin-
stained basement membrane components, which increased with DMCAO.  
Based on our data showing that aging and DMCAO cause increased association of 
CSF Aβ1-40 with the lectin-stained basement membrane, we next assessed the contribution of 
fibronectin and the integrin family of receptors to this phenotype.  In addition to fibronectin, 
we selected integrin-α5 because previous work has shown that it is strongly expressed in the 
basement membrane,257,258 regulates the binding of multiple beta subunits to fibronectin,259 
and is associated with increased Aβ accumulation in disease states.260   
Image quantification at 30 DPI revealed that DMCAO increased the expression of 
FITC-lectin-stained basement membrane components (Fig. 4-10B, ii., [F(1, 19) = 5.756, p = 
0.0269]).  Aging also exhibited a trend for increased FITC-lectin staining, but it failed to 
reach statistical significance [F(1, 19) = 3.252, p = 0.0872].  Additionally, we found that 
perivascular fibronectin staining increased with DMCAO in both young and aged animals 
(Fig. 4-10B, i., F[1, 12] = 19.5, p < 0.001) and colocalized with the lectin-stained basement 
membrane (Fig. 4-10A). Furthermore, intracisternally injected FITC-Aβ1-40 colocalized with 
fibronectin within the basement membrane across all conditions, and was most apparent in 
aged animals with DMCAO (Fig. 4-10A).  This indicates that fibronectin was a marker of 
sites within the basement membrane that were predisposed to Aβ1-40 deposition, which 
further increased with aging and DMCAO.  This suggests a potential mechanism of Aβ1-40 
deposition via its association with fibronectin. 
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Figure 4-10.  Fibronectin expression colocalized with sites of CSF Aβ1-40 deposition. (A.) 
Colocalization of intracisternally injected FITC-Aβ1-40 with fibronectin occurs within the 
lectin stained basement membrane at low levels in young sham mice, which worsens with 
aging and DMCAO. Low-power images were acquired at 10X magnification, and high power 
images were acquired at 40X magnification.  (B.) Quantification of (i.) fibronectin and (ii.) 
lectin staining at 30 DPI.  n = 3 – 5 per group for all experiments. Data are analyzed by two-
way ANOVA with Sidak’s post-hoc test. *p < 0.05, **p < 0.01.  Scale bar = 200 µm.   
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Despite observing colocalization with Aβ1-40, we did not observe consistent increases 
in fibronectin expression in aged animals.  Therefore, we next explored the impact of aging 
and DMCAO on it’s major receptor, integrin-α5, to determine whether it could further 
modulate Aβ1-40 distribution in the aged brain.  We found that perivascular integrin-α5 
staining in the aged brain further increased with DMCAO, and colocalized with the lectin-
stained basement membrane (Fig. 4-11A).  Furthermore, intracisternally injected FITC-Aβ1-
40 colocalized with integrin-α5 within the basement membrane across all conditions, and was, 
again, most apparent in aged animals with DMCAO (Fig. 4-11A).  Total expression of 
vascular integrin-α5 was highest in aged animals with DMCAO (Fig. 4-11B), with main 
effects of DMCAO (F[1, 12] = 344.6, p < 0.001) and aging (F[1, 12] = 15.1, p = 0.002) on 
increased expression, with a significant interaction effect (F[1, 12] = 27.9, p < 0.001).  
Increased expression of integrin-α5 could alter the affinity of the basement membrane by 
complexing with its major ligand, fibronectin.  Alternatively, it could possess additional 
binding sites for Aβ1-40. 
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Figure 4-11.  Integrin-α5 expression colocalized with sites of CSF Aβ1-40 deposition. (A.) 
Colocalization of intracisternally injected FITC-Aβ1-40 with integrin-α5 occurs within the 
lectin stained basement membrane at low levels in young sham mice, which worsens with 
aging and DMCAO. Low-power images were acquired at 10X magnification, and high power 
images were acquired at 40X magnification.  (B.) Quantification of integrin-α5 staining at 30 
DPI. n = 3 – 5 per group for all experiments.  Scale bar = 200 µm.  Data are analyzed by 
two-way ANOVA with Sidak’s post-hoc test. *p < 0.05, **p < 0.01.  Scale bar = 200 µm. 
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4.3.6: Fibronectin treatment increased the perivascular deposition of CSF Aβ1-40.   
Previous work has suggested that plasma fibronectin may bind serum amyloid species 
via the fibronectin type I domain,217 but there are a lack of studies examining its potential 
affinity to the Aβ1-40 fragment, especially in the context of the brain microenvironment.  
Therefore, to first assess the binding characteristics of fibronectin to Aβ1-40, recombinant 
fibronectin was incubated with 125I-Aβ1-40 (Fig. 4-12A, i.).  We found that fibronectin bound 
Aβ1-40 in vitro with an EC50 of 216 nM (Fig. 4-12A, ii.).  Then, to determine whether 
fibronectin impacted CSF flow or Aβ1-40 deposition, fibronectin or vehicle control was 
incubated with CB-d3 and 647-Aβ1-40, and then injected intracisternally (Fig. 4-12B).  
Fibronectin treatment increased the 647-Aβ1-40/CB-d3 ratio (Fig. 4-12C, [F(1, 8) = 11.2, p = 
0.01]), which decreased with tissue depth [F(4, 32) = 18.1, p < 0.001].  Furthermore, an 
interaction between fibronectin treatment and tissue depth was also observed [F(4, 32) = 3.1, 
p = 0.028].  Treatment did not affect total CB-d3 ([F(1, 8) = 0.05, p = 0.835]) or 647-Aβ1-40 
influx ([F(1, 8) = 0.6, p = 0.468]).  These data demonstrate that fibronectin-Aβ1-40 binding 
occurred, and that this interaction was sufficient to induce the selective accumulation of Aβ1-
40 within the superficial cortex, without impacting bulk CSF influx. 
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Figure 4-12.  Fibronectin conjugation altered the perivascular transport of Aβ1-40. (A.) 
(i.) Experimental design of in vitro fibronectin binding assay. (ii.) Binding kinetics of 
fibronectin and 125I-Aβ1-40. (B.)  Representative images showing increased distribution of 
fibronectin-Aβ1-40 conjugates compared to unconjugated Aβ1-40 following intracisternal 
injection into naïve young mice.  (C.) Comparison of (i.) CB-d3 uptake, (ii.) 647-Aβ1-40 
uptake and (iii.) 647-Aβ1-40/CB-d3 ratio.  n = 5 - 6 per group for all experiments. Data are 
analyzed by Student’s t-test, *p < 0.05. 
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4.3.6: Aging and DMCAO induced impairments in motor function, cognition, and 
exploratory behavior.   
Previous work has shown that young mice develop cognitive impairment after 
DMCAO.11 To evaluate whether aging and DMCAO induced similar behavioral changes in 
our animals, we tested mice on DigiGait, Barnes maze and open field (Fig. 4-3, C-D).  We 
found that stroke induced left forepaw rotation at 3 DPI (Fig. 4-3C, [F(1, 31) = 21.4, p < 
0.0001]), which resolved by 7 DPI ([F(1, 21) = 1.6, p = 0.214).  Aging also induced mild 
forepaw rotation at 3 DPI [F(1, 31) = 4.7, p = 0.037) and 7 DPI [F(1, 21) = 5.6, p = 0.028].  
No significant interaction of aging and DMCAO were observed at 3 DPI [F(1, 31) = 0.9, p = 
0.35] or 7 DPI [F(1, 21) = 1, p = 0.333].  These data indicate that both aging and DMCAO 
induce motor impairment, with DMCAO-induced motor deficits recovering by 7 DPI. 
Aging increased the latency to find the escape hole on the Barnes maze (Fig. 4-3D, 
[F(1, 26) = 8.3, p = 0.008).  No major effect of DMCAO on latency was observed [F(1, 26) = 
1.2, p = 0.287), likely due to a trending interaction between aging and DMCAO [F(1, 26) = 
3.3, p = 0.082), as DMCAO worsened Barnes maze performance in young (Sidak test, p = 
0.049), but not aged animals (p = 0.8784).  Finally, aging reduced total movement on open 
field testing (F(1, 26) = 12.6, p = 0.002), with no effect of DMCAO [F(1, 26) = 0.003, p = 
0.96] or interaction observed [F(1, 26) = 0.06, p = 0.817].  Taken together, these data indicate 
that cognitive deficits existed in conditions of reduced CSF flow, even when motor deficits 
were no longer detectable by gait measurement. 
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4.4: Discussion 
4.4.1: Aging and stroke impair the perivascular flow of CSF through the basement 
membrane.   
 Previous work has shown that aging82 and multiple types of brain injury, including 
traumatic brain injury,261 multiple microinfarction208 and AD,209 all reduce the perivascular 
bulk flow of CSF.  However, it was not previously known whether focal ischemic stroke 
impairs the perivascular flow of CSF.  Furthermore, no study had examined whether normal 
aging or stroke impact the deposition of CSF Aβ1-40 within the basement membrane. 
In agreement with previous studies of CSF influx, we found that both aging and 
stroke impaired the transport of CSF through the basement membrane.  However, we newly 
showed that these effects occured independently of each other: while stroke reduced CSF 
influx in young animals, it showed minimal further reduction in aged animals, who were 
already severely impaired at baseline.  This is surprising, because recent work showed that 
age-related glymphatic impairment significantly worsened with experimental induction of 
multiple microinfarction.208  However, our study differed in several important respects:   
1. Injury model differences. We performed a single, focal stroke (modeled by 
distal MCA occlusion), while their model relied on the induction of 
multiple small infarctions via intravenous latex microbeadbead injection.  
Differences in the pathophysiology of these two diseases could explain 
disparate findings, and suggest that focal and repeated infarction may have 
distinct effects on CSF flow in the aged brain.   
2. Age differences. Their study used 12-month-old mice as their aged 
population, while we used much older 20 month-old mice that are more 
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analagous to elderly stroke patients.  Given that Kress et al. (2014) found 
that CSF influx continues to decline between 12 and 18 months,82 
indicating major differences in baseline CSF flow, these further reductions 
could have made it more difficult to detect stroke-induced impairment in 
our aged animals.   
3. Tracer differences. Third, their study used fluorescent ovalbumin (45 kD), 
while ours used fluorescent dextrans (3 and 2000 kD).  Given that our early 
validation studies, detailed in Chapter 3, showed molecular size-dependent 
distribution of CSF solutes in the basement membrane, it is possible that 
their study measured CSF flow in a different layer of basement membrane 
than where Aβ1-40 (~4.5 kD) is transported. 
Overall, further work using multiple experimental stroke models and differently sized tracers 
is required to definitively determine if stroke worsens age-related impairments in 
perivascular CSF flow. 
In addition to changes in total CSF flow, our study also examined whether aging and 
stroke had specific impacts on the deposition of CSF Aβ1-40.  One recent publication found 
that Aβ1-40 can re-enter the brain from the CSF and associate with pre-existing amyloid 
plaques within the brain parenchymal extracellular space.209  In this case, the distribution of 
Aβ1-40 was altered by binding to these pre-existing plaques, which trapped them within the 
brain tissue rather than allowing them to circulate back out to the cisterns.  Based on these 
data, CSF Aβ1-40 is ideally positioned to contribute to the perivascular Aβ deposits that are 
characteristic of CAA.   
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This novel source of Aβ1-40 could explain several interesting characteristics of CAA 
pathophysiology, including the early involvement of leptomeningeal and penetrating arteries, 
the initial deposition within the basement membrane, as well as the primarily ‘outside-in’ 
cortical distribution of plaques, with worse pathology being observed in the superficial 
cortical layers.  We newly discovered that aging and stroke selectively increase the 
deposition of CSF Aβ1-40, which occurs independently of changes in bulk CSF flow.  This 
finding suggests that other factors, such as the diffusion of Aβ1-40 between glycosylated 
extracellular basement membrane proteins (stained with lectin), play a major role in 
determining the amount and location of Aβ1-40 deposition within the basement membrane, 
particularly in aging and stroke.  One potential implication of this finding is that the 
movement of Aβ1-40 within the PVS cannot be approximated by dextran flux, which is 
problematic for all but one209 of the previously discussed studies of glymphatic flow.  Other 
factors, including the degree of basement membrane glycosylation, play a more important 
role in modulating the distribution of CSF Aβ1-40.  
Overall, my work supports the notion that aging and brain injury both reduce the 
perivascular flow of CSF.  It also newly shows that stroke specifically disrupts the transport 
of CSF-derived Aβ1-40, which correlates with upregulation of lectin-stained basement 
membrane proteins, as well as fibronectin.  This deposition of CSF Aβ1-40 occurs even in 
wild-type mice that do not have pre-existing amyloid plaque pathology.   These studies 
provide a potential new mechanism by which aging and stroke sensitize cortical vessels to 
the development of CAA pathology.   
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4.4.2: Aging and stroke interact to remodel the vascular basement membrane.   
My findings suggest multiple facets of a potential new mechanism of CAA 
development, including both the physiological route of the initial perivascular Aβ deposition 
after stroke, as well as the specific extracellular matrix components that pathologically 
enhance this Aβ deposition after stroke.  While previous studies have examined the 
independent effects of aging and stroke on basement membrane composition,165,181,194 there is 
a significant gap in the literature with respect to the impact of stroke on the aged basement 
membrane.  A better understanding of how aging and stroke impact the regulation of 
basement membrane composition is critical to developing new and effective therapies to 
combat CAA. 
I first examined how aging and stroke impact the overall morphology of the vascular 
network by staining the basement membrane with lectin.  Similar to previous studies, I found 
that stroke increased the density of microvessels.  Following stroke, aged animals also 
produced new vessels.  However, many of these peri-infarct vessels appeared “string-like,” 
which is a sign of nonperfused vasculature.  Given the dependence of bulk flow on the 
pulsation of arteriolar blood vessels, these likely do not contribute to effective CSF flow.  As 
such, these vessels may be the most prone to the development of CAA after stroke, given that 
they exhibited reduced ability to transport CSF through the PVS. 
I then hypothesized that post-stroke basement membrane fibrosis includes chronic 
changes in both fibronectin and a subunit of its receptor, integrin-α5, which together ‘prime’ 
the basement membrane matrix for the binding of CSF-derived Aβ.  Indeed, my findings 
indicate that stroke induces the chronic deposition of extracellular fibronectin as well as 
lectin+ matrix proteins (which are most likely enriched for HSPG) and integrin-α5.  
	   92 
Surprisingly, while the total amount of fibronectin dramatically increased after stroke, this 
response was not different between young and aged animals.  However, I did detect increased 
lectin+ matrix and integrin-α5 expression in aged animals with stroke.  Both of these proteins 
directly interact with fibronectin within the basement membrane.  Given that fibronectin is a 
highly modular protein that is subject to alternative splicing, post-translational modification 
and fibrillogenesis, the “quality” of fibronectin, rather than the “quantity,” may change with 
aging.  Further work with targeted mass spectrometry is needed to sequence fibronectin and 
determine if any of its domains are being altered with aging, and whether this can enhance its 
affinity for Aβ1-40 in aged animals with stroke. 
Overall, I found that stroke chronically alters basement membrane morphology and 
composition in a way that strongly resembles CAA plaques.  These changes are characterized 
by increases in lectin+ matrix and fibronectin content, within foci of basement membrane 
thickening.  Targeting these early changes may help to reduce CAA in stroke survivors. 
 
4.4.3: Fibronectin may trap Aβ1-40 within the basement membrane by multiple 
mechanisms.  
 I found that CSF Aβ1-40  selectively deposited in regions of thickened basement 
membrane, which displayed high levels of lectin+ matrix, fibronectin and integrin-α5.  
Furthermore, I also found that treatment with fibronectin increases CSF Aβ1-40 deposition 
within superficial cortical layers (Fig. 5).  Finally, I confirmed these findings in a cell-free in 
vitro assay, where I found that fibronectin binds Aβ1-40 with high affinity.  Fibronectin may 
impact multiple physiological factors that could play a role in determining the degree to 
which CSF Aβ1-40 becomes deposited in the aged brain, which might be further altered with 
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brain injury such as stroke.  In particular, fibronectin may alter several distinct factors that 
modulate the diffusion of Aβ1-40 through the extracellular space (Reviewed in Syková & 
Nicholson, 2008).202 
First, there is significant evidence that astrogliosis increases the geometric tortuosity 
of brain tissue, which may also apply to the basement membrane.212,262,263  I found that areas 
of increased fibronectin expression also exhibited increased numbers of GFAP+ perivascular 
reactive astrocytes (see Chapter 5), which may act as a cellular barrier to the diffusion of Aβ, 
effectively ‘trapping’ it within the PVS.  Second, post-stroke angiogenesis, which also 
involves fibronectin, may induce the focal trapping of CSF solutes by increasing the volume 
of physiologic dead space within the PVS (i.e. regions that do not participate in CSF flow).  I 
found that stroke increased the thickness of the lectin-stained basement membrane, which 
also exhibited increased branching and lacunarity.  Third, fibronectin overexpression may 
increase the viscosity of the basement membrane, which could trap CSF Aβ1-40.  Previous 
work has shown that cortical stab wound in rats leads to local astrogliosis and increased 
deposition of numerous ECM proteins throughout the injured hemisphere, although 
fibronectin levels were not examined.264  However, the above factors appear to play a minor 
role in Aβ1-40 deposition due to the fact that we did not observe the same increases in size-
matched dextran levels, as examined the preceding chapter.  This points to a specific property 
of Aβ1-40 that is independent of molecular weight, which we investigated in the present 
experiments. 
Rather than exploring these more nonspecific mechanisms, we evaluated whether 
fibronectin was a novel ECM receptor for CSF Aβ1-40, which could explain the unique 
pattern of deposition that we observed in the basement membrane.  Increased fibronectin may 
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positively charge the basement membrane,265 which could contribute to selective binding of 
negatively charged CSF proteins, such as Aβ40 peptide (pI = 5.17).  Under normal conditions, 
the basement membrane retains a negative charge due to the high glycosaminoglycan 
content.241  This protective effect may be lost following injury due to increases in positively 
charged proteins, including fibronectin, although this may be balanced in some regions with 
increases in HSPG content, although this would need to be verified by more specific staining. 
Due to its charge, numerous potential binding sites and its central role in the assembly 
of the basement membrane, increases in fibronectin may selectively mediate the deposition 
of CSF Aβ1-40 by direct binding.  Previous work has shown that plasma fibronectin binds 
aggregated amyloid proteins via the Type 1 domain, and colocalizes with amyloid plaques in 
human AD brain sections.217  I newly found that fibronectin bound soluble Aβ1-40 in vitro 
with high affinity, and that these conjugates deposited more readily within the murine 
basement membrane than free Aβ1-40.  This suggested an additional binding partner, which Ι 
identified as integrin-α5, which strongly colocalized with the distribution of Aβ1-40 in all 
conditions.  Overall, these data indicate that fibronectin binds soluble Aβ1-40, which then 
becomes sequestered in the basement membrane by binding to integrin-α5.  These 
interactions most likely occur via Type I and Type III fibronectin domains, respectively.  
However, more work with specific blocking antibodies or fibronectin mutants are required to 
confirm the specific amino acid residues that are involved in this process. 
This work clearly establishes the role of fibronectin and integrin-α5 in contributing to 
the initial phases of post-stroke CSF Aβ1-40  deposition via direct binding to the Aβ1-40 
peptide, especially in aged animals.   While other factors such as increased cellularity, dead 
space and viscosity generally impair the bulk flow of solutes deep into the brain, within the 
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superficial layers of cortex, I found that even low levels of bulk flow supported abnormal 
Aβ1-40 deposition within peri-infarct vessels.   
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CHAPTER 5 
TGF-β Stimulates A2 Astrocytes to Remodel the Basement Membrane  
and Impair the Perivascular Flow of CSF After Stroke 
 
5.1: Introduction 
5.1.1: Overview.   
The results outlined in the preceding chapters demonstrate that aging and stroke 
simultaneously impair the bulk flow of CSF and induce the perivascular deposition of CSF-
derived Aβ1-40.  They further indicate that fibronectin/integrin-α5 complexes contribute to 
this phenomenon by sequestering soluble CSF Aβ1-40 within the basement membrane, and 
that they may also act as a physical barrier to perivascular CSF flow.  Importantly, these 
complexes could be expressed by perivascular astrocytes, providing a link between reactive 
astrogliosis, abnormal AQP4 expression and Aβ1-40 deposition.  However, it is not known 
how stroke and TGF-β alters the phenotype of perivascular astrocytes, or whether these 
ubiquitous cells are the major source of fibronectin and integrin-α5 expression after stroke.   
 
5.1.2: Significance.   
Astrocytes are the most common glial cell in the brain,266 and are in direct 
communication with neurons,267 oligodendrocytes,268 microglia240 and blood vessels.91  In 
addition to maintaining homeostasis under normal conditions,269 astrocytes possess a pre-
programmed response that becomes activated with neuroinflammatory insults,240 including 
brain injuries such as stroke, termed ‘reactive astrogliosis.’239  When exposed to noxious 
stimuli, astrocytes upregulate a set of ‘pan-reactive’ genes, including increased expression of 
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intermediate filaments such as GFAP and vimentin,239 which allow the astrocytes to orient 
towards the site of inflammation, hypertrophy and form a glial scar to contain the source of 
the stimulus.270  These responses may become dysregulated with aging, necessitating the use 
of aged animal models to develop therapies that reflect the average human stroke patient.  
Exciting new research suggests that astrocytes can tune their responses to the specific 
type of injury, generally falling into two broad polarization states, termed ‘A1’ and ‘A2’.239  
The so-called ‘A1’ astrocytes are stimulated via microglial secretion of pro-inflammatory 
cytokines, including interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α 
(TNF-α), which induce a set of genes that impairs their ability to regulate synaptic function, 
inhibits AQP4 polarization to astrocytic endfeet, alters their production of ECM products, 
and causes the secretion of as-yet undiscovered products that cause direct neurotoxicity.240  
In addition to these acute responses, baseline A1 activation also increases over the course of 
normal aging, and could further impact the responses of the aged brain to acute 
neuroinflammation.271   
Surprisingly, following middle cerebral artery occluision (MCAO) in young animals, 
astrocytes instead take on an ‘A2’ phenotype,239 but comparatively little is known about their 
functionality or regulation.  Unlike A1 astrocytes, A2 astrocytes could be stimulated by pure 
hypoxia, or require co-stimulation with other cytokines, such as TGF-β, to effectively make 
this transition to an A2 phenotype.  Furthermore, while it is tempting to ascribe a ‘beneficial’ 
role for A2 astrocytes in brain injury, there is no definitive evidence to support this notion.  
As such, the functionality of the A2 astrocyte still needs to be elucidated by more 
mechanistic studies.  Even if A2 astrocytes play a beneficial role in young animals, these 
responses may also change in the aged brain, which alters the extracellular microenvironent 
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in numerous ways, including a predisposition to increased TGF-β signaling and Aβ 
pathology.  Overall, more research is needed to better understand how A2 astrocytes shape 
their responses to ischemia, and whether this changes with aging. 
TGF-β has been shown to reverse the activation of A1 astrocytes,240 returning them to 
a more undifferentiated, ‘pan-reactive’ state.  However, TGF-β signaling may play a different 
role in ischemia-activated A2 astrocytes.  Previous work indicates that TGF-β levels are 
elevated in mouse models of CAA,218 and that overexpression of TGF-β in wild-type mice 
leads to reactive astrogliosis, fibronectin expression and microvascular damage.219,220  
Previous work in young animals has shown that knockout of astrocytic TGF-β signaling has 
been shown to reduce astrocyte activation and inhibit the formation of a GFAP+ glial scar 
after stroke, but this was associated with worse functional recovery.229  This suggests that A2 
astrocytes may respond differently to TGF-β than their A1 counterparts, instead being 
stimulated by TGF-β, rather than inhibited.  This responsivity to TGF-β may also differ in 
aging, as they shift to a more A1 phenotype at baseline.271  It is not known how TGF-β 
antagonism affects astrocyte activation or functional recovery in the aged animals with 
stroke, who may be more sensitive to its negative, pro-fibrotic effects.223,233 
Following stroke, aging could alter the specific levels of different TGF-β isoforms, or 
shift the balance of downstream signaling pathways, such as the canonical Smad signaling 
cascade.221  While previous work has focused on post-stroke Smad2 activation by 
phosphorylation,223 Smad3 is actually the major Smad isoform that is involved in modulating 
protein expression via direct binding to DNA.272  Phosphorylated Smad3 levels have been 
previously shown to disproportionately increase with fibrotic diseases in aged animals, 
including pulmonary fibrosis273 and skeletal muscle degeneration.274  Furthermore, Smad3 
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knockout has been shown to reduce renal and cardivascular fibrosis, and improve function, in 
a mouse model of renovascular hypertension.275  Similar results were found in a mouse 
model of hepatic fibrosis, with Smad3 knockouts exhibiting reduced fibrosis after liver 
injury.276  In the brain, Smad3 induces APP expression by astrocytes, due to binding to the 
zinc finger nuclear factor, CTCF.277  Furthermore, inhibiting Smad2/3 activation in innate 
immune cells prevented the formation of amyloid pathology in Tg2576 mice, an animal 
model of Alzheimer’s disease.278 While much of this data indicates that TGF-β-Smad3 
signaling is a major driver of fibrosis in age-related diseases, it is not known how this 
pathway impacts the function of perivascular astrocytes in aging or stroke, and whether this 
is specifically associated with altered AQP4 expression and basement membrane fibrosis.  As 
we described in the preceding chapter, these changes in the perivascular niche may sensitize 
the brain to the development of CAA by reducing perivascular CSF flow and increasing the 
affinity of the basement membrane for CSF Aβ1-40. 
Overall, the role of TGF-β during brain injury remains controversial, and the few 
studies performed in aged animals suggest a detrimental effect of astrocytic TGF-β signaling.  
Astrocytic endfeet form the outer wall of the PVS, and regulate the composition of the outer 
basement membrane, which is involved early in the pathogenesis of CAA.181,196  
Furthermore, reactive astrocytes are associated with impaired CSF flow during normal 
aging,235 multiple microinfarction,236,237 traumatic brain injury235  and Alzheimer’s 
disease.209,238  However, the relationship between TGF-β, perivascular astrocytes and 
perivascular CSF flow is not well understood.  Additionally, dysregulated TGF-β signaling, 
which may occur after stroke in the aged brain,223 could further impact A2 responses to 
ischemic injury and induce the abnormal production of ECM proteins, such as 
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fibronectin/integrin-α5 complexes.  Therefore, I hypothesize that TGF-β signaling in aging 
stimulates A2 astrocytes to further impair AQP4-mediated water uptake and increase 
basement membrane fibrosis.  I further hypothesize that inhibiting TGF-β signaling will 
improve perivascular CSF flow and reduce CSF Aβ1-40 deposition in aged mice with 
DMCAO.  
 
5.1.3: Experimental design.   
Our first aim was to fully evaluate the molecular and cellular mediators underlying 
basement membrane remodeling and alterations in CSF flow after stroke.  Therefore, we first 
hypothesized that aging worsens post-stroke reactive gliosis due to altered TGF-β signaling.  
We further hypothesized that TGF-β activates A2 astrocytes to secrete fibronectin and 
downregulate AQP4 expression, two major factors that impact perivascular CSF flow.  To 
test this hypothesis, we first performed DMCAO and examined GFAP, vimentin, AQP4, 
Smad2/3 phosphorylation and TGF-β levels at 7 DPI.  Then, we cultured primary cortical 
astrocytes from both P1 wild-type pups, and examined how oxygen glucose deprivation 
(OGD), an in vitro model of ischemia,257 differentially impacts activation and phenotype by 
gene microarray, western blot and immunocytochemistry (ICC).  Next, we examined whether 
TGF-β and Aβ1-40 co-stimulation induced changes in gene/protein expression by the same 
methods, and additionally examined how they affected in vitro FITC-Aβ1-40 deposition and 
3H2O uptake. Finally, we verified our results in vivo and measured whether intracisternal 
TGF-β injection increased perivascular gliosis, fibronectin expression and reduced the bulk 
flow of CSF (measured by intracisternal injection of 3H2O and 14C-Inulin). 
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We next hypothesized that TGF-β signaling to astrocytes is the major driver of 
basement membrane fibrosis and reductions in CSF flow after stroke. To test this hypothesis 
in vivo, we first performed DMCAO in young and aged wild-type mice, and measured 
astrocyte reactivity and TGF-β expression after stroke.  To explore the potential translational 
relevance of global TGF-β inhibition, we performed DMCAO in aged mice and treated them 
with a continuous peripheral infusion of a TGF-βR1/R2 antagonist (GW788388 Hydrate), 
then measured the impact of chronic treatment on histology, physiology and functional 
outcomes. 
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5.2: Methods 
5.2.1: Animals.   
All assays were performed using tissues and cells derived from Mus musculus 
(C57/Bl6).  For aging studies, young (3 month-old, Charles River) and aged (20 month-old, 
National Institute of Aging) wild-type male mice were obtained and housed simultaneously 
within UT Health for at least 2 weeks prior to beginning any experiments. In all cases, mice 
were fed standard dry chow ad libitum, and kept on a 12-hour light-dark cycle.  Additionally, 
mice were examined regularly by the veterinary staff, as well as trained members of the lab 
for any signs of illness following DMCAO, or gross pathology following sacrifice.  All 
protocols were approved by the UTHealth IACUC and carried out in an AAALAC-approved 
facility.  Finally, animals were randomized to experimental conditions, and investigators 
were blinded to treatment.  
 
5.2.2: Experimental stroke model.   
Permanent DMCAO was performed as described in Chapter 4.  Briefly, mice were 
anesthetized with isoflurane, the dorsolateral cranium was incised and a burr hole was drilled 
to expose the MCA.  Following brief MCA cauterization to induce ischemia, the burr hole 
was closed with dental cement, and the incision sutured.  Sham surgeries were performed 
without cauterization.  All surgeries were performed under aseptic conditions, and mice were 
periodically monitored for signs of pain, infection or weight loss following the procedure. 
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5.2.3: Animal sacrifice.   
Mice were deeply anesthetized with Avertin (250 mg/kg), then the ventral abdomen 
was incised and the ribcage was reflected to expose the heart muscle.  An 18-gauge butterfly 
needle was then placed into the left ventricle, and the right atrium opened with a small 
incision. Mice were perfused with ice-cold PBS supplemented with 0.2% heparin using an 
automated pump set to a rate of 10 mL/min, until draining perfusates became clear.  For 
studies requiring fresh tissue, brains were then extracted, cortices dissected from underlying 
structures and then snap-frozen on dry ice for future assays.  For studies requiring fixed 
tissue, mice were first perfused with ice-cold 4% PFA for 5 minutes, and brains were then 
extracted and post-fixed in 4% PFA at room temperature for 24 hours, then dehydrated/stored 
in 30% sucrose at 4°C prior to sectioning. 
 
5.2.4. Immunohistochemistry.  
Fixed brain sections (24 µm thickness) were mounted onto slides, then washed for 3 x 
5 minutes in wash buffer (Tris Buffered Saline + 0.1% Tween).  Following this, heat-
mediated antigen retrieval was performed in 100 mM Sodium Citrate buffer + 0.1% Tween at 
95°C for 20 minutes in a vegetable steamer.  Slides were washed 3 x 5 minutes, then 
incubated for 2 hours in blocking buffer (wash buffer supplemented with 0.5% Triton-X, 1% 
BSA and 5% normal goat serum) for 2 hours.  Then, slides were incubated in blocking buffer 
with anti-GFAP-Cy3 (Mouse, 1:1000, Millipore Sigma, cat. C9205), Lycopersicon 
esculentum lectin (1:100, Vector Laboratories, cat. DL-1177), anti-AQP4 (Rabbit, 1:5000, 
Millipore Sigma, cat. HPA014784), anti-integrin-α5 (Rabbit, 1:100, abcam, cat. EPR7854) or 
anti-fibronectin (Rabbit, 1:100, abcam, cat. ab2413) antibodies.  Then, slides were washed 3 
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x 5 minutes, then incubated with secondary antibodies in blocking buffer (anti-Rabbit (Goat, 
abcam, Alexa-Fluor, 1:500, λ = 488, 594 or 647 nm).  Following a final 3 x 5 minute 
washing step, slides were submerged in Tris-Buffered Saline, then cover-slipped with 
Vectashield containing DAPI (Vector Laboratories, cat. H-1200).   
 
5.2.5: Protein isolation, SDS-PAGE and western blotting.   
The right cortex was thawed on ice and manually homogenized in buffer containing 
1% NP-40, 1 mM PMSF, cOmplete (Roche) and PhosSTOP (Roche).  Following sonication 
and centrifugation, the supernatant was removed and diluted to 4 mg/mL in 4x Laemmli 
Sample Buffer (Bio-Rad, cat. 161-0737) supplemented with 4% β-mercaptoethanol, then 
heated to 95°C for 5 minutes.  Following sample preparation, 10 µL (40 µg) of each lysate 
was run on a 4-15% Criterion TGX 26-well gels (Bio-Rad, cat. 5671085) at 120V for 60 
minutes.  Protein bands were subsequently transferred to a PVDF membrane, blocked in 5% 
BSA or non-fat dry milk and probed with anti-fibronectin (Rabbit, 1:1000, abcam, cat. 
ab2413), anti-α5 Integrin (Rabbit, 1:1000, abcam, cat. EPR7854), anti-Vimentin (Rb, 
1:1000, abcam, cat. ab9257), anti-GFAP (Rabbit, 1:500, Cell Signaling, cat. 12389S), anti-
pSmad2/3 (Rabbit, 1:500, Cell Signaling, cat. 8828S), anti-Smad2/3 (Rabbit, 1:500, Cell 
Signaling, cat. 8685S), anti-β-actin (Mouse/HRP conjugated, 1:50,000, Sigma, cat. A3854) 
or anti-vinculin antibody (Rabbit, 1:10,000, abcam, cat. EPR8185).  Blots were then probed 
with HRP-conjugated goat anti-rabbit secondary antibody (1:10,000, Vector Laboratories, 
cat. PI-1000) and imaged using a Bio-Rad ChemiDoc Imager. 
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5.2.6: Multiplex assays.   
The absolute level of TGF-β1 was quantified using a Bio-Plex Pro TGF-β 3-Plex 
Assay (Bio-Rad, cat. 171W4001M).  Briefly, cortical lysates were diluted to 8 mg/mL in 
NP40 buffer, then underwent acid-mediated antigen retrieval and were further diluted in 
dH2O to a final concentration of 1 mg/mL, and supplemented with 0.5% BSA.  Plates were 
loaded and incubations/washes were performed according to the manufacturer’s instructions.  
Following this, plates were read with the Luminex-based Bio-Plex 200 (Bio-Rad) using the 
manufacturer’s protocol, and unknown values interpolated with the Bio-Plex Manager 
Software (Bio-Rad). 
 
5.2.7: Cell culture techniques 
• Harvesting of primary cortical astrocytes. Mouse pups (P1) were anesthetized on ice, 
cleaned with 70% ethanol, and decapitated.  Then, under a laminar flow hood, brains 
were extracted from the cranium with blunt forceps and placed in sterile Hank’s 
Balanced Salt Solution (HBSS, Ca2+/Mg2+-free) in a sterile 3 cm petri dish under a 
dissecting microscope.  The meninges were then removed and the cortex was 
separated from the underlying brain structures with sharp forceps.  Isolated cortices 
were then placed in fresh, sterile, ice-cold HBSS (Ca2+/Mg2+-free) prior to digestion.  
Once all cortices were harvested, the tissue was placed in enzymatic digestion buffer 
(MACS Neural Dissociation Kit [~400 µL/brain]), manually disrupted by passing 
through a P200 pipet tip 15-20 times, and then digested for 30 minutes at 37°C.  
Digests were visually inspected for any remaining clumps, and passed through a P200 
pipet tip an additional 15-20 times until a grossly homogenous solution was obtained.  
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The enzymes were then quenched via the addition of 600 µL of HBSS (with 
Ca2+/Mg2+) per brain, and the total mixture was then centrifuged at 600 x g for 10 
minutes at room temperature.  Cells were washed with 1 mL HBSS, centrifuged and 
then resuspended in 1 mL cell culture media (Dulbecco’s modified eagle medium 
[DMEM], 10% Fetal Bovine Serum [FBS], 1% Penicillin-Streptomycin) per brain.  
Cells were then stained with Trypan Blue and counted using the Countess II 
Automated Cell Counter (Thermo Fisher).  Finally, cells were then diluted and plated 
on Poly-D-Lysine-coated 12-well plates or glass cover slips at a density of ~2 x 105 
live cells/well.   
• Maintenance and purification of primary astrocytes.  At 1 day in vitro (1 DIV), the 
media was changed to remove dead cells and other debris, then replaced once weekly 
until the completion of experiments.  Cells were examined periodically to monitor 
growth and check for signs of bacterial or fungal contamination.  Following 
confluence of the astrocyte monolayer, the remaining microglia were then depleted at 
14 DIV by exposure to a 50 mM solution of leucine methyl ester (pH = 7.4) for 2 
hours, as previously described.279 To further increase the efficacy of the depletion, 
plates were then shaken at 200 revolutions per minute (RPM) for 4 hours at 37°C, and 
the media exchanged.  The following day, the media was changed again to remove 
any floating (dead) microglia, and the astrocyte monolayer was visually inspected 
under polarized light to confirm successful microglial depletion (fewer than 5% of 
visible cells by area).   
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• Oxygen-glucose deprivation and peptide stimulation. Oxygen-glucose deprivation 
(OGD) and peptide stimulation experiments were carried out at 19 – 21 DIV in a 
balanced salt solution (BSS) containing 125 mM NaCl, 5 mM KCl, 1.2 mM 
NaH2PO4, 26 mM NaHCO3, 1.8 mM CaCl2, 0.9 mM MgCl2, 10 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), supplemented with 10 mM 
glucose for normoxic (NO) controls.   Cultures were washed with NO or OGD media 
3 times prior to the experiment to remove any serum or antibiotics present in the 
normal culture media.  Recombinant human TGF-β1 (Peprotech) and Aβ1-40 
(Anaspec) was reconstituted in BSS, then diluted to a working concentration of 3 
ng/mL and 10µM, respectively.  Immediately prior to OGD, media was equilibrated 
with 5% CO2 balanced with nitrogen.  Following the addition of equilibrated media, 
cells were placed in a warmed hypoxic chamber and OGD performed for 6 hours.  
Then, cells were re-oxygenated and either placed on ice and immediately harvested 
(acute studies), or culture media was supplemented with 10 mM glucose and cells 
were allowed to survive for 18 hours at 37°C (chronic studies).   
• Isolation of protein from primary cells.  Cells were lysed in 200 µL 
radioimmunoprecipitation assay buffer (RIPA) buffer (Sigma) supplemented with 1 
mM PMSF (Sigma), cOmplete (Roche) and Phos-Stop (Roche).  Cells were manually 
disrupted with a P200 pipet tip, then sonicated on ice for 10 seconds.  Lysates were 
then centrifuged at 18,000 x g for 20 minutes at 4°C.  Finally, supernatants were 
removed, aliquoted and stored at -80°C prior to further assays. 
 
	   108 
• Astrocytic 3H2O uptake studies. Primary astrocytes were washed 3 x 5 minutes in 
BSS with glucose, then exposed to 1 x 106 CPM of 3H2O at 37°C for 30 minutes at 
room temperature.  Exposing empty wells to 3H2O controlled for background 
radioactivity and nonspecific binding of 3H2O to the culture vessel.  Then, cells were 
rapidly washed with fresh BSS and immediately lysed in Solvable (see Liquid 
scintillation counting methods).  
• Astrocytic Aβ1-40 uptake studies.  Coverslips containing live cells were incubated in 
NO/OGD culture media supplemented with 2 µM FITC-Aβ1-40 or PBS control at 
37°C for 30 minutes.  Following this, coverslips were washed 3 times with PBS, then 
fixed with 4% PFA for 10 minutes.  Fixed coverslips were stored at 4°C in PBS prior 
to ICC and imaging studies. 
• Immunocytochemistry. Coverslips were first washed with wash buffer (50 mM Tris-
HCl buffer [pH = 7.8]) 3 x 5 minutes.  Then, heat-mediated antigen retrieval was 
performed in 100 mM Sodium Citrate buffer + 0.1% Tween at 95°C for 5 minutes in 
a microwave oven (10% power).  After cooling to room temperature, coverslips were 
again washed 3 x 5 minutes in wash buffer, then blocked with triton-carrageenan-
TBS (TCT) solution (1% Carrageenan, 0.5% Triton-X) for 30 minutes at room 
temperature.  Next, coverslips were incubated overnight at 4°C with primary 
antibodies (GFAP, 1/1000; AQP4, 1/500; Fibronectin, 1/500; and/or Integrin-α5, 
1/500).  The following day, coverslips were washed 3 x 5 minutes with detergent 
wash buffer (50 mM Tris-HCl buffer + 0.1% Triton-X [pH = 7.8]), then incubated 
with anti-Rabbit secondary antibodies (1/1000) in TCT for 1 hour at room 
temperature.  After washing for 3 x 5 minutes with detergent wash buffer, coverslips 
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were then submerged in regular wash buffer, then dipped in dH2O and mounted with 
Vectashield + DAPI (Vector Laboratories), then sealed with nail polish.  Slides were 
allowed to cure for 3 days at 4°C prior to imaging.  To control for potential 
background fluorescence, secondary controls were exposed to identical conditions, 
except for incubation with the secondary antibody. 
• Isolation of RNA from primary cells. RNA was harvested and purified using the 
RNEasy Mini Kit (Qiagen) according to the manufacturer’s instructions.  Briefly, 
cells were directly lysed by immersion in lysis buffer supplemented with 1% β-
mercaptoethanol.  Then, lysates were transferred to eppendorf tubes and thoroughly 
vortexed at high speed to ensure complete lysis of cells.  Next, ethanol was added to a 
concentration of 35% and the mixture transferred to the RNEasy spin column.  
Following DNAse treatment and repeated washes, RNA was then eluted into RNAse 
free water, then stored at -80°C prior to use. 
 
5.2.8: Synthesis of complementary DNA.  
Complementary DNA (cDNA) was generated using the iScript cDNA Synthesis Kit 
(Bio-Rad) according to the manufacturer’s instructions.  Briefly, in each sample, messenger 
RNA (mRNA) quality and content was estimated by measuring absorbance (260/280 nm) 
with the Nanodrop 2000 (Thermo Fisher), and then concentrations were normalized by 
dilution with RNAse-free dH2O.  Then, 25 µg of RNA was loaded into the cDNA synthesis 
reaction containing 4 µL of RT supermix.  These mixtures were then incubated in a thermal 
cycler (Bio-Rad, CFX96 Touch) for 5 minutes at 25°C (priming step), then 20 minutes at 
42°C (reverse transcription step), then 5 minutes at 85°C (RT inactivation step), and finally 
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cooling to 4°C.  Following this, the newly synthesized cDNA was then transferred to a fresh 
eppendorf tube and stored at -80°C prior to performing qPCR assays. 
 
5.2.9: qPCR measurement of gene expression.  
Gene expression was measured using custom PrimePCR Microarrays (Bio-Rad).  To 
carry out each assay, cDNA samples were diluted 1:1 with dH2O, then 19 µL of diluted 
cDNA was mixed with 331 µL of dH2O and 350 µL of SYBR green (Bio-Rad) to a final 
volume of 700 µL.  Then, 10 µL of this mixture was loaded into wells pre-loaded with 
primers (Table 6-1), a genomic DNA control, two RNA quality controls, a no reverse 
transcriptase control or a PCR positive control.  Then, reactions were incubated in a thermal 
cycler (Bio-Rad CFX384 Touch), and gene expression measured over 39 cyclic amplification 
steps, according to the manufacturer’s instructions. 
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Gene Information Assay Information 
Symbol Gene Name Assay ID Length  Design 
Agrn agrin qMmuCID0006603  70 Intronic  
Amigo2 adhesion molecule with Ig like domain 2  qMmuCED0049592  99 Exonic  
App amyloid beta (A4) precursor protein  qMmuCID0017777  88 Intron-spanning  
Aspg asparaginase homolog (S. cerevisiae)  qMmuCID0027304  161 Intron-spanning  
B3gnt5 beta-1,3-N-acetylglucosaminyltransferase 5  qMmuCED0039654  120 Exonic  
Ccl11 chemokine (C-C motif) ligand 11  qMmuCED0044849  83 Exonic  
Cd109 CD109 antigen  qMmuCED0049647  74 Exonic  
Cd14 CD14 antigen  qMmuCED0049648  99 Exonic  
Cd44 CD44 antigen  qMmuCED0061009  86 Exonic  
Clcf1 cardiotrophin-like cytokine factor 1  qMmuCED0040924  94 Exonic  
Col16a1 collagen, type XVI, alpha 1  qMmuCID0024725  167 Intron-spanning  
Cp ceruloplasmin  qMmuCED0045372  89 Exonic  
Cxcl10 chemokine (C-X-C motif) ligand 10  qMmuCED0049500  84 Exonic  
Cxcl13 chemokine (C-X-C motif) ligand 13  qMmuCID0006355  118 Intron-spanning  
Cxcl16 chemokine (C-X-C motif) ligand 16  qMmuCED0044879  96 Exonic  
Emp1 epithelial membrane protein 1  qMmuCED0038081  115 Exonic  
Fbln5 fibulin 5  qMmuCED0044306  77 Exonic  
Fkbp5 FK506 binding protein 5  qMmuCED0046340  84 Exonic  
Fn1 fibronectin 1  qMmuCED0045687  61 Exonic  
Gapdh glyceraldehyde-3-phosphate dehydrogenase  qMmuCED0027497  75 Exonic  
Gbp2 guanylate binding protein 2  qMmuCED0048024  74 Exonic  
Gfap glial fibrillary acidic protein  qMmuCID0020163  107 Intron-spanning  
Ggta1 glycoprotein galactosyltransferase alpha 1, 3  qMmuCID0017837  108 Intron-spanning  
H2-D1 histocompatibility 2, D region locus 1  qMmuCED0041320  60 Exonic  
H2-T23 histocompatibility 2, T region locus 23  qMmuCED0040619  100 Exonic  
Hsbp1 heat shock protein 1  qMmuCED0038398  88 Exonic  
Hspg2 perlecan (heparan sulfate proteoglycan 2)  qMmuCID0021282  119 Intron-spanning  
Iigp1 interferon inducible GTPase 1  qMmuCED0038266  77 Exonic  
Il6 interleukin 6  qMmuCED0045760  70 Exonic  
Il10 interleukin 10  qMmuCED0044967  84 Exonic  
Itga5 integrin alpha 5 (fibronectin receptor alpha)  qMmuCID0015586  103 Intron-spanning  
Itgb1 integrin beta 1 (fibronectin receptor beta)  qMmuCED0046395  89 Exonic  
Lcn2 lipocalin 2  qMmuCED0045799  64 Exonic  
Osmr oncostatin M receptor  qMmuCID0005690  82 Intron-spanning  
Psmb8 proteasome subunit, beta type 8 qMmuCED0045963  114 Exonic  
Ptgs2 prostaglandin-endoperoxide synthase 2  qMmuCED0047314  107 Exonic  
Ptx3 pentraxin related gene  qMmuCED0026777  105 Exonic  
S1pr3 sphingosine-1-phosphate receptor 3  qMmuCID0020240  190 Intron-spanning  
S100a10 S100 calcium binding protein A10 (calpactin)  qMmuCED0049492  119 Exonic  
Sdc2 syndecan 2  qMmuCED0046013  97 Exonic  
Serpina3n serine peptidase inhibitor, clade A, member 3N  qMmuCED0044644  90 Exonic  
Serping1 serine peptidase inhibitor, clade G, member 1  qMmuCED0060967  107 Exonic  
Slc10a6 solute carrier family 10, member 6  qMmuCID0027010  141 Intron-spanning  
Sphk1 sphingosine kinase 1  qMmuCED0040475  61 Exonic  
Spp1 secreted phosphoprotein 1  qMmuCED0061675  93 Exonic  
Srgn serglycin  qMmuCID0009102  143 Intron-spanning  
Steap4 STEAP family member 4  qMmuCID0017408  119 Intron-spanning  
Tbp1 TATA box binding protein  qMmuCID0040542  102 Intron-spanning  
Tgfb1 transforming growth factor, beta 1  qMmuCED0044726  116 Exonic  
Tgfb2 transforming growth factor, beta 2  qMmuCID0024408  108 Intron-spanning  
Tgfb3 transforming growth factor, beta 3  qMmuCED0045203  61 Exonic  
Tgfbr1 transforming growth factor, beta receptor I  qMmuCID0026554  80 Intron-spanning  
Tgm1 transglutaminase 1, K polypeptide  qMmuCID0022777  169 Intron-spanning  
Thbs1 thrombospondin 1  qMmuCED0048851  105 Exonic  
Timp1 tissue inhibitor of metalloproteinase 1  qMmuCED0044729  92 Exonic  
Tm4sf1 transmembrane 4 superfamily member 1  qMmuCED0047458  113 Exonic  
Tnf tumor necrosis factor  qMmuCED0004141  119 Exonic  
Uggt1 UDP-glucose glycoprotein glucosyltransferase 1  qMmuCID0005905  110 Intron-spanning  
Vim vimentin  qMmuCED0046651  60 Exonic  
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Table 5-1. PCR assay design. Bio-Rad PrimePCR assays were selected and custom 384-
well plates created to independently measure the expression of 54 genes.   
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5.2.10: Intracisternal injection protocols 
• TGF-β injections.  As described in Chapter 3, aCSF containing Na+ (150 mM), 
HCO3 (24.1 mM), K+ (3 mM), Ca2+ (1.4 mM), P (1.0 mM) and Mg (0.8 mM) was 
prepared in sterile Ultrapure Water.  Then, recombinant human TGF-β1 was 
reconstituted in aCSF at a concentration of 50 ng/µL and stored at -20°C prior to 
experiments.   To perform the injection, mice were anesthetized with an 
intraperitoneal injection of Ketamine (120 mg/kg) and Xylazine (10 mg/kg), then 
placed in a stereotaxic frame.  Following exposure of the dorsal neck musculature, the 
needle was inserted into the cisterna magna.125 Then, TGF-β1 or vehicle control was 
infused into the cisterna magna at a rate of 2 µL/min over 5 minutes, after which mice 
were transferred to a warmed cage and allowed to survive for 24 hours prior to 
sacrifice. 
• Radiotracer injections.  For studies involving radioactive tracers, stock solutions of 
14C-Inulin (Perkin Elmer, ~2 x 105 CPM/uL) and 3H2O (Perkin Elmer, ~2 x 106 
CPM/uL) were dissolved in aCSF and radioactivity normalized via liquid scintillation 
counting.  Then, stock solutions were combined to a final concentration of 1 x 105 
CPM/uL 14C-Inulin and 1 x 106 CPM/uL 3H2O in aCSF.  Tracer mixtures were kept 
on ice for up to 4 hours, then vortexed for 5 seconds immediately prior to infusion.  
Tracer was infused into the cisterna magna at a rate of 2 µL/min over 5 minutes, after 
which mice were transferred to a warmed cage.  Finally, 30 minutes after beginning 
the injection, mice were sacrificed by Avertin overdose (250 mg/kg).  For radiouptake 
measurement, fresh brains were extracted and cortex isolated, then snap frozen and 
stored at -80°C for later processing. 
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• Fluorescent tracer injections.  For studies involving fluorescent tracers, lyophilized 
FITC-Aβ1-40 (100 µM stock, Anaspec) and lysine-fixable 3 kD TR dextran (TR-d3, 
3,000 MW, 4% stock, Thermo Fisher) were subsequently dissolved in aCSF, then 
combined to a final solution of 10 µM FITC-Aβ1-40 and 2% TR-d3. In all cases, tracer 
mixtures were kept on ice for up to 4 hours, then vortexed for 5 seconds immediately 
prior to infusion. Tracer was infused into the cisterna magna at a rate of 2 µL/min 
over 5 minutes, after which mice were transferred to a warmed cage.  Finally, 30 
minutes after beginning the injection, mice were sacrificed by Avertin overdose (250 
mg/kg).  Then, transcardial perfusion with 0.2% heparin-PBS, and 4% PFA was 
performed, and brain tissue was then removed and stored in 4% PFA for subsequent 
processing.   
 
5.2.11: Alzet pump implantation.  
To administer the equivalent of ~10 mg/kg/day dosage of TGF-βR1/R2 antagonist 
(GW788388 Hydrate), 10 mg of lyophilized GW788388 Hydrate was reconstituted in a 
solution of 50% DMSO, 12.5% ethanol and 37.5% water, then loaded into implantable Alzet 
mini osmotic pumps according to the manufacturer’s instructions.  Additional sets of pumps 
were loaded with vehicle solution to serve as controls.  Then, mice were anesthetized with 
isoflurane and the pump implanted subcutaneously over the dorsal back musculature.  
Following surgery, mice were examined daily for any signs of infection or excessive weight 
loss.   
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5.2.11: Liquid scintillation counting.   
Samples were thawed on ice, then placed in 5 mL glass vials and dissolved in 1 mL 
Solvable (Perkin-Elmer) overnight at 37°C.  Then, homogenates were vortexed and mixed 
with 4 mL Hionic-Fluor scintillation cocktail (Perkin-Elmer).  Following this, β-emissions 
were measured using a Tri-Carb LSC (Perkin-Elmer), with 3H2O emissions counted at less 
than 20 keV, and 14C-Inulin measured counted between 20 and 150 KeV.  Control vials 
containing aCSF alone, aCSF + 14C-Inulin and aCSF + 3H2O were used to account for 
background radiation, as well as to normalize emission signals from samples for subsequent 
analyses. 
 
5.2.12: Fluorescent microscopy and tracer imaging.   
Following perfusion, brains were extracted and post-fixed for 24 hours in 4% PFA.  
Then, brains were dehydrated in 30% sucrose, frozen to -20°C and sectioned to 24 µm 
(IHC/cresyl violet staining) or 100 µm (tracer quantification) sections. Sections were then 
mounted onto slides and coverslipped.  For experiments involving colocalization with lectin, 
sections were first stained with Lycopersicon esculentum (Tomato) lectin (see 
Immunohistochemistry).  Sections were imaged under fluorescence with a Leica DMi8 
microscope at 10X magnification.  A blinded investigator imaged the lateral cortex (0.38 mm 
anterior to Bregma, 2.5 mm lateral, 1.5 mm deep).  Then, 100 µm Z stack images were 
obtained, and maximum intensity projections performed with LAS X software.  Images were 
then quantified in ImageJ (see Data Analysis).  
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5.2.13: DigiGait.   
The impact of aging, stroke and genetic/pharmacological manipulation on motor 
function was assessed using DigiGait (Mouse Specifics) at 6 and 13 DPI in a double-blinded 
manner.  Mice were first acclimated to the system, and then the speed was gradually 
increased to 15 cm/second in young animals, and 10 cm/second in aged animals.  
Locomotion was recorded for 60 seconds, and then parameters of gait analyzed with DigiGait 
software.  
 
5.2.14: Data Analysis. 
• Quantification of protein expression. Intensity values for each band were measured 
using the Bio-Rad ImageAnalyzer software.  Then, each intensity value was 
normalized by dividing it by the intensity of the loading control (either Vinculin or β-
actin).  Finally, these values were normalized to the mean value of the control group, 
plotted and statistically analyzed in Prism. 
• Quantification of gene expression. Cycle threshold (CT) values for every gene of 
interest, loading control and quality control were first exported from Bio-Rad CFX 
software into Microsoft Excel.  Given the large number of samples and genes 
involved (~3,840 assays), prior to further analysis, samples of poor quality were 
removed (~10%) based on the following pre-defined criteria: (1) presence of genomic 
DNA contamination, (2) poor RNA quality, (3) positive no RT control, or (4) loading 
control not detected.  Then, relative gene expression was estimated by the following 
equation: ΔΔCT = (CT1 – CT1/GAPDH) – (CT2 – CT2/GAPDH), where CT1 is expression 
of the gene of interest in sample 1, CT2 is the mean expression of the gene of interest 
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in the control samples (NO + Vehicle treated), and CTGAPDH is the expression of the 
loading control (GAPDH).  Since CT values are expressed on a logarithmic scale, to 
convert these values to fold-change, we then used the formula Expression = 2-ΔΔCT.  
After this last conversion step, fold-change values were imported into Prism, and any 
statistical outliers were removed on a gene-by-gene basis based on a positive Grubb’s 
test (pre-determined threshold set at p < 0.05).  Finally, to generate a heat map of 
genes related to astrocyte phenotype, expression values were Z-transformed based on 
the sample population mean and standard deviation (SD) for each individual gene. 
• Atrophy quantification.  High resolution images of cresyl violet-stained coronal brain 
sections (24 µm) were obtained.  Then, ventricular volume and hemisphere size were 
quantified as previously described.255,256 Tissue atrophy percentage was calculated by 
the formula: % tissue loss = 100 - ([total ipsilateral tissue/total contralateral tissue] 
× 100). 
• Tracer intensity.  Tracer influx was quantified by measuring intensity as a function of 
tissue depth using ImageJ.  Then, average intensity values were imported into Excel, 
and integrated into 50 µm bins.  Absolute binned intensity values were then plotted as 
raw intensity (A.U.).  To reduce experimental variability and further improve the 
quality of our data, tracer intensity in the injured hemisphere was then normalized to 
intensity in the contralateral hemisphere, and then converted to a percentage value 
prior to statistical analysis. 
• Immunohistochemical quantification.  IHC images were acquired and quantified in 
a double-blinded manner.  Based on lectin staining, ROI’s were drawn around 3 peri-
infarct vessels/image across 3 brain sections for a total of 27 vessels/brain.  Threshold 
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was held constant between brains, and the area and average pixel intensity of AQP4, 
GFAP, fibronectin and integrin-α5 was measured relative to the ROI.   
• Statistics.  All statistical analyses were performed using Prism 7.  Data are reported as 
mean (+/-) SEM with the number of animals/repetitions per group.  When only two 
groups were compared, Student’s t-test (two-tailed) was used to compare normally 
distributed data of equivalent variance, and Welch’s correction was applied when data 
were normally distributed, but of unequal variance (denoted in figure legends).  When 
three groups were compared, one-way ANOVA with Tukey’s test for multiple 
comparisons was performed.  When four or more groups were compared, two-way 
ANOVA with either Tukey’s or Dunnet’s test for multiple comparisons was utilized 
(denoted in figure legends).  Asterisks indicate statistical significance levels based on 
the P-value: *p < 0.05, **p < 0.01, ***p < 0.001. 
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5.3: Results 
5.3.1: DMCAO produced widespread perivascular reactive astrogliosis that worsened with 
aging.   
To first characterize how stroke alters perivascular astrocyte phenotypes in vivo, we 
performed DMCAO on young (3 month-old) animals and then examined their brains at 7 DPI 
by IHC (Fig. 5-1A).  We found that DMCAO dramatically increased the expression of 
GFAP+ reactive astrocytes in the peri-infarct cortex, striatum and white matter, which was 
associated with major increases in lectin-stained glysocylated basement membrane 
components throughout vessels within the injured hemisphere (Fig. 5-1A, i. - ii.).  We then 
performed high magnification 3-dimensional reconstruction of perivascular astrocytes and 
found that DMCAO also altered the morphology of glial endfeet, inducing widespread 
changes characterized by hypertrophy, increased GFAP expression and reduced AQP4 
polarization (Fig. 5A, iii. – viii.).   
Then, to assess whether aging also increased perivascular gliosis, we performed 
DMCAO in young (3 month) and aged (20 month) old animals, and similarly assessed 
astrocyte morphology (Fig. 5-1B).  We found that aged animals with stroke exhibited further 
increases in GFAP expression within perivascular reactive astrocytes compared to their 
younger counterparts (Fig. 5-1B, iv.)  Finally, to confirm age-induced changes in reactive 
gliosis quantitatively, we then obtained cortical lysates at 7 DPI and assessed the expression 
of both GFAP and vimentin, an additional marker of reactive gliosis, by western blot (Fig. 5-
1C, i.).  We found that aging (F[1, 19] = 20.96, p < 0.001) and DMCAO (F[1, 19] = 50.75, p 
< 0.001) both produced statistically significant increases in cortical GFAP expression, with a 
trending interaction effect between aging and DMCAO (Fig. 5-1C, ii., F[1, 19] = 3.51, p = 
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0.076).  Similarly, we also found that aging (Fig. 5-1C, iii., F[1, 18] = 11.17, p = 0.004) and 
DMCAO (F[1, 18] = 68.94, p < 0.001) both increased vimentin expression within the cortex, 
with a significant interaction effect (F[1, 18] = 8.85, p = 0.008).  Overall, these data indicate 
that stroke induces perivascular astrocyte reactivity, which worsens with aging.  These 
stroke-induced changes are associated with altered basement membrane glycosylation and 
impaired AQP4 polarization to astroglial endfeet. 
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Figure 5-1. Reactive astrogliosis occurs after DMCAO and is worse in aged animals. 
(A.) (i., ii.) Representative fluorescent mosaic micrographs from aged mice showing 
increased levels of lectin and GFAP staining throughout the injured hemisphere after 
DMCAO (7 DPI). (iii. – viii.) 3-dimensional reconstruction showing increased GFAP 
staining and reduced AQP4 polarization within the perivascular region following DMCAO in 
aged animals.  (B.) Comparison of cortical GFAP staining outside of the ischemic penumbra 
between young and aged mice.  White arrows denote high levels of perivascular GFAP 
staining in aged mice with DMCAO.  (C.) Western blot analysis showed the highest levels of 
GFAP and Vimentin expression in aged mice with DMCAO. n = 5 – 8 mice per group. Data 
are analyzed by Tukey’s post-hoc test for multiple comparisons. Significance: **p < 0.01, 
***p < 0.001. Scale Bar = 50 µm. 
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5.3.2. DMCAO differentially induces TGF-β-Smad signaling pathways with aging.   
Previous work has shown that stroke induces TGF-β signaling, which may increase 
with aging.223 However, there is limited data on how the absolute levels of individual TGF-β 
isoforms change after stroke in aged animals, or how downstream Smad phosphorylation is 
affected.  We found that DMCAO increased TGF-β1 levels at 7 DPI in both age groups (F[1, 
18) = 74.05, p < 0.001), with no effect of aging (Fig. 5-2A).  However, we observed that 
aging differentially affected downstream Smad2/3 phosphorylation by western blot (Fig. 5-
2B).  Total levels of phosphorylated Smad2 (phospho-Smad2) increased following DMCAO 
(Fig. 5-2C, i., F[1, 19] = 7.88, p = 0.013), with a significant interaction effect between aging 
and DMCAO (F[1, 19] = 11.84, p = 0.003).  In contrast, total levels of Smad2 significantly 
increased with aging (Fig. 5-2C, ii., F[1, 19] = 34.35, p < 0.001), and reduced following 
DMCAO in aged, but not young animals (interaction, F[1, 19] = 14.71, p = 0.001).  Relative 
Smad2 phosphorylation was lower in aged animals (Fig. 5-2C, iii., F[1, 19] = 9.79, p = 
0.006), with a trending increase in mice with DMCAO (F[1, 19] = 2.81, p = 0.11) and no 
significant interaction effect.  In contrast, total levels of phospho-Smad3 increased with aging 
(Fig. 5-2D, i., F[1, 19] = 26.63, p < 0.001), with a significant interaction between aging and 
DMCAO (F[1, 19) = 16.03, p < 0.001).  There was also a weak interaction effect on total 
Smad3 levels (Fig. 5-2D, ii., F[1, 19] = 4.41, p = 0.049), and a main effect of age on 
increasing Smad3 phosphorylation (Fig. 5-2D, iii., F[1, 19] = 7.06, p = 0.02).  Overall, these 
data indicate that Smad2 signaling predominates in young animals with DMCAO, while 
Smad3 signaling may play a more prominent role in aged animals.   
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Figure 5-2. TGF-β signaling is differentially activated by aging and DMCAO. (A.) 
Cortical TGF-β1 levels similarly increase after DMCAO in young and aged mice. n = 5 – 8 
per group. (B.) Representative western blot images of Smad proteins. (C., D.) Smad2 
phosphorylation is higher in young animals, while Smad3 phosphorylation predominates in 
aged animals.  n = 5 – 7 per group. Data are analyzed by Tukey’s post-hoc test for multiple 
comparisons. Significance: *p < 0.05, **p < 0.01, ***p < 0.001. 
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5.3.3. Exposure to OGD, TGF-β and Aβ1-40 acutely impact astrocyte polarization, ECM 
production and cytokine expression in vitro.   
Previous studies have shown that a significant number of reactive astrocytes take on 
an ‘A2’ phenotype after stroke in vivo,239 but the relative effects of hypoxia, TGF-β and Aβ1-
40 on the post-stroke induction of A2 astrocytes is not known.  Therefore, we evaluated 
whether OGD, an in vitro model of ischemic stroke, would stimulate the transcription of A2 
genes.  We further hypothesized that this transition would be inhibited by co-stimulation with 
recombinant TGF-β1 and Aβ1-40 peptides.  To test this hypothesis, we generated primary 
astrocyte cultures from P1 mouse pups, then subjected the astrocyte monolayer to 6 hours of 
OGD in the presence of vehicle, TGF-β1 or Aβ1-40 and collected RNA for qPCR microarray.  
As we expected, we found that OGD induced an A2 phenotype, however, this was not 
significantly impacted by TGF-β costimulation (Fig. 5-3A; see Table 5-2 for F-values).  In 
contrast, we found that Aβ1-40 stimulation induced a classical pro-inflammatory A1 
phenotype under normoxic conditions, and suppressed the transition to A2 phenotype under 
OGD conditions (Fig. 5-3A).   
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Figure 5-3. Expression of cellular phenotype and ECM-related genes in primary 
astrocytes following acute stimulation. (A.) Heat map showing variation in expression of 
genetic markers of astrocyte phenotype following with ischemia and/or co-stimulation.  
ddCT values are plotted as Z-scores.. (B.) (i. – viii.) Expression (ddCT) of ECM-related 
genes. (ix.) Expression of APP.  n = 5 – 8 per group.  Heat map data in panel (A) are 
analyzed by two-way ANOVA with Dunnet’s test for multiple comparisons to compare ddCT 
values of experimental groups against vehicle/NO control.  All other expression data in panel 
(B) are analyzed by two-way ANOVA with Tukey’s post-hoc test for multiple comparisons. 
Significance: *p < 0.05, **p < 0.01, ***p < 0.001. 	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  Interaction Perfusion Co-Stimulation 
  F{DFn, DFd) P-value S F{DFn, DFd) P-value S F{DFn, DFd) P-value S 
Agrn F (2, 47) = 5.8 P=0.005 ** F (1, 47) = 25 P<0.001 *** F (2, 47) = 0.7 P=0.498 ns 
Amigo2 F (2, 39) = 0.4 P=0.661 ns F (1, 39) = 4.1 P=0.05 * F (2, 39) = 3 P=0.063 ns 
App F (2, 47) = 3.4 P=0.043 * F (1, 47) = 3.6 P=0.066 ns F (2, 47) = 1.3 P=0.281 ns 
Aspg F (2, 35) = 0.7 P=0.501 ns F (1, 35) = 0.1 P=0.706 ns F (2, 35) = 0.6 P=0.537 ns 
B3gnt5 F (2, 47) = 2.4 P=0.101 ns F (1, 47) = 5.3 P=0.026 * F (2, 47) = 2.1 P=0.137 ns 
Ccl11 F (2, 31) = 3.4 P=0.048 * F (1, 31) = 0.1 P=0.764 ns F (2, 31) = 0.3 P=0.744 ns 
Cd109 F (2, 47) = 1.3 P=0.281 ns F (1, 47) = 0.4 P=0.506 ns F (2, 47) = 0.7 P=0.483 ns 
Cd14 F (2, 47) = 38 P<0.001 *** F (1, 47) = 94.7 P<0.001 *** F (2, 47) = 32.8 P<0.001 *** 
Cd44 F (2, 47) = 14.1 P<0.001 *** F (1, 47) = 26.5 P<0.001 *** F (2, 47) = 1 P=0.375 ns 
Clcf1 F (2, 47) = 3.8 P=0.029 * F (1, 47) = 61.2 P<0.001 *** F (2, 47) = 3.3 P=0.046 * 
Col16a1 F (2, 40) = 4 P=0.026 * F (1, 40) = 1.4 P=0.251 ns F (2, 40) = 0.7 P=0.509 ns 
Cp F (2, 47) = 5.4 P=0.008 ** F (1, 47) = 1.5 P=0.232 ns F (2, 47) = 6.4 P=0.004 ** 
Cxcl10 F (2, 46) = 90.4 P<0.001 *** F (1, 46) = 60.7 P<0.001 *** F (2, 46) = 101 P<0.001 *** 
Cxcl16 F (2, 45) = 9.7 P<0.001 *** F (1, 45) = 0.3 P=0.614 ns F (2, 45) = 14.1 P<0.001 *** 
Fbln5 F (2, 44) = 4.4 P=0.018 * F (1, 44) = 0.1 P=0.794 ns F (2, 44) = 5 P=0.011 * 
Fkbp5 F (2, 44) = 1.9 P=0.159 ns F (1, 44) = 15 P<0.001 *** F (2, 44) = 1.3 P=0.274 ns 
Fn1 F (2, 44) = 3.6 P=0.037 * F (2, 44) = 2.5 P=0.092 ns F (1, 44) = 2.2 P=0.145 ns 
Gbp2 F (2, 47) = 84.2 P<0.001 *** F (1, 47) = 118 P<0.001 *** F (2, 47) = 96.6 P<0.001 *** 
Gfap F (2, 47) = 0.1 P=0.939 ns F (1, 47) = 20.2 P<0.001 *** F (2, 47) = 5.5 P=0.007 ** 
Ggta1 F (2, 47) = 0.3 P=0.714 ns F (1, 47) = 21.2 P<0.001 *** F (2, 47) = 1.9 P=0.16 ns 
H2-D1 F (2, 47) = 11.2 P<0.001 *** F (1, 47) = 114 P<0.001 *** F (2, 47) = 10.7 P<0.001 *** 
H2-T23 F (2, 47) = 23.2 P<0.001 *** F (1, 47) = 113 P<0.001 *** F (2, 47) = 22.2 P<0.001 *** 
Hsbp1 F (2, 47) = 0.2 P=0.858 ns F (1, 47) = 0.6 P=0.44 ns F (2, 47) = 23 P<0.001 *** 
Hspg2 F (2, 46) = 1.2 P=0.312 ns F (1, 46) = 0.5 P=0.486 ns F (2, 46) = 1.6 P=0.205 ns 
Iigp1 F (2, 44) = 118 P<0.001 *** F (1, 44) = 140 P<0.001 *** F (2, 44) = 128 P<0.001 *** 
Il10 F (2, 43) = 6.9 P=0.003 ** F (1, 43) = 90.8 P<0.001 *** F (2, 43) = 6.5 P=0.004 ** 
Il6 F (2, 44) = 5 P=0.011 * F (1, 44) = 53.5 P<0.001 *** F (2, 44) = 23.5 P<0.001 *** 
Itga5 F (2, 45) = 0.5 P=0.585 ns F (1, 45) = 28.5 P<0.001 *** F (2, 45) = 1.9 P=0.162 ns 
Itgb1 F (2, 47) = 0.2 P=0.861 ns F (1, 47) = 0.01 P=0.918 ns F (2, 47) = 0.3 P=0.767 ns 
Lcn2 F (2, 46) = 9.5 P<0.001 *** F (1, 46) = 14.7 P<0.001 *** F (2, 46) = 14.3 P<0.001 *** 
Osmr F (2, 47) = 1.2 P=0.312 ns F (1, 47) = 50.7 P<0.001 *** F (2, 47) = 16.2 P<0.001 *** 
Psmb8 F (2, 47) = 33.4 P<0.001 *** F (1, 47) = 64.5 P<0.001 *** F (2, 47) = 22.7 P<0.001 *** 
Ptgs2 F (2, 43) = 0.3 P=0.749 ns F (1, 43) = 66.4 P<0.001 *** F (2, 43) = 0.6 P=0.573 ns 
Ptx3 F (2, 46) = 3.6 P=0.034 * F (1, 46) = 3.9 P=0.055 ns F (2, 46) = 10.6 P<0.001 *** 
S100a10 F (2, 47) = 1.3 P=0.285 ns F (1, 47) = 3.7 P=0.06 ns F (2, 47) = 0.2 P=0.835 ns 
S1pr3 F (2, 46) = 1.5 P=0.224 ns F (1, 46) = 61.4 P<0.001 *** F (2, 46) = 5 P=0.011 * 
Sdc2 F (2, 46) = 2.2 P=0.128 ns F (1, 46) = 3 P=0.09 ns F (2, 46) = 3.6 P=0.036 * 
Serpina3n F (2, 47) = 0.1 P=0.91 ns F (1, 47) = 5.7 P=0.021 * F (2, 47) = 0.6 P=0.536 ns 
Serping1 F (2, 46) = 0.27 P=0.768 ns F (1, 46) = 27.4 P<0.001 *** F (2, 46) = 4 P=0.024 * 
Sphk1 F (2, 42) = 3.2 P=0.053 ns F (1, 42) = 48.7 P<0.001 *** F (2, 42) = 3.2 P=0.049 * 
Spp1 F (2, 47) = 0.8 P=0.467 ns F (1, 47) = 0.8 P=0.366 ns F (2, 47) = 3.8 P=0.03 * 
Srgn F (2, 46) = 7.5 P=0.002 ** F (1, 46) = 3 P=0.089 ns F (2, 46) = 1.4 P=0.251 ns 
Steap4 F (2, 45) = 10.4 P<0.001 *** F (1, 45) = 22.1 P<0.001 *** F (2, 45) = 12.3 P<0.0001 *** 
Tgfb1 F (2, 46) = 6 P=0.005 ** F (1, 46) = 35.9 P<0.001 *** F (2, 46) = 2.5 P=0.096 ns 
Tgfb2 F (2, 47) = 0.6 P=0.57 ns F (1, 47) = 0.6 P=0.435 ns F (2, 47) = 9.8 P<0.001 *** 
Tgfb3 F (2, 42) = 2.3 P=0.115 ns F (1, 42) = 3.3 P=0.077 ns F (2, 42) = 2.3 P=0.108 ns 
Tgfbr1 F (2, 45) = 0.6 P=0.57 ns F (1, 45) = 3 P=0.09 ns F (2, 45) = 0.2 P=0.856 ns 
Tgm1 F (2, 35) = 1.4 P=0.255 ns F (1, 35) = 7.9 P=0.008 ** F (2, 35) = 12 P<0.001 *** 
Thbs1 F (2, 47) = 4.4 P=0.017 * F (1, 47) = 59.6 P<0.001 *** F (2, 47) = 7.9 P=0.001 ** 
Timp1 F (2, 45) = 1 P=0.372 ns F (1, 45) = 1.7 P=0.201 ns F (2, 45) = 0.7 P=0.523 ns 
Tm4sf1 F (2, 47) = 0.8 P=0.443 ns F (1, 47) = 2.9 P=0.094 ns F (2, 47) = 3.7 P=0.031 * 
Tnf F (2, 40) = 123 P<0.001 *** F (1, 40) = 131 P<0.001 *** F (2, 40) = 137 P<0.001 *** 
Uggt1 F (2, 47) = 1.1 P=0.343 ns F (1, 47) = 0.2 P=0.665 ns F (2, 47) = 0.3 P=0.75 ns 
Vim F (2, 47) = 0.6 P=0.5730 ns F (1, 47) = 6 P=0.018 * F (2, 47) = 1.6 P=0.214 ns 
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Table 5-2. Effects of perfusion, co-stimulation and interaction on gene expression in 
primary cultured astrocytes. Tabulation of F-values, degrees of freedom and p-values for 
all PCR assays detailed in Fig. 5-3 through Fig. 5-5.  n = 5 – 8 per group.  Data are analyzed 
by two-way ANOVA.  Significance: ns, no significance, *p < 0.05, **p < 0.01, ***p < 0.001. 
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We next broadly assessed how these stimuli impacted the production of ECM 
components by primary astrocytes.  To accomplish this, we examined the mRNA levels of 
agrin (AGRN), collagen XVI (COL16A1), fibulin-5 (FBLN5), fibronectin (FN1), perlecan 
(HSPG2), syndecan-2 (SDC2), integrin-α5 (ITGA5) and integrin-β1 (ITGB1) immediately 
following OGD (Fig. 5-3B; Table 5-2).  We found that exposure to OGD reduced agrin 
expression (p < 0.001) and upregulated integrin-α5 (p = 0.001).  Treatment with vehicle, 
TGF-β1 or Aβ1-40 differentially impacted fibulin (p = 0.011) and syndecan-2 expression (p = 
0.036).  Finally, we also observed statistically significant interaction effects between OGD 
and co-stimulation on the expression of agrin (p = 0.005), collagen XVI (p = 0.026), fibrillin 
(p = 0.018) and fibronectin (p = 0.037).  Overall, these data indicate that A2 astrocytes 
produce a unique compliment of ECM proteins following ischemia, which is further 
modulated by exposure to TGF-β1 or Aβ1-40 in the extracellular milieu during ischemia. 
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Figure 5-4. Expression of TGF-β-related genes in primary astrocytes following acute 
stimulation. (A. – D.) Expression (ddCT) values of TGF-β signaling genes. n = 5 – 8 per 
group. Data are analyzed by two-way ANOVA with Tukey’s post-hoc test for multiple 
comparisons. Significance: *p < 0.05, **p < 0.01, ***p < 0.001. 
We then examined the impact of OGD and co-stimulation on the expression of TGF-β 
signaling components.  To assess this, we measured mRNA levels of TGF-β1 (TGFB1), 
TGF-β2 (TGFB2), TGF-β3 (TGFB3) and TGF-βR1 (TGFBR1) immediately following OGD 
(Fig. 5-4; Table 5-2).  We found that OGD exposure reduced the expression of TGF-β1 (p < 
0.001) and TGF-β3 (p = 0.038), and concurrently increased the expression of TGF-βR1 (p = 
0.02).  Treatment with exogenous TGF-β1 or Aβ1-40 increased astrocytic TGF-β1 expression 
(p = 0.003), but reduced the expression of TGF-β2 (p < 0.001).  Finally, we also observed 
statistically significant interaction effects between OGD and treatment on the expression of 
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TGF-β1 (p = 0.002).  Overall, these data suggest that A2 astrocytes may exhibit increased 
sensitivity to TGF-β signaling due to increased expression of TGF-βR1, but this might be 
balanced by downregulation of astrocytic production of TGF-β isoforms following 
stimulation by OGD, TGF-β or Aβ1-40.  However, further studies of downstream Smad 
activation are required to address this point. 
Finally, we also sought to characterize the impact of OGD and co-stimulation on the 
expression of various cytokines related to ischemic stroke and CAA.  To assess this, we 
measured mRNA levels of C-X-C motif chemokine 10 (CXCL10), C-X-C motif chemokine 
16 (CXCL16), IL-6 (IL6), interleukin-10 (IL-10, IL10), osteopontin (SPP1) and TNF-α (TNF) 
immediately following OGD (Fig. 5-5; Table 5-2).  We found that OGD increased IL-6 (p < 
0.001) and IL-10 levels (p < 0.001), reduced TNF-α expression (p < 0.001) and had 
differential impacts on CXCL10 (p < 0.001) and CXCL16 (p < 0.001) expression.  Treatment 
with TGF-β1 or Aβ1-40 increased the expression of IL-6 (p < 0.001), TNF-α (p < 0.001), 
CXCL10 (p < 0.001), CXCL16 (p < 0.001), but reduced IL-10 expression (p = 0.003) and 
differentially impacted SPP1 expression (p = 0.031).  Finally, we also observed a statistically 
significant interaction between OGD and treatment on the expression of IL-6 (p < 0.001), IL-
10 (p = 0.004), TNF-α (p < 0.001), CXCL10 (p < 0.001) and CXCL16 (p < 0.001).  Overall, 
these data indicate that stimulation with OGD, TGF-β1 and Aβ1-40 all generally upregulated 
cytokine expression by reactive astrocytes, with the notable exception of the anti-
inflammatory cytokine IL-10, which was suppressed by both TGF-β1 and Aβ1-40. 
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Figure 5-5. Expression of inflammatory cytokine genes in primary astrocytes following 
acute stimulation. (A. – D.) Expression (ddCT) of inflammatory cytokine genes. n = 5 – 8 
per group. Data are analyzed by two-way ANOVA with Tukey’s post-hoc test for multiple 
comparisons. Significance: *p < 0.05, **p < 0.01, ***p < 0.001. 
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5.3.4. Chronic TGF-β exposure modulates astrocytic ECM production, and may ‘prime’ 
the ECM for the deposition of Aβ1-40.   
Next, we sought to determine whether chronic TGF-β stimulation influences ECM 
composition and its affinity for Aβ1-40 deposition.  Our previous studies, detailed in Chapter 
4, found that fibronectin and integrin-α5 form a complex that binds soluble Aβ1-40 within the 
basement membrane after stroke.  However, neither the cell types nor the upstream signaling 
mechanisms by which stroke increases fibronectin/integrin-α5 expression were explored in 
those studies.  Therefore, we next hypothesized that chronic stimulation with TGF-β would 
induce the deposition of exogenous Aβ1-40 due to upregulation of fibronectin and integrin-α5 
by astrocytes. 
To test this hypothesis, we first treated primary astrocytes with recombinant TGF-β1 
peptide for 24 hours, then measured the binding of exogenous Aβ1-40 to the ECM following 
incubation in a 2 µM solution of FITC-Aβ1-40  for 30 minutes.  We found that TGF-β1 
treatment increased the uptake of FITC-Aβ1-40 by the astrocyte monolayer (Fig. 5-6A, i., t[5] 
= 5.94, p = 0.002).  In contrast with our acute studies of gene expression, examination of 
total protein levels by western blot further showed that chronic TGF-β1 treatment 
significantly increased the expression of fibronectin (Fig. 5-6A, iii., t[6] = 4.91, p = 0.003), 
and there was also a nonsignificant trend for increased integrin-α5 expression with treatment 
(Fig. 5-6A, iv., t[3] = 1.74, p = 0.172, t-test with Welch’s correction).  Chronic TGF-β1 
treatment significantly reduced GFAP expression (Fig. 5-6A, v., t[6] = 3.19, p = 0.011), with 
a nonsignificant trend for decreased vimentin expression (Fig. 5-6A, vi., t[6] = 1.14, p = 
0.296), indicating reduced expression of ‘pan-reactive’ astrocyte activation markers.  To 
determine whether increased FITC-Aβ1-40 binding was directly related to the increase in 
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ECM protein expression, we then performed ICC and found that FITC-Aβ1-40 binding 
colocalized with regions of increased fibronectin (Fig. 5-6B, vehicle [i – iii.], TGF-β1 [vii. – 
ix.]) and integrin-α5 expression (Fig. 5-6B, vehicle [iv. – vi.], TGF-β1 [x. – xii.]).  Overall, 
these results indicate that astrocytes are a source of both fibronectin and integrin-α5 
expression, and also show that fibronectin expression is stimulated by TGF-β1 treatment in 
vitro.  They further confirm that these increases in fibronectin are directly associated with 
increased Aβ1-40 binding, although it does not rule out increased endocytosis of FITC-Aβ1-40 
as a potential contributor to this phenotype. 
 Next, to confirm the in vivo relevance of TGF-β1-induced stimulation of fibronectin 
expression,  we intracisternally injected naive young mice with recombinant TGF-β1, and 
then collected the cerebral cortex for western blot and IHC analysis 24 hours later.  Similar to 
our in vitro studies, we found that TGF-β1 treatment upregulated fibronectin expression (Fig. 
5-6C, ii., t[5] = 2.62, p = 0.047).  However,  TGF-β1 treatment had no impact on GFAP 
levels (Fig. 5-6C, ii., t[5] = 0.058, p = 0.956).  We further confirmed that our injections 
successfully activated TGF-β signaling by examining Smad phosphorylation.  We found that 
chronic treatment with TGF-β1 increased phospho-Smad2 expression (Fig. 5-6C, iv., t[5] = 
4.03, p = 0.01), but did not significantly alter the levels of total Smad2 (Fig. 5-6C, vi., t[5] = 
0.64, p = 0.55), producing a relative increase in Smad2 phosphorylation (Fig. 5-6C, vi., t[5] = 
3.47, p = 0.018).  We verified that these changes occured within perivascular astrocytes by 
IHC (Fig. 5-6D), and found that TGF-β1 treatment increased the association of astrocytes 
with the vasculature, as well as fibronectin expression.  Overall, these results confirm our in 
vitro findings that TGF-β stimulates fibronectin expression within the ECM, and further 
shows that these changes occur within the basement membrane in vivo. 
	   136 
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Figure 5-6. TGF-β stimulation increases Aβ1-40 binding and fibronectin expression.  (A.) 
(i.) Quantification of Aβ1-40 binding by primary astrocyte cultures treated with TGF-β. n = 3 
per group. (ii.) Representative western blots of primary astrocytes treated with vehicle or 
TGF-β. (iii. – vi.) Quantification of protein expression changes by western blot.  (B.) ICC 
showing colocalization of exogenous FITC-Aβ1-40 with ECM proteins in primary astrocytes. 
n = 4 – 5 per group. (C.) (i.) Representative western blots of brain tissue from mice that 
received intracisternal injection of vehicle or TGF-β. (ii. – vi.) Quantification of protein 
expression changes by western blot. n = 3 – 4 per group. (D.) IHC localizing increased 
fibronectin expression in mice treated with TGF-β localizes with the basement membrane of 
brain cortical vessels.  All data are analyzed by Student’s t-test. Significance: *p < 0.05, **p 
< 0.01.  Scale bar = 100 µm. 
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Figure 5-7. OGD increases Aβ1-40 binding in primary astrocytes. (A.) Fluorescent images 
showing that FITC-Aβ1-40 binding increases with OGD, and was highest in cultures that were 
co-stimulated with Aβ1-40 during OGD.  (B.) Quantification of FITC-Aβ1-40 binding.  n = 3 
per group.  Data are analyzed by two-way ANOVA with Tukey’s post-hoc test for multiple 
comparisons.  *p < 0.05, ***p < 0.001. 
 
5.3.5. Ischemia, TGF-β and Aβ1-40 interact to further increase the uptake of Aβ1-40 within 
the astrocyte monolayer.   
We next sought to further characterize how ischemia, TGF-β and Aβ1-40 interact to 
increase the in vitro binding of Aβ1-40 to the ECM produced by primary cultured astrocytes 
(Fig. 5-7A).  We hypothesized that OGD would increase the uptake of FITC-Aβ1-40, which 
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would be further accelerated by co-stimulation with recombinant TGF-β1 and Aβ1-40.  We 
found that FITC-Aβ1-40 uptake was increased by both OGD (Fig. 5-7B, F[1, 14] = 27.78, p = 
0.001) and co-stimulation (F[2, 14] = 4.95, p = 0.024).  We also observed a statistically 
significant interaction effect between OGD and co-stimulation on FITC-Aβ1-40 uptake (Fig. 
5-7B, F[2, 14] = 5.01, p = 0.023).  Overall, these data indicate that ischemia, TGF-β and Aβ1-
40 interact to increase the in vitro uptake of FITC-Aβ1-40 within the astrocyte monolayer.  
However, further work is needed to address the mechanism of this phenomenon, in particular 
how pre-treatment with Aβ1-40 induces such dramatic increases in FITC-Aβ1-40 uptake, and 
why this increase in uptake appears to be conditional on exposure to OGD conditions. 
 
5.3.6. TGF-β stimulation alters astrocytic AQP4 polarization and impairs water uptake 
both in vitro and in vivo.   
Our initial studies showed that DMCAO upregulated TGF-β1 expression (Fig. 5-2A) 
and altered AQP4 polarization on reactive astrocytes (Fig. 5-1A). Therefore, we 
hypothesized that TGF-β impairs AQP4 polarization, water uptake and bulk flow.  To 
address this hypothesis, we first stimulated primary cultured astrocytes with recombinant 
TGF-β1 for 24 hours, and assessed the impact on AQP4 polarization by ICC (Fig. 5-8A).  
We found that TGF-β1 treatment altered the pattern of AQP4 staining and induced swelling 
of cultured astrocytes (Fig. 5-8A, i – ii.).  To measure the functional consequences of these 
histological changes, we examined the in vitro uptake of 3H2O, a substrate for AQP4, for 30 
min into the astrocyte monolayer, and found that it was significantly reduced by TGF-β1 
treatment (Fig. 5-8A, iii., t[8] = 2.31, p = 0.049).  To confirm these findings in vivo, we 
injected naive young mice with TGF-β1 and examined AQP4 polarization, as well as the 
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uptake of 3H2O uptake and 14C-inulin (used as an extracellular space marker) from the CSF.  
We found that treatment with TGF-β1 significantly reduced uptake of 3H2O (Fig. 5-8B, ii., 
t[10] = 3.77, p = 0.004) and 14C-inulin (Fig. 5-8B, iii., t[7] = 2.75, p = 0.029) from the CSF.  
This indicates that TGF-β1 treatment is sufficient to impair CSF flow in the healthy young 
brain, suggesting that it may also contribute to impairments in aging and after stroke.  
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Figure 5-8. TGF-β stimulation alters AQP4 polarization and impairs water uptake. (A.) 
(i., ii.) Fluorescent micrographs showing altered AQP4 polarization in TGF-β-treated 
primary astrocytes by ICC.  (iii.) Quantification of 3H2O uptake by primary astrocytes treated 
with vehicle or TGF-β. n = 4 – 8 per group. (B.) Quantification of (i.) 3H2O and (ii.) 14C-
Inulin uptake by mice intracisternally injected with vehicle or TGF-β.  n = 3 – 4 per group.  
Data are analyzed by Student’s t-test.  Significance: *p < 0.05, **p < 0.01. 
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5.3.7: Early TGF-βR1 antagonism following DMCAO increases infarct volume and may 
modulate astrogliosis in an age-dependent manner.  In order to further examine the 
translational value of TGF-β antagonism in modulating injury severity, astrogliosis and 
basement membrane fibrosis after stroke, we first performed a pilot study with continuous 
peripheral administration of GW788388 (10 mg/kg/day), a TGF-βR1/R2 antagonist, from 3 – 
7 DPI in young (3 month) and aged (20 month)-old mice with DMCAO.  Similar to previous 
studies using conditional knockout mice,229 we hypothesized that early inhibition of TGF-β 
signaling would slightly increase injury volume, but would have the beneficial effect of 
reducing gliosis.  We also newly hypothesized that this would reduce fibronectin and 
integrin-α5 expression in the injured cortex.  Somewhat unexpectedly, we found that early 
TGF-β antagonism significantly increased injury volume (Fig. 5-9A, F[1, 4] = 22, p = 0.009), 
which worsening with aging (F[1, 4] = 10.02, p = 0.034).  We next examined the impact on 
gliosis by western blot, and found similar trending interaction effects of aging and early 
TGF-β antagonism on the expression of GFAP (Fig. 5-9B, i., F[1, 8] = 2.92, p = 0.127) and 
vimentin (Fig. 5-9B, ii., F[1, 8] = 2.54, p = 0.149) at 7 DPI.  Finally, we similarly examined 
the impact of treatment on ECM remodeling, and found similar trending interactions in the 
expression of fibronectin (Fig. 5-9C, i., F[1, 8] = 4.66, p = 0.063) and integrin-α5 (Fig. 5-9C, 
ii., F[1, 8] = 2.91, p = 0.127) at 7 DPI by western blot.  Overall, these preliminary data are 
interesting in that they show a potential age dimorphism in the role of TGF-β signaling in 
regulating gliosis and ECM remodeling after stroke, with a potential slight benefit to aged 
animals despite increases in injury volume.   
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Figure 5-9. Age-specific effects of subacute TGF-βR1 antagonism following DMCAO. 
(A.) (i.) Quantification of cavity size at 7 DPI. (ii.) Representative cresyl violet stained 
coronal sections from vehicle and drug-treated aged mice.  n = 2 per group. (B.) GFAP and 
vimentin expression at 7 DPI quantified by western blot. n = 3 per group. (C.) Fibronectin 
and integrin-α5 expression at 7 DPI quantified by western blot. n = 3 per group. Data are 
analyzed by two-way ANOVA with Tukey’s post-hoc test for multiple comparisons. *p < 
0.05. 
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5.3.8: Delayed TGF-βR1 antagonism following DMCAO reduces gliosis and ECM 
remodeling, while also improving perivascular CSF flow in aged animals.   
Based on the mixed results of the preceding pilot study, we next modified the dosing 
regimen by shifting the treatment window to 7 – 14 DPI in aged (20 month-old) mice by 
Alzet pump.  We hypothesized that delayed TGF-βR1/R2 antagonism after DMCAO would 
reduce gliosis and fibronectin/integrin-α5 expression, but have no major impact on injury 
volume or motor recovery in aged animals.  We further hypothesized that these reductions in 
astrogliosis and basement membrane fibrosis would correlate with improved perivascular 
CSF flow and reduced FITC-Aβ1-40 deposition. 
 We found that DMCAO increased GFAP expression, which was rescued by treatment 
with the TGF-βR1/R2 antagonist (F[2, 12] = 6.2, p = 0.014).  We also found that DMCAO 
increased fibronectin expression, which was significantly reduced by treatment (F[2, 12] = 
5.8, p = 0.017).  These changes in fibrosis were correlated with alterations in perivascular 
CSF flow.  We found that DMCAO significantly inhibited glymphatic influx of CSF 
(measured as dextran [d3] uptake), which was rescued by treatment (Fig. 5-10D, i., F[2, 12] 
= 5.38, p = 0.022).  Despite these reductions in overall CSF flow, we saw no corresponding 
impact on relative FITC-Aβ1-40 uptake (Fig. 5-10D, ii., F[2 , 12] = 0.81, p = 0.469).  
However, normalization to d3 levels, which accounts for individual differences in overall 
CSF flow, showed a relative increase in FITC-Aβ1-40/d3 ratio with DMCAO that was rescued 
by treatment (Fig. 5-10D, iii., F[2, 12] = 5.93, p = 0.016).  Overall, these data show that 
TGF-β signaling impairs perivascular CSF flow after DMCAO, which is associated with a 
disequilibrium in the transport of Aβ1-40.  Treatment improved CSF flow and reduced this 
imbalance in Aβ1-40 transport. 
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Figure 5-10. Delayed TGF-βR1 antagonism reduces fibrosis and improves perivascular 
flow following DMCAO in aged mice. (A.) Representative images showing increased 
GFAP and fibronectin expression in the peri-infarct cortex following DMCAO, which is 
rescued with GW788388 treatment. (B.) Fluorescence intensity quantification of GFAP and 
fibronectin expression. (C.) Representative images showing reduced dextran and increased 
Aβ1-40 distribution following DMCAO, which is rescued with GW788388 treatment. (D.) 
Fluoresence intensity quantification of tracer uptake. n = 4 – 5 per group. Data are analyzed 
by two-way ANOVA with Tukey’s post-hoc test for multiple comparions. *p < 0.05. 
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5.4: Discussion. 
5.4.1: Aging alters TGF-β signaling and reactive gliosis after stroke.   
The current study builds on previous work examining the impact of stroke on glial 
scar formation in aged animals by our laboratory and others,223,229,233 and offers new insight 
into age-related alterations in canonical TGF-β signaling pathways.  Similar to previous 
studies, we found that DMCAO produced a large, GFAP+ glial scar in the ischemic 
penumbra by 7 DPI in young animals.  We further showed that this was associated with 
alterations in ECM glycosylation, measured by lectin staining, indicating increases in 
glycosylated proteins including heparan sulfate proteoglycans (HSPGs), chondroitin sulfate 
proteoglycans (CSPGs) and/or other glycosylated proteins such as fibronectin.  While these 
changes have been previously shown to occur after experimental stroke, we newly observed 
that the glial scar extended beyond the ischemic penumbra and into the surrounding PVS, 
which form a continuous network through the ipsilateral cortex and striatum.  We found that 
stroke produced a striking increase in GFAP+ perivascular reactive astrocytes, which was 
associated with abnormal lectin staining, indicating potentially major alterations in the 
basement membrane.  We also found that the polarization of the omnipresent water channel, 
AQP4, was also disrupted in gliotic vessels.   
Together, these changes may prime the basement membrane for the development of 
CAA in three ways (as described in detail in Chapter 4): (1) altering the tortuosity of the 
perivascular microenvironment for the diffusion of solutes (2) increasing the affinity of the 
basement membrane for Aβ1-40 due to alterations in protein composition (e.g. fibronectin 
expression), or (3) impairing water transport, and thus slowing the bulk flow of CSF, by 
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mislocalization of AQP4.  Similar changes have been shown to occur in animal models of 
CAA,280 and with constitutive TGF-β overexpression.219 
 We further found that aging induced an increase in perivascular reactive gliosis, and 
was associated with further increases in total GFAP and vimentin expression throughout the 
injured hemisphere.  Since TGF-β signaling is increased in aged animals with stroke,223 and, 
in a separate paper, was also found to be a major contributor to glial scar formation by 
signaling to astrocytes after stroke,229 we elected to explore this further by first examining the 
levels of TGF-β in whole cortical lysate by multiplex ELISA, and then by probing the 
phosphorylation of downstream canonical Smad signaling pathways by western blot.  While 
we found that young and aged animals exhibited similar concentrations of TGF-β1, the 
predominant TGF-β isoform, we found interesting differences in the downstream Smad 
signaling pathways, indicating that aging induces a potentially dysregulated response to 
TGF-β signaling following stroke.  In young animals, this TGF-β stimulation is associated 
with increases in Smad2/3 phosphorylation, however, this is balanced by increases in 
Smad2/3, potentially acting to blunt these changes.  In contrast, Smad2/3 levels decline in 
aged animals with stroke, and the relative levels of phosphorylation increase.  This decline in 
total Smads could help to explain the increased sensitivity of the aged brain to TGF-β 
signaling (and the gliotic response).  In particular, relative increases in Smad3 
phosphorylation could provide a potent stimulus for the transcription of ‘reactive’ genes 
following stroke, although our in vitro data show that TGF-β stimulation alone is not 
sufficient to induce increases in classical markers of astrocyte reactivity, including GFAP 
expression.  This discrepancy suggests that TGF-β plays a role in modulating the response to 
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hypoxia or other stimuli, rather than directly inducing astrocyte reactivity, as was previously 
thought. 
 
5.4.2: Astrocyte polarization is differentially regulated by hypoxia, TGF-β and Aβ1-40.   
Recent work found that reactive astrocytes represent a more diverse population of 
cells than previously thought.239  While all reactive astrocytes generally express so-called 
‘pan-reactive’ markers, such as GFAP and vimentin, depending on the stimulus, astrocytes 
can take on two distinct genotypes: A1 and A2.239  Using in vivo mouse models, A1 
astrocytes were shown to be induced by peripheral LPS stimulation, while A2 were shown to 
be induced following MCAO.239  However, a very recent paper found this to be incorrect, as 
A1 astrocytes lack toll-like receptor-4 and, therefore, could not directly respond to LPS.240  
Instead, the study showed that A1 astrocytes were induced by the microglial cytokines IL-1β, 
IL-6 and TNF-α.240  To date, no such study has followed up on whether A2 astrocytes are 
induced by hypoxia, or if they instead similarly require co-stimulation with microglial 
cytokines.  Furthermore, while A1 astrocytes have generally detrimental effects following 
activation (mislocalization of AQP4, induce aberrant synaptic function and secretion of 
neurotoxic products), the actual phenotype of activated A2 astrocytes is not known.   
To address this gap in the literature, and to determine how A2 astrocytes are induced 
following stroke, we first sought to determine the specific factors that are sufficient to induce 
an A2 phenotype in vitro.  We elected to model stroke in vitro by performing OGD on 
astrocyte monolayers.  Although it is nearly impossible to isolate a truly ‘pure’ population of 
astrocytes from primary glial cultures, we chose to use microglia-depleted primary astrocyte 
monolayers to increase the relevance to our in vivo studies.  When we performed OGD and 
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collected RNA from our cultured astrocytes, we newly found that hypoxia alone was 
sufficient to induce an A2 astrocyte phenotype without any exogenous co-stimulation.  
Additionally, while previous studies found that even delayed treatment with TGF-β inhibits 
A1 astrocyte activation, we found that the A2 phenotype remained intact even with TGF-β 
co-stimulation.  Finally, to provide some insight for future studies into the role of Aβ1-40 in 
modulating the phenotype of astrocytes, we assessed the impact of Aβ1-40 stimulation under 
both normoxic and hypoxic conditions.  We newly found that Aβ1-40 induces classical A1 
astrocyte activation with NO, and inhibits the transition to A2 that normally occurs under 
hypoxic conditions.  This very interesting finding suggests that stroke and AD may produce 
opposing astrocyte phenotypes, which may be significant in the pathogenesis of vascular 
dementia. 
 
5.4.3: Reactive astrocyte subsets produce different patterns of extracellular matrix and 
cytokines, which can be further modified by co-stimulation.   
Since understanding astrocytic basement membrane production was a major goal of 
our studies, we next assessed the transcription of ECM genes by astrocytes under hypoxia 
and co-stimulation.  We found that OGD-induced A2 astrocytes upregulated fibronectin, 
integrin-α5 and (potentially) perlecan expression, yet down-regulated expression of other 
ECM-related genes, including agrin, collagen XI and fibulin-5.  They also showed no 
significant changes in integrin-β1, demonstrating again that integrin-α5 is the major subunit 
that changes with ischemia.  These findings are in line with our previous studies, outlined in 
Chapter 4, which showed that stroke induced the upregulation of fibronectin and integrin-α5 
within the basement membrane in vivo, and newly show that astrocytes are a major source of 
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these proteins.  Future studies should assess whether downregulation of agrin, collagen XVI 
or fibulin-5 also contributes to the deposition of CSF Aβ1-40 and the formation of CAA 
plaques after stroke.   
We also examined how cytokine expression changes under hypoxia and/or co-
stimulation.  We first examined changes in TGF-β-related genes, and found that OGD 
reduced the expression of TGF-β1, but increased the expression of TGF-βR1.  This is 
interesting, because it suggests that activated astrocytes may be more sensitive to TGF-β1 
due to increased receptor expression.  When we examined other cytokines, we found that Aβ-
stimulated A1 astrocytes produced significantly more TNF-α, CXCL10 and CXCL16, which 
was inhibited by hypoxia.  In contrast, A2 astrocytes produced high levels of IL-6 and IL-10.  
TGF-β simultaneously stimulated IL-6 (pro-inflammatory cytokine) and inhibited IL-10 
(anti-inflammatory cytokine) production, suggesting that it could be shifting the phenotype of 
A2 astrocytes to a more pro-inflammatory state.  This needs to be clarified with further 
studies examining a wider panel of inflammatory cytokines and surface markers. 
 
5.4.4: TGF-β modifies multiple astrocyte functions that are involved in CSF flow.   
While previous studies have shown that TGF-β induces fibrosis with injury, it was 
not known how it impacted astrocyte ECM production, or how these ECM changes modulate 
the deposition of Aβ1-40.  Our results indicate that TGF-β stimulation upregulates fibronectin, 
which was confirmed in vivo.  It also increased in vitro Aβ1-40 uptake, which colocalized with 
regions of increased fibronectin/integrin-α5 expression, indicating that this deposition 
occured extracellularly.  In light of our results from Chapter 4, this finding supports the 
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hypothesis that TGF-β induces astrocytes to modify the basement membrane in a way that 
favors CSF Aβ1-40 deposition. 
 Although previous studies have shown an association between reactive astrogliosis, 
altered AQP4 polarization and impaired CSF flow, it was not know whether TGF-β 
stimulation was sufficient to induce these phenotypes.  Our results indicate that TGF-β 
altered AQP4 expression on astrocytes and induced cell swelling, which impaired water 
uptake.  The impact of TGF-β on these physiological parameters was also confirmed in vivo, 
which occured in the absence of significant increases in GFAP expression.  This indicates 
that classical markers of astrocyte reactivity do not fully predict the functionality of 
perivascular astrocytes, instead requiring the use of A1 and A2-specific markers. 
 
5.4.5: Inhibition of TGF-β signaling rescued fibrosis and perivascular CSF flow in aged 
animals. 
 We first examined the impact of TGF-βR1 antagonism in the subacute phase of injury 
(3 – 7 DPI), and found that it increased injury volume in both you and aged animals.  We 
also found an interesting trend, which suggests an age-specific impact of TGF-βR1 
antagonism in young and aged mice.  While both groups exhibited an increase in injury size, 
only young mice had a corresponding increase in gliosis and ECM fibrosis.  This suggests 
that TGF-β antagonism may actually reduce gliosis in aged mice, but this effect is masked by 
an increase in injury volume.  To test this theory, we repeated the experiment in aged mice, 
but delayed the inhibitor treatment until 7 – 14 DPI to further avoid potential impacts on 
injury volume.  When we used this dosing regimen, we found that TGF-βR1 antagonism 
significantly reduced GFAP and fibronectin expression.  Furthermore, this was associated 
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with increased perivascular CSF flow and a relative decrease in CSF Aβ1-40 deposition.  This 
suggests that this therapy could be used to favorably modulate CSF-ISF exchange in a way 
that boosts the bulk flow of CSF without also increasing the deposition of CSF Aβ1-40.  This 
could be useful in the treatment of CAA in stroke survivors. 
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CHAPTER 6 
Serum Biomarkers of Basement Membrane Fibrosis Are Diagnostic of  
CAA After Intracerebral Hemorrhage 
 
6.1: Introduction   
6.1.1: Overview.   
Our preclinical studies, detailed in the preceding chapters, indicate that TGF-β 
signaling to astrocytes may drive post-stroke CAA by inducing a set of ECM changes termed 
‘basement membrane fibrosis,’ impairing CSF flow.  In particular, fibronectin appears to 
play a major role early in the disease process by sequestering CSF Aβ1-40, potentially causing 
the classic “outside-in” induction of CAA pathology that is typically observed in cortical 
vessels.  Based on these findings, we also sought to explore the contribution of MMPs, which 
are a set of upstream enzymes that release both of these proteins from the ECM during states 
of inflammation.  The studies detailed in this chapter indicate that TGF-β, MMPs and 
fibronectin are biomarkers of CAA-related intracerebral hemorrhage (ICH) in human 
patients.  These interesting results further validate our previous findings in animal models, 
and increase their potential translational value to human disease. 
 
6.1.2: Significance.  
ICH is caused by acute rupture of cerebral vessels, and affects approximately 2 
million individuals each year.281 While hypertension remains the most common cause of 
spontaneous ICH, accounting for half of brain hemorrhages,1 CAA is an additional major 
cause of lobar ICH that will likely increase due to our aging population.97 While probable 
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CAA can be diagnosed by a set of MRI-based radiologic measurements termed the Boston 
criteria, definitive diagnosis requires an invasive brain biopsy that is not feasible for most 
patients.20,282 In theory, identification of a CAA-specific blood biomarker profile could 
facilitate an earlier, cheaper and less invasive diagnosis of CAA.  Additional information 
about the underlying pathology and the prospects for recovery could help to guide 
individualized patient care, significantly improving the clinical management of CAA and 
patient outcomes after ICH.   
CAA is a chronic disease process that involves the progressive accumulation of 
vascular amyloid plaques, leading to reduced vessel integrity, cognitive decline and increased 
susceptibility to ICH.23  Underlying CAA may alter vascular responses to acute ICH, which 
could produce a unique molecular signature that can be measured peripherally.  This 
molecular signature may involve fibronectin, TGF-β and MMPs, which are all interrelated 
molecules that are upregulated centrally in the brains of CAA patients,251,283 as well as 
peripherally in the general response to ICH.  During ICH, MMPs act to enzymatically 
degrade basement membrane fibronectin284–286 and also cleave latent TGF-β, releasing the 
active form into the brain extracellular space.287,288 Degradation of the basement membrane 
leads to BBB disintegration, inducing extravasation of vascular components into the brain 
parenchyma, leading to increased fluid uptake, and recruitment of peripheral immune cells – 
all contributing to secondary injury.289 In contrast, release of TGF-β plays a major role in the 
resolution of brain injury via inducing phagocytosis and the formation of fibrotic scar 
tissue.228,290 Alterations in this divergent pathway could influence recovery from ICH, and 
could also provide insight into the existence of underlying CAA pathology. 
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While the role of these mediators in ICH has been studied to a greater extent in 
animal models, there is less literature on whether they can be used as prognostic markers 
clinically.  Given the central role that MMPs, TGF-β and fibronectin are thought to play in 
the pathophysiology of secondary injury and recovery from ICH, we hypothesize that the 
levels of these mediators are not only associated with initial injury severity, but also with 
long-term functional deficits.  Furthermore, due to significant overlap between expression of 
these markers in CAA and ICH, opening up the potential for disease-specific interactions, we 
also hypothesize that these mediators can also be used to diagnose CAA in the context of 
ICH.   
 
6.1.3: Experimental design.  
For all experiments, we utilized ICH patient data and serum samples from clinical 
repositories at both UT Health and Hartford Hospital.  To test the hypothesis that the serum 
levels of these proteins are biomarkers of injury severity, we performed spearman correlation 
of these putative biomarkers against clinical measures of severity, including hematoma 
volume, radiologic measures of edema, as well as neurological scales of acute injury.  Then, 
to determine whether these biomarkers were independent predictors of functional recovery, 
we developed a multivariable model to compare initial biomarker levels (< 5 DPI) and 
modified Rankin Scale (mRS) score at 90 DPI, which controlled for injury severity and other 
confounding clinical variables.  Finally, to test the hypothesis that these biomarkers can be 
used alone or in combination to diagnose CAA, we performed receiver operating 
characteristic (ROC) analysis to determine whether these cytokines can discriminate between 
CAA and non-CAA hemorrhage in two independent cohorts.   
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6.2: Methods   
6.2.1: Study population.   
The current study utilized ICH patient data and serum samples from Hartford 
Hospital and the University of Texas Health Science Center in Houston (n = 63 patients).  
The study was approved by the Institutional Review Boards at both institutions, and all 
patients participating were consented.  Patient data were abstracted from prospective ICH 
databases detailing admission data, radiology, hospital course and functional outcomes. 
Patients with hemorrhages due to underlying vascular lesions or traumatic brain injury were 
excluded from the study.  For analysis of biomarker correlation with injury etiology, patients 
were divided into three groups: lobar hemorrhage of suspected CAA etiology (n = 21) and 
deep hemorrhage (n = 42). Lobar and deep hemorrhages were defined by the location of the 
ictus on CT, as interpreted by an independent neuroradiologist and confirmed by an 
experienced neurologist. Probable CAA was defined via the Boston criteria and was 
supported by pathological evidence in the majority of patients.20,31 
 
6.2.2: Measurement of neurological function.  
Initial ICH severity was assessed using ICH score,291 National Institute of Health 
Stroke Scale (NIHSS),292 Glasgow Coma Scale (GCS)293 and mRS.294  Additionally, long-
term functional outcomes were assessed by mRS at time of discharge and at 90 DPI.  
 
6.2.3: Radiologic measurements.  
Our primary radiologic outcomes were hematoma volume and intraventricular 
hemorrhage (IVH) volume as quantified via computer-based analysis with MIPAV 
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(Medical Image Processing, Analysis, and Visualization) software.  IVH was scored on a 10-
point scale developed at UT Health.295  Hematoma and IVH volumes were determined 
throughout the patient’s entire hospitalization via review of every head CT obtained as a part 
of routine clinical care until discharge.   
 
6.2.4: Serum sample collection.   
Serum samples were obtained from our study cohort at pre-specified time points from 
0 to 5 days post-ictus. Serial samples were collected from each patient when possible, for a 
total of 136 serum samples. In order to minimize timing bias, all biosamples were timed from 
the onset of ICH ictus and collected by a biospecimen collection team who were blinded to 
the clinical status of the patient.  Samples were processed within 1 hour of collection and 
stored at -80 degrees Celsius until use. 
 
6.2.5: Measurement of serum analytes.   
Samples were thawed on ice for 1 hour and thoroughly vortexed prior to beginning 
any assays.  Serum fibronectin was measured using the Human Fibronectin Quantikine 
ELISA Kit (R&D Systems).  Following activation of latent TGF-β by acidification, TGF-β1, 
TGF-β2 and TGF-β3 were measured using the Bio-Plex Pro TGF-β 3-PLEX Assay (Bio-
Rad).  Similarly, MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, and MMP10 were 
measured using the Bio-Plex Pro Human MMP Panel (Bio-Rad). All assays were performed 
and read according to the manufacturer’s instructions.  
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6.2.6: Statistics.  
Descriptive statistics, including frequency, percent, mean, median, SD, interquartile 
range (IQR), were provided for demographics and admission variables in the subgroups of 
CAA hemorrhage, hypertensive hemorrhage, and overall groups.  Wilcoxon rank sum test 
was used to compare values between CAA and hypertensive hemorrhage (Table 6-1). 
Cytokine levels were averaged between repeated samples from 0 – 5 DPI.  For the combined 
CAA and hypertensive group, spearman correlation method was used to evaluate their 
relation to initial injury scores. P values were adjusted by Benjamini and Hochberg procedure 
(1995)20 to control the false discovery rate (FDR) at 0.05 (Table 6-2). Similar correlation 
analysis was done for mRS at discharge and at 90 days (Table 6-3). Furthermore, a 
multivariable model was used to study the association between mRS at 90 days and several 
early cytokine levels separately, adjusted for hemorrhage type, age, systolic blood pressure, 
hematoma volume, GCS score, IVH and coagulopathy. Descriptive statistics (median and 
IQR) was provided for early cytokine levels and Wilcoxon rank sum test was used to 
compare them between CAA and hypertension hemorrhage (Table 6-4). P values are 
adjusted to control FDR within 0.05. Univariate or multivariable logistic regression was used 
to provide receiver operating characteristic (ROC) curve to discriminate between CAA and 
hypertensive hemorrhage, which was quantified in SAS as the area under the curve (AUC) 
(Fig. 6-1).  All p values were adjusted similarly to control FDR at 0.05. All data analyses 
were performed in SAS software 9.4 (Cary, NC). 
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6.3: Results 
6.3.1: Fibronectin, MMPs and TGF-β are differentially associated with initial hemorrhage 
burden.   
To assess whether peripheral markers were related to injury severity, serum samples 
were first obtained from a total of 62 ICH patients that were subdivided by radiologic 
findings; 21 were patients with acute lobar hemorrhage that met the Boston criteria for 
definite or probable CAA, and 41 were patients with deep hypertensive hemorrhages.  
Groups significantly differed by age, systolic blood pressure, stroke severity (NIHSS, GCS) 
as well as injury volume and IVH (Table 6-1).   
Following correction for the FDR (p < 0.5), we found several cytokines correlated 
with injury severity in our initial univariate analysis (Table 6-2).  All three families of 
cytokines were associated with initial neurological function, as measured by the Glasgow 
Coma Scale (GCS).  Specifically, elevated serum fibronectin was associated with better 
neurological function on admission (GCS, p = 0.003).  In contrast, elevated TGF-β1 (p = 
0.003), TGF-β2 (p = 0.005) and TGF-β3 (p = 0.004) correlated with worse initial 
neurological deficits.  Similarly, patients with high levels of MMP1 (p = 0.003), MMP3 (p = 
0.032), MMP8 (p = 0.003), MMP9 (p < 0.001) and MMP10 (p = 0.002) also exhibited worse 
neurological deficits on admission.  When the ICH score was used to estimate injury severity, 
we found that MMP3 (p = 0.041), MMP8 (p = 0.041), MMP9 (p = 0.012) and MMP10 (p = 
0.041) were also positively associated with increased injury severity.  Finally, MMP10 also 
correlated with increased IVH (p = 0.002).  In summary, these results indicate that 
fibronectin, TGF-β and MMP isoforms are biomarkers of initial injury severity in our cohort 
of ICH patients. 
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Characteristics 
Total 
Cohort 
(n = 63) 
CAA 
Hemorrhage 
(n = 21) 
Hypertensive 
Hemorrhage 
(n = 42) 
P-value Significance 
Age, years (mean [SD]) 67.79 (14.38) 75.76 (9.64) 63.71 (14.78) p = 0.003 ** 
Female (n [%]) 26 (41.94) 10 (47.62%) 16 (39.02%) p = 0.516 ns 
            
Race           
Black (n [%]) 10 (16.39) 2 (9.52%) 8 (19.51%) p = 0.367 ns 
White (n [%]) 39 (63.93) 16 (76.19%) 23 (56.1%) p = 0.367 ns 
Asian (n [%]) 3 (4.92) 0 (0%) 3 (7.32%) p = 0.367 ns 
Hispanic/other (n [%]) 9 (14.75) 2 (9.52%) 7 (17.07%) p = 0.367 ns 
            
Admission systolic blood 
pressure, mm Hg (mean 
[SD]) 
188.04 
(32.34) 
171.55 
(27.23) 202 (30.44) p = 0.03 * 
Admission diastolic blood 
pressure, mm Hg (mean 
[SD]) 
109.83 
(35.25) 96.45 (16.63) 121.15 (42.99) p = 0.145 ns 
GCS (median [IQR]) 14 (4.25) 15 (1) 9.5 (4.5) p = 0.039 * 
ICH score (median [IQR]) 2 (2) 1 (1.5) 2 (2) p = 0.667 ns 
NIHSS (median [IQR]) 12 (17.5) 7 (10) 17 (17.25) p < 0.001 *** 
Initial hematoma volume, 
cm3 (mean [SD]) 
25.76 
(22.74) 37.44 (28.04) 19.08 (15.98) p = 0.015 * 
IVH score (median [IQR]) 0 (5.5) 0 (0) 16 (6) p = 0.006 ** 
 
Table 6-1. Demographics and admission variables by study group. Data are analyzed by 
Wilcoxin Rank Sum Test.  *p < 0.05, **p < 0.01, ***p < 0.001.  
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Admission 
Variable Cytokine Correlation P-value, raw 
Significance, 
raw 
P-value, 
FDR 
adjusted 
Significance, 
FDR adjusted 
Age 
TGF-β1 -0.293 p = 0.021 * 0.144 ns 
TGF-β3 -0.271 p = 0.033 * 0.144 ns 
MMP9 -0.263 p = 0.039 * 0.144 ns 
NIHSS 
TGF-β1 0.356 p = 0.007 ** 0.058 ns 
TGF-β3 0.34 p = 0.01 * 0.058 ns 
MMP1 0.286 p = 0.032 * 0.09 ns 
MMP9 0.296 p = 0.027 * 0.09 ns 
GCS 
Fibronectin 0.495 p < 0.001 *** 0.003 ** 
TGF-β1 -0.484 p < 0.001 *** 0.003 ** 
TGF-β2 -0.431 p = 0.004 ** 0.005 ** 
TGF-β3 -0.446 p = 0.003 ** 0.004 ** 
MMP1 -0.472 p = 0.001 ** 0.003 ** 
MMP3 -0.338 p = 0.027 * 0.032 * 
MMP8 -0.471 p = 0.001 * 0.003 ** 
MMP9 -0.596 p < 0.001 *** p < 0.001 *** 
MMP10 -0.52 p < 0.001 *** 0.002 ** 
ICH Score 
TGF-β1 0.269 p = 0.039 * 0.072 ns 
TGF-β3 0.278 p = 0.033 * 0.072 ns 
MMP1 0.327 p = 0.012 * 0.041 * 
MMP8 0.315 p = 0.015 * 0.041 * 
MMP9 0.414 p = 0.001 ** 0.012 * 
MMP10 0.345 p = 0.008 ** 0.041 * 
Initial Hematoma 
Volume 
TGF-β2 0.289 p = 0.033 * 0.198 ns 
MMP3 0.283 p = 0.036 * 0.198 ns 
IVH Score 
MMP8 0.49 p = 0.018 * 0.065 ns 
MMP9 0.524 p = 0.01 * 0.057 ns 
MMP10 0.609 p = 0.002 ** 0.023 * 
 
Table 6-2. Early cytokine levels and their relation to initial injury scores.  Data are 
analyzed by Spearman correlation, and both raw and FDR-corrected P-values are presented.  
Raw and FDR-adjusted significance: *p < 0.05, **p < 0.01, ***p < 0.001, ns: no 
significance. 
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Outcome 
Variable Cytokine Correlation P-value, raw 
Significance, 
raw 
P-value, Significance, 
FDR 
adjusted 
FDR 
adjusted 
mRS at 
discharge 
TGF-β1 0.336 0.037 * 0.143 ns 
TGF-β3 0.352 0.028 * 0.143 ns 
MMP9 0.326 0.043 * 0.143 ns 
mRS at 90 
days 
Fibronectin -0.302 0.049 * 0.089 ns 
TGF-β1 0.478 0.001 ** 0.012 * 
TGF-β2 0.39 0.01 * 0.035 * 
TGF-β3 0.456 0.002 ** 0.012 * 
MMP1 0.376 0.013 * 0.035 * 
MMP9 0.312 0.042 * 0.089 ns 
 
Table 6-3. Early cytokine levels as predictors of functional outcome scores. Data are 
analyzed by Spearman correlation, and both raw and FDR-corrected P-values are presented.  
Raw and FDR-adjusted significance: *p < 0.05, **p < 0.01, ***p < 0.001, ns: no 
significance. 
	  
6.3.2: Early elevations of TGF-β predict the degree of long-term functional deficits.   
 We next evaluated whether serum fibronectin, TGF-β and/or MMPs were predictive 
of functional outcomes in our ICH patients. Specifically, we analyzed whether cytokine 
levels were associated with mRS at discharge and at 90 days by univariate analysis (Table 6-
3).  While no cytokines significantly correlated with mRS at discharge, increased levels of 
TGF-β1 (p = 0.012), TGF-β2 (p = 0.035), TGF-β3 (p = 0.012) and MMP1 (p = 0.035) were 
all significantly associated with poor mRS at 90 DPI.  To confirm these findings, we then 
performed a multivariate regression to determine whether these effects were independent of 
group differences in admissions data (identified in Table 6-1).  Even when hemorrhage type, 
age, systolic blood pressure, hematoma volume, GCS score, IVH score and coagulopathy 
diagnosis were controlled for, TGF-β1 (p = 0.013), TGF-β2 (p = 0.041) and TGF-β3  
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Table 6-4. Comparison of serum cytokine values in CAA and hypertensive hemorrhage 
patient populations. In general, individual cytokine values did not discriminate between 
CAA and hypertensive hemorrhage. Data were analyzed by Wilcoxon rank sum test, and 
both raw and FDR-corrected P-values are presented.  Raw and FDR-adjusted significance:  
*p < 0.05, **p < 0.01, ***p < 0.001, ns: no significance. 
 
(p = 0.018) remained significant predictors of mRS at 90 DPI.   Overall, these data indicate 
that elevated serum levels of TGF-β1, TGF-β2 and TGF-β3 are biomarkers of poor long-term 
functional recovery, independent of initial injury, baseline characteristics or type of ICH. 
 
 
Cytokine CAA Median (IQR) 
Hypertensive 
Median (IQR) P-value, raw 
Significance, 
raw 
P-value, FDR-
adjusted 
Significance, 
FDR-
adjusted 
Fibronectin 238.92 (136.23) 301.57 (120.76) p = 0.027 * 0.2569  ns 
TGF-β1 33016.03 (78087.73) 
37810.92 
(25226.81) p = 0.094 ns 0.2569 ns 
TGF-β2 1439.43 (9633.69) 
1437.38 
(197.48) p = 0.925 ns 0.9248 ns 
TGF-β3 1300.95 (1795.86) 
1337.94 
(307.26) p = 0.257 ns 0.4035 ns 
MMP1 837.35 (1491.25) 
611.56 
(2100.66) p = 0.693 ns 0.7627 ns 
MMP2 21995.26 (11778.3) 
17540.91 
(11822.09) p = 0.14 ns 0.2569 ns 
MMP3 3384.31 (6346.49) 
4946.22 
(7424.91) p = 0.547 ns 0.6687 ns 
MMP7 2044.58 (1374.17) 
2702.82 
(1530.49) p = 0.129 ns 0.2569 ns 
MMP8 2292.1 (3026.67) 
2473.47 
(4843.15) p = 0.422 ns 0.5796 ns 
MMP9 22055.53 (12685.96) 
28395.04 
(39910.81) p = 0.122 ns 0.2569 ns 
MMP10 1670.3 (892.67) 
2237.56 
(2138.41) p = 0.071 ns 0.2569 ns 
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Figure 6-1. Biomarkers of small vessel fibrosis discriminate between CAA and 
hypertensive hemorrhage. (A) ROC curve comparing CAA and hypertensive hemorrhage 
within the UT Health cohort. (B) ROC curve comparing CAA and hypertensive hemorrhage 
within the Hartford Hospital cohort. 
 
6.3.3: Serum biomarkers distinguish CAA from deep hypertensive hemorrhages.   
 In order to determine whether these biomarkers could function as a diagnostic panel 
for CAA, we first compared individual cytokine levels between CAA and deep hypertensive 
hemorrhage ICH patients (Table 6-4).  Univariate analysis showed that CAA patients tended 
to have lower serum levels of fibronectin and MMPs after ICH, however, none reached 
statistical significance following FDR correction (Table 6-4).  However, when fibronectin, 
MMPs and TGF-β were included in an exploratory multivariable ROC model, the AUC was 
0.8701 (Fig. 6-1A), which was also found in a second exploratory cohort (AUC = 0.8393) 
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(Fig. 6-1B). These results indicate that this test may reliably distinguish between CAA and 
deep hypertensive hemorrhage, but requires further validation in larger independent cohorts. 
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6.4: Discussion  
 In the current study, we extensively characterized the expression profile of multiple 
MMP isoforms along with two downstream targets, TGF-β and fibronectin, in the serum of 
patients with CAA and hypertensive ICH.  We found that these cytokines were modulated by 
both hemorrhage etiology and initial hemorrhage burden.  Importantly, we also delineated 
cytokine profiles that can be associated with (1) positive diagnosis of CAA and (2) long-term 
functional outcomes.  Overall, these preliminary findings highlight multiple candidate 
families of biomarkers that could one day be used to improve the diagnosis and management 
of ICH.  Our ultimate goal is to identify candidate blood biomarkers for CAA-related ICH.  
CAA diagnosis is currently accomplished by cortical biopsy20 or a complex set of radiologic 
measurements termed the Boston criteria.282   However, there are disadvantages to both 
strategies, including cost, invasiveness and requirement for extensive technical expertise, 
making these tests prohibitively challenging outside of highly specialized medical centers.  
Therefore, identification of biomarkers could one day lead to a simple blood test that could 
enable CAA diagnosis in a broader clinical setting.   
 Previous work has shown that CAA is associated with local (e.g. brain tissue) 
changes in TGF-β,251,296,297 fibronectin,251,297 and MMP activation.298,299 However, there is a 
general lack of studies examining these cytokines peripherally (e.g. in the serum) of CAA 
patients with ICH.  We found that CAA was associated with a distinct pattern of cytokine 
expression.  Similar to previous work, we found that TGF-β alone was not diagnostic for 
CAA.300  However, when TGF-β was included with fibronectin and MMPs, the panel as a 
whole could reliably distinguish CAA from deep hypertensive hemorrhage in two 
independent exploratory cohorts.  Further studies with larger patient cohorts are warranted to 
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explore individual cytokines that failed to reach statistical significance, which could further 
improve the diagnostic potential of the cytokine panel in lobar ICH. 
 We also sought to determine how the expression profiles of MMPs, TGF-β, and 
fibronectin relate to clinical characteristics at admission. MMP9 has been previously 
associated with edema and neurologic deterioration after ICH.301 While one previous study 
found that acute reductions in TGF-β were associated with worse long-term outcomes after 
ICH, that study did not differentiate patients by likely CAA and examined platelet-depleted 
plasma228  Finally, previous work using cellular fibronectin-specific antibodies suggested 
high levels of cellular fibronectin in the serum was associated with hematoma expansion and 
poorer outcomes,302 however, cellular fibronectin likely represents a small portion of the total 
circulating fibronectin, measured in our study.  Our data indicates that elevated expression of 
TGF-β and several MMP isoforms were associated with greater initial hemorrhage burden, 
while total serum fibronectin levels were associated with reduced injury severity. Serum 
fibronectin could competitively inhibit MMPs by occupying the MMP active site; further 
work in animal models is required to determine a potential mechanism linking fibronectin 
and reduced ICH severity. 
 Additionally, we also examined whether serum levels of MMPs, TGF-β, and 
fibronectin could serve as prognostic blood biomarkers of long-term functional outcome. 
Previous work has suggested high levels of cellular fibronectin and MMP9 are associated 
with hematoma expansion,302 but there is minimal data regarding long-term prognostication 
(for instance, at 90 DPI).228,301 One study found that MMP3 and MMP9 levels correlated with 
worse functional outcomes after ICH.303  While we found a similar association between mRS 
and MMP9 in our univariate analysis, it did not reach the FDR threshold in our study due to 
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the higher number of cytokines analyzed.  However, we did find that patients with higher 
early levels of TGF-β isoforms exhibited worsened functional outcomes after ICH.  While 
TGF-β may be beneficial in acute injury, chronic exposure to this potent cytokine stimulates 
astrocytes to hypertrophy, divide, and secrete a variety of extracellular matrix proteins, 
leading to increased glial scarring, that has been shown to impede recovery in animal models 
of brain injury, in part by reducing angiogenesis and axonal reorganization.251,304,305,223,306 As 
such, TGF-β measurement during acute injury may allow healthcare providers to better 
identify patients who are most at-risk for long-term disability as early as 24 hours after ICH, 
independent of clinical severity.  
 Altogether, our study suggests these markers of BBB remodeling and fibrosis are 
differentially expressed in CAA and hypertensive hemorrhage, and may serve as serum 
biomarkers of initial injury severity and long-term functional outcomes.  Further work is 
needed to confirm these findings and to refine these targets into a diagnostic panel for CAA.  
A better understanding of the differences in the pathophysiology of deep and lobar 
hemorrhage may aid in future site-specific biomarker identification and the eventual 
development of targeted therapeutics for different types of ICH. 
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CHAPTER 7 
Discussion & Future Directions 
 
7.1: Summary and overview of the literature.   
CAA represents a fascinating area of research, having a wide variety of seemingly 
unrelated risk factors, impacting some individuals and not others, and leading to cognitive 
decline via multiple, potentially overlapping mechanisms.  The etiology of the disease is not 
well understood, and there are no disease-modifying treatments available to CAA patients.  
Our studies represent an attempt to cast a light over the earliest stages of this disease, to 
determine where, when and how the initial induction of amyloid pathology can occur in 
individuals with ischemic stroke.  While the picture is still incomplete, this work serves as a 
starting point for a unified mechanism of CAA induction, and new treatment strategies for 
this devastating disease. 
The story of CAA began when the famed pathologist Rudolph Virchow first 
described amyloid deposits in 1854.23  Over 50 years later, in 1906, a clinical psychiatrist and 
neuroanatomist named Alois Alzheimer discovered brain atrophy when he came across the 
case of Auguste Deter, a 55 year-old woman who suffered from rapidly progressive memory 
disturbances, sleep disruption, mood changes and increasing confusion before her death.307  
At a major medical conference, he described these findings as a “peculiar severe disease 
process of the cerebral cortex” and theorized that her amyloid deposits were the underlying 
cause of her symptoms.307  Like most revolutionary thinkers, his presentation went largely 
unnoticed; fortunately, progress in the field quietly continued forward.307  Just three years 
later, a pathologist named Gustav Oppenheim found that cerebral amyloid deposits tended to 
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occur in two distinct extracellular locations: the parenchymal tissue between neurons, as well 
as the perivascular regions around cerebral vessels, a type of pathology later termed ‘amyloid 
angiopathy’.23  Subsequent investigations confirmed that CAA was an independent disease 
process distinct from Alzheimer’s disease.23  Finally, in 1979, a neuropathologist named 
Haruo Okazaki was the first to associate CAA with vessel wall stenosis, microinfarction, 
microhemorrhages and lobar hemorrhage in dozens of autopsy cases at the Mayo Clinic,308 
bringing us to our current general understanding of the pathogenesis of CAA. 
Since then, the most significant advances in CAA research, from a medical 
perspective, have to do with the detection of disease.  In 1982, C.Q. Mountjoy developed the 
first CAA grading scheme, which assigned an ‘amyloid score’ based on the number of 
amyloid positive vessels in autopsy cases.309  However, this needed further refinement, as it 
did not significantly predict cognitive decline prior to death.309  In 1991, John Vonsattel 
developed a more sensitive/specific grading scheme for CAA, based on brain biopsy.19,20  In 
contrast with the earlier scheme, this method examines individual blood vessels for multiple 
characteristics of CAA, including the amount of amyloid present, the thickness of the tunica 
media, as well as the degree of vessel leakage and fibrinoid necrosis.19  Later, in 1995, John 
Olichney developed a separate scale, which grades the severity of CAA purely based on how 
many leptomeningeal and cortical vessels in a given brain section exhibit amyloid deposits, 
as well as how large the amyloid deposits are on each vessel (Olichney 1995).310  While the 
latter two methods remain in use today, and are required to establish definitive CAA 
diagnosis, the use of non-invasive imaging has spurned an additional leap forward in the 
early detection of CAA.   
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In 2001, Steve Greenberg published validation of the ‘Boston criteria’, which can 
make a non-invasive diagnosis of CAA by counting the number of MRI-visible 
microhemorrhages.31  Since then, these criteria have been updated to include the presence of 
lacunar infarction, leukoairaiosis, superficial siderosis, cortical atrophy and enlarged PVS.311  
Future diagnostic strategies include measurement of CSF Aβ1-40,150 as well as PET imaging 
with fluorbetapir, a compound that binds amyloid deposits in the brain.312  Additionally, the 
development of blood biomarkers for distinguishing CAA hemorrhage from hypertensive 
hemorrhage could further improve the diagnosis of CAA in patients, as we have found in our 
research (see Chapter 6). 
While earlier and more sensitive diagnosis of CAA has already improved patient care, 
in contrast, the search for a cure has raised as many questions as answers.  The bottom line is 
that, while we can now detect earlier disease, the progressive vessel damage and cognitive 
decline cannot be stopped with current therapies.  We still do not understand how this disease 
progresses, and why it impacts more than half of individuals over the age of 80.  These 
outstanding questions largely have to do with a poor understanding of the underlying cause 
of CAA.  For example, why does amyloid pathology develop around the cerebral arteries, 
and not the veins?  Why do these arterial plaques first tend to develop in the cortex and 
cerebellum, rather than other areas of the brain?  Is there a common thread running through 
the multitude of genetic and cardiovascular risk factors for CAA?  Why does sporadic CAA 
only affect the elderly?  In isolation, without predisposing risk factors, do focal events such 
as stroke induce amyloid pathology, or merely accelerate an existing disease process?   
I began my search for answers by examining the literature, and found that a newly 
discovered system of perivascular flow, termed the ‘glial lymphatic’ (or glymphatic) system, 
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bathes the basement membrane of cortical arteries, arterioles and capillaries in a constant 
supply of fresh CSF.125  My research led me to find papers indicating that CSF contains 
waste products such as Aβ1-40,149,150,313 and to wonder whether small amounts of Aβ1-40 could 
recirculate through the arterial basement membrane.  Previous work suggested that stroke 
modifies basement membrane composition,90 but much of this earlier work was studied in the 
context of angiogenesis155,258 or trafficking of immune cells through the BBB.166,169  
Furthermore, the impact of aging on post-stroke basement membrane remodeling had not 
been defined, providing a few potential areas to add to the literature.  Given that CAA is 
associated with basement membrane alterations,280 that pathology is initiated within the 
superficial cortical PVS,20,314 and that elevated levels of CSF Aβ1-40 represents the earliest 
biomarker of CAA development,250 I proposed that we could build a coherent mechanism of 
CAA based around this newly discovered physiology. 
 
7.2: Review and critical analysis of current research findings. 
Upon beginning our work at UT Health, I first independently confirmed the existence 
of perivascular CSF flow in a series of early experiments, detailed in Chapter 3.  We used 
intracisternal Evans blue dye injection to grossly examine CSF flow pathways through the 
cisterns that surround the brain, and then sectioned the brains to confirm that this dye rapidly 
penetrated into the deepest brain structures.  Next, we verified that this dye influx occurred 
along perivascular routes by simultaneously labeling plasma and CSF with fluorescent dyes, 
and found that they co-labeled vascular structures.  With this basic knowledge in hand, we 
then performed a series of quantitative time-course experiments to examine the influx 
kinetics of small tracers into the brain, as well as the clearance of Αβ1-40 relative to larger 
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proteins.  Over the course of these experiments, we discovered something interesting: CSF 
solutes were partitioned into separate layers of the basement membrane based on size.  This 
unexpected finding provided us with early evidence that the basement membrane plays an 
active role in regulating the distribution of CSF solutes, which could have significant 
implications for our current understanding of how and why Αβ1-40 deposits within the 
basement membrane in certain individuals. 
Based on both my literature review and these exciting preliminary data, I developed a 
new hypothesis that a family of stroke-induced basement membrane changes, broadly 
defined as fibrosis, could impact the perivascular flow of CSF in two major ways.  First, I 
imagined that overall hypertrophy of the basement membrane could provide focal 
interruptions in the flow of CSF through these perivascular pathways.  This might be similar 
to how a blood clot occludes an artery, but outside of the vessel.  Second, I predicted that 
increases in perivascular fibronectin, a common component of blood clots, amyloid plaques 
and the injured basement membrane, could bind CSF Aβ1-40 at physiologically relevant 
concentrations, forming the beginnings of perivascular pathology.  Together, these 
phenomena could lay a trap for CSF Aβ1-40 as it circulates through the basement membrane 
after stroke.  This could further worsen in aged animals due to their reduced CSF turnover 
and increased propensity to form fibrotic glial scars after injury, explaining why aged 
individuals are particularly vulnerable to CAA. 
After some debate, we decided to model experimental stroke by using permanent 
DMCAO, a well-established experimental model of cortical infarction,253 which I had been 
introducing to our laboratory as a new technique.  While the injury size in the ischemic-
sensitive Balb/c mice proved to be too large for accurate physiology measurements, we found 
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that C57BL/6 mice exhibited a loss of just 10-15% of brain tissue within the injured 
hemisphere, which was not modified by aging.  The latter combination provided an ideal 
model for several reasons, including a restricted cortical location, greater reproducibility of 
injury size for our physiological measurements, low mortality for our longer-term studies, 
and no significant impact of aging on injury volume.   
Upon beginning our experiments, we quickly found that DMCAO increased the 
expression of fibronectin and its co-receptor integrin-α5, and also increased tomato lectin 
binding to the basement membrane (presumed to be due to increased vascular HSPG 
content).  In particular, integrin-α5 and lectin+ matrix was highest in aged animals with 
stroke, which had not been shown previously.  When we measured CSF influx using 
fluorescent 3 kD dextran particles, we discovered that aging and stroke both dramatically 
restricted the distribution of these solutes.  The intensity of basement membrane lectin 
staining exhibited a weak, but statistically significant negative correlation with dextran influx 
in aged mice with stroke.  This was our first suggestion that basement membrane proteins 
could impact perivascular CSF flow.  At the same time, when we co-injected fluorescent Aβ1-
40, we found that they formed superficial, perivascular deposits in aged mice with stroke.  
This was particularly apparent in vessels around the infarct, as well as more broadly in an 
astrocyte and fibronectin-rich region of the brain called the glia limitans.  In contrast to 
dextran, we found that the degree of Aβ1-40 deposition strongly correlated with lectin 
intensity.  We also found that Aβ1-40 deposits strongly colocalized with fibronectin and 
integrin-α5 staining.  Additionally, we tested the affinity of fibronectin for Aβ1-40 in vitro, and 
found that they bound each other at physiological concentrations.  These fibronectin-Aβ1-40 
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conjugates deposited more readily into the brains of naïve young mice, indicating that 
fibronectin contributes to the deposition of Aβ1-40 in aging and after stroke. 
The above experiments support our hypothesis that the basement membrane 
specifically impacts the transport of CSF Aβ1-40, which was particularly evident in aged mice 
with stroke.  A major strength of this study is the use of a disease-relevant injury model in 
aged animals, which adds significant translational value to our findings.  Another strength is 
that, unlike many of our contemporaries,208 we used recombinant Aβ1-40 in addition to size-
matched dextran molecules.  This proved to be important, as we found that the behavior of 
Aβ1-40 differed significantly in vivo, highlighting the need to use the actual peptide to draw 
any relevant conclusions about its transport through the brain extracellular space. 
My decision to use wild-type mice, which do not develop amyloid pathology with 
aging, provides some interesting benefits and drawbacks to our study.  We chose to use these 
mice over the existing transgenic AD model mice because we were most interested in 
studying the very earliest stages of CAA pathology.  My choice to inject recombinant Aβ1-40, 
rather than relying on genetic overexpression, allowed us to precisely control the timing and 
route of exposure, providing us with the ability to specifically study the behavior of CSF 
Aβ1-40 in the absence of any pre-existing amyloid pathology.  However, there are downsides 
to our approach.  The biggest weakness is that it raises the question as to whether or not we 
are really modeling CAA—we have no way of knowing whether these small deposits, which 
form over the course of just 30 minutes, are stable and could develop into mature CAA 
plaques.  Since these wild-type mice cannot develop CAA pathology, we could not directly 
study the impact of CAA on post-stroke cognitive function.  Additionally, due to the need to 
remove the brain to measure tracer distribution, we were restricted to single time-point 
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studies and therefore could not study the growth of these deposits over time (this has since 
been remedied by the establishment of an in vivo two-photon microscopy core).  We are 
currently working to address these weaknesses by performing DMCAO in multiple strains of 
AD model mice, including Tg2576, TgSwDI, and APP/PS1, then staging plaque pathology 
and measuring cognitive function.  This will be further elaborated in later discussions of 
future directions. 
The other major weakness is the lack of fibronectin knockout experiments, which 
would be a useful final confirmation of the importance of fibronectin in the context of stroke.  
While we had considered this experiment, we concluded that it was not feasible for us, 
because fibronectin knockout is embryonically lethal, and alternative strategies, such as 
antibody therapies, do not cross the BBB efficiently.  Future studies could be performed to 
engineer an inducible knockout of fibronectin using a cre/flox system, but establishing these 
lines is very expensive and time-consuming, forcing us to conclude that it was beyond the 
scope of my fellowship.  However, this weakness is partially addressed in the next set of 
experiments, which indirectly reduces perivascular fibronectin expression by inhibiting 
upstream signaling pathways with a more translational approach. 
After establishing the role of basement membrane fibrosis in impairing the transport 
of CSF Aβ1-40, I next sought to better understand how basement membrane composition is 
regulated in the brain, and whether manipulating these upstream pathways can reverse post-
stroke increases in fibronectin in young and aged animals.  Returning to the literature, I 
found that astrocytes, endothelial cells and pericytes all play potential roles in regulating the 
composition of the basement membrane,90,196 and that TGF-β is a major inducer of 
fibronectin expression and CAA pathology.219,251,280,304  However, it was not known which 
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cell types that TGF-β stimulates to produce fibronectin, or whether inhibiting TGF-β 
signaling would sufficiently reduce these changes after stroke.  Earlier on, I had acquired 
some preliminary data showing that stroke increased perivascular GFAP expression, which is 
a nonspecific marker of astrocyte activation, and that this activation primarily occurred on 
astrocytic endfeet apposed to perivascular fibronectin deposits.  This led me to hypothesize 
that TGF-β activates astrocytes to remodel the basement membrane, impair the perivascular 
flow of CSF, and produce fibronectin to trap CSF Aβ1-40.  Based on this idea, I further 
hypothesized that delayed inhibition of TGF-β could reduce perivascular gliosis, reverse 
basement membrane fibrosis and improve perivascular CSF flow. 
We first examined how aging and stroke interact to induce astrocyte reactivity by 
performing DMCAO in young and aged mice, then examining GFAP and vimentin 
expression seven days later.  We found that aging increased astrocyte reactivity at baseline 
and following stroke, and that this phenomenon also occurred in perivascular astrocytes.  
Surprisingly, while aging did not increase total TGF-β expression, it did alter the downstream 
signaling pathways to a potentially detrimental Smad3 phenotype.  To better understand how 
ischemia, TGF-β and Aβ1-40 interact to regulate astrocyte phenotype (defined as A1 and A2), 
we then cultured primary murine astrocytes and exposed them to those stimuli in various 
combinations.  We found that Aβ1-40 and ischemia induced opposing phenotypes (A1 and A2, 
respectively), and that TGF-β played more of a modulatory role in altering the expression of 
a variety of ECM proteins and cytokines.  Beyond these acute changes in astrocyte 
phenotype and gene expression, we also found that chronic exposure to TGF-β induces 
astrocytes to express fibronectin and integrin-α5 at high levels, which colocalized with 
fluorescent Aβ1-40 in vitro.  We further found that TGF-β altered AQP4 polarization, and 
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reduced water uptake by astrocytes, which has been shown to also be important for 
maintaining efficient CSF flow by other laboratories.125  We confirmed our findings by 
injecting TGF-β into young mice in vivo, and found similar effects of treatment.  Overall, 
these studies uniformly support a detrimental role of TGF-β on basement membrane fibrosis, 
Aβ1-40 distribution and CSF flow.    
Based on all of this information, we finally sought to determine whether inhibiting 
TGF-β could rescue the stroke-induced changes in astrocyte reactivity, basement membrane 
composition and CSF Aβ1-40 transport that we had repeatedly observed in our previous sets of 
experiments.  We initially bred GFAPcre/wt x TGFβR2flox/flox mice to specifically inhibit TGF-
β signaling to astrocytes, but found that peripheral treatment with a TGF-βR1/R2 antagonist 
was a far more effective strategy.  As predicted, we found that TGF-β inhibition reduced 
astrocyte reactivity, downregulated perivascular fibronectin expression, rescued CSF flow 
and reduced the binding of CSF Aβ1-40 to the basement membrane.  These final experiments 
confirm the role of TGF-β in mediating these changes, but leave a question hanging over the 
sole importance of astrocytes in this process.  
One strength of these experiments is the use of primary cells for our in vitro models, 
which we feel better represents the function of astrocytes in our animal models than 
immortalized cell lines.  An additional strength is that we confirmed our most important 
findings with both in vitro and in vivo systems, further improving our confidence in these 
data.  Finally, another strength is the use of a peripheral TGF-β antagonist following stroke, 
which provides a more translational approach for drug delivery than other potential 
strategies. 
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However, there are also some weaknesses in our approach.  First, while gliosis was 
higher in the aged animals, the absolute levels of TGF-β did not change.  We attribute this 
discrepency to different patterns of Smad activation, but we were not able to confirm this 
with Smad mutant mice as it was beyond the scope of my aims.  This could be examined by 
more robust follow-up studies involving knockouts of these various downstream signaling 
pathways.  An additional potential weakness is that we elected to use in vitro stimulation of 
primary astrocyte cultures, rather than a more intensive approach involving in vivo 
stimulation of astrocytes, followed by ex vivo cell sorting techniques used by other 
laboratories.240  While in vivo stimulation may provide a more accurate representation of in 
vivo cellular responses,239 we selected our approach because it allowed us to study the 
behavior of these cells in isolation over longer periods of time.  This gave us a chance to also 
measure the impact of chronic stimulation on protein expression, Aβ1-40 deposition and water 
uptake.  However, other cells, particularly pericytes and endothelial cells, could also be 
playing a role in vivo, necessitating further studies of other cell types.  Finally, the biggest 
weakness of these studies is that GFAPcre/wt x TGFβR2flox/flox genotype was significantly less 
effective than the inhibitor studies in our hands.  While our initial experimental design 
dictated that we induce the knockout a full seven days after stroke to avoid detrimental 
effects due to increased inflammation,229 pre-stroke induction may be more effective at 
inhibiting TGF-β signaling.  In addition to these technical issues, other cell types may 
respond to TGF-β in similar ways, potentially compensating for the effects of the conditional 
knockout compared to the more effective global inhibitor strategy. 
As we completed these animal experiments, I also began to examine whether 
molecules associated with basement membrane fibrosis could be used as clinical biomarkers 
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of CAA in the serum of human ICH patients.  A review of the literature revealed that there 
were very few studies of serum biomarkers for CAA, with the majority examining the levels 
of serum amyloid species and finding contradictory results.315  I hypothesized that serum 
levels of levels of fibronectin, TGF-β and MMPs would correlate with CAA diagnosis, injury 
severity and functional outcomes.  I was fortunate to collaborate with a clinical researcher 
who had collected serial serum samples and obtained extensive medical records from ICH 
patients.  Based on a combination of imaging and histopathological criteria, we were able to 
classify patients with lobar hemorrhages due to probable CAA, and compare those with 
patients who had deep hypertensive hemorrhages. We found that MMPs positively correlated 
with injury severity in a univariate analysis, TGF-β negatively correlated with functional 
outcomes even with multivariate correction, and when all cytokines were included in a 
preliminary ROC analysis, we found that they provided a panel for CAA diagnosis that was 
sufficiently sensitive and specific to reliably discriminate CAA from other types of ICH.  
The strengths of our study include the use of prospective ICH cohorts from two 
separate institutions, which allowed us to independently validate our findings with respect to 
the ROC analysis.  Also, the use of plasma allows for minimally inavasive screening of 
CAA, compared to other strategies that involve expensive and time-consuming MRI, or 
potentially dangerous collection strategies such as lumbar puncture to collect CSF, or even 
invasive brain biopsies requiring removal of the skull and cortical tissue.  An additional 
strength was the overall novelty of the findings and the immediate potential for translation to 
human patients.  The lack of a realistic and reliable screening test for patients represents a 
major roadblock to early intervention in the pathogenesis of CAA, which can only be 
remedied by the development of more reliable blood biomarkers such as these molecules. 
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Of course, this study has some important limitations.  First, due to limited sample 
availability, we were faced with some underpowered comparisons and an overall lack of 
statistical significance of individual cytokines between CAA and hypertensive hemorrhages.  
This weakness will be remedied in future follow-up studies with larger patient cohorts, for 
which we are already seeking funding.  Second, missing time-points over the five day 
collection period required us to average values from each patient, rather than directly 
comparing individual time-points.  While this is not ideal, we found that cytokine values 
were stable over this collection period, with no statistically significant variation with time, 
mitigating this problem.  Finally, we were unable to obtain histopathological confirmation of 
CAA in all of the ‘probable CAA’ patients, as it would have required an invasive brain 
biopsy that was sometimes not needed by the patient.  This required us to rely on suboptimal 
MRI biomarkers to define CAA in a subset of our patients.  This will be addressed in future 
studies with larger cohorts, which will allow us to require a definitive, biopsy-confirmed 
positive or negative diagnosis in all patients. 
 Overall, while each study has their own unique strengths and weaknesses, as a whole 
they provide an interesting take on CAA that deserves further study.  From recombinant 
peptides, to cultured cells, to mouse models, and all the way up to human patients, our 
experiments consistently demonstrate the importance of these molecules in influencing the 
spread of amyloid pathology after injury.  In the remainder of this discussion, I will attempt 
to synthesize these results with the existing literature into an updated model of CAA 
pathogenesis.  Then, I will describe several exciting new areas of investigation, a few of 
which are already underway in our laboratory. 
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Figure 7-1: Working model of CAA pathogenesis.  CAA can be divided into multiple 
phases, with early CAA being characterized as “pre-pathology” and advanced CAA 
characterized by perivascular amyloid plaques and microhemorrhages. 
 
7.3: Developing a new model of CAA pathogenesis.   
While previous disease models begin with perivascular amyloid pathology, my data 
indicate that there are predictable, early changes that occur within the basement membrane 
before this pathology develops.  This provides a potential unified mechanism that could 
predict areas that are susceptible to CAA before significant damage occurs.  Based on my 
findings and the most current literature, CAA can be broken down into three general stages: 
early, intermediate and late.  In the early stages of CAA, insults such as ischemic stroke 
increase TGF-β expression, which signals to astrocytes to induce basement membrane 
fibrosis.  These fibrotic changes include an increase in fibronectin, integrin-α5 and overall 
lectin+ matrix.  In the intermediate phase, fibrosis promotes the initial sequestration of CSF 
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Aβ1-40, which freely circulates through perivascular flow networks under normal conditions.  
As Aβ1-40 deposition increases, plaque size in affected vessels begins to increase rapidly.  
Finally, in the late stages of CAA, mature plaques induce chronic inflammation that leads to 
microhemorrhage and/or lobar ICH, as well as cognitive decline.   
This proposed pathogenesis of CAA is analagous to atherosclerotic plaque formation, 
which occurs due to the deposition of cholesterol within areas of fibrosis that line the vessel 
lumen.316  In the early stages of atherosclerosis, the walls of vessels become fibrotic due to 
repeated insults, including hypertension, hyperglycemia and free radicals.  In the 
intermediate stage, cholesterol deposits within this scarred area and forms an atherosclerotic 
plaque.  Finally, in the late stages, this deposition causes a local inflammatory response that 
can result in thrombi and acute ischemia.  This simple model has led to the development of a 
plethora of disease biomarkers, pharmacological treatments and even surgical interventions 
to protect patients from advanced atherosclerosis, unstable plaque formation and blood 
clotting.  Application of these ideas could lead to similar advances in the diagnosis or even 
treatment of CAA. 
If this new model of CAA is correct, then the underlying disease process which drives 
cognitive decline in stroke survivors could be targeted in several places.  The most 
straightforward method would be to prevent damage from occuring in the early stages of 
disease, most effectively by primary prevention of stroke and other risk factors such as 
hypertension, hyperglycemia and hypercholesterolemia.  Following stroke, the intermediate 
phase could be targeted by reversing overall basement membrane fibrosis (for example, with 
a TGF-β antagonist) or by directly inhibiting individual receptors that bind to CSF Aβ1-40 
(fibronectin, integrin-α5 or HSPGs).  An alternative strategy would be to develop drugs that 
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reduce the levels of CSF Aβ1-40, which may at least slow the development of the plaques, 
analagous to the use of statins in patients with hypercholesterolemia.  Once the disease 
reaches the later stages, where secondary vessel damage has occurred and the patient has 
multiple microhemorrhages, it may be too late to intervene with these strategies.  
Unfortunately, most patients are not diagnosed with CAA until this very late stage of disease, 
highlighting the need for early detection.315  However, we found that these molecules are 
useful biomarkers for CAA in this population, which may help to identify at-risk patients and 
reduce the prescription of anticoagulant drugs, which could put them at further increased risk 
of repeated hemorrhage. 
While this new disease model is interesting, there are several areas that require further 
discussion and more research to refine it into a useful predictive tool.  First, translating this 
work to AD model mice would help to confirm that these early and intermediate changes in 
the basement membrane lead to CAA plaques in AD model mice.  Second, a better 
understanding of how multiple basement membrane receptors for CSF Aβ1-40 interact to 
favor the development of CAA would help to develop more selective therapeutics.  Third, the 
number and function of different basement membrane sub-layers, and how disrupted 
perivascular flow in each compartment contributes to CAA pathogenesis, needs to be better 
understood.  Further evaluation of the regulation of CSF Aβ1-40 levels could also lead to the 
development of an alternative class of therapeutics for CAA.  Overall, given the evidence 
that we have obtained from our experiments, post-stroke CAA may share mechanisms with 
so-called ‘sporadic’ CAA, which could significantly expand the applicability of our findings 
to numerous other patients, beyond stroke survivors. 
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7.4: Exploring the contribution of reactive astrocytes to CAA pathology.   
My previous work found that TGF-β stimulates astrocytes to deposit fibronectin 
within the extracellular matrix in vitro, which is associated with reduced fluid uptake and 
increased Aβ1-40 deposition.  We further found that inhibition of TGF-β reduced fibronectin 
expression, improved CSF flow and reduced CSF Aβ1-40 deposition following stroke in aged 
wild-type mice.  While this research indicates that basement membrane fibrosis occurs prior 
to Aβ1-40 deposition, we do not yet know whether these changes accelerate CAA plaque 
formation.  Furthermore, we also have not yet determined the long-term impact of CAA 
pathology on basement membrane composition, perivascular flow, recovery from stroke or 
overall cognitive function.  Finally, we also do not know whether long-term TGF-β inhibition 
can rescue these phenotypes associated with advanced CAA.   
Therefore, to better understand the significance of these findings on overall CAA 
pathogenesis, we propose to study the impact of DMCAO and TGF-β inhibition in Tg2576 
mice, an animal model of Alzheimer’s disease, using in vivo two-photon microscopy and 
cognitive testing.  We hypothesize that DMCAO will accelerate CAA progression in Tg2576 
mice, leading to worse cognitive function after stroke.  We further hypothesize that these 
phenotypes will be rescued by inhibiting TGF-β signaling in Tg2576 mice with stroke. 
 To characterize whether stroke-induced deposition of CSF Aβ1-40 contributes to CAA, 
we will first place a cranial window in Tg2576 and wild-type animals, then perform 
DMCAO or sham surgeries one month later.  Since Tg2576 mice do not generally develop 
CAA pathology until 13 months of age, we will examine the impact across different stages of 
pathology by using 3, 9, 13 and 18-month-old age-matched controls for all experiments.  To 
evaluate CAA pathology, mice will be repeatedly injected with Methoxy-X04 (a congo red-
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derivative amyloid staining fluorescent dye) and imaged by two-photon microscopy over one 
month.  Cognitive testing (Fear conditioning, Y maze, novel object recognition test [NORT], 
Barnes maze) will also be performed on these animals prior to sacrifice.  Finally, we will also 
perform IHC after sacrifice to determine how genotype, age and surgery interact to alter 
basement membrane composition.   
In a second set of experiments, mice will receive an intracisternal injection of FITC-
Aβ1-40 at the time of two-photon imaging to determine whether CSF Aβ1-40 contributes to the 
development of these mature CAA plaques.  Finally, in a third set of experiments, instead of 
DMCAO, both genotypes will receive ICV injections of recombinant TGF-β, and the impact 
of treatment on the above histopathological and behavioral measures will be assessed over 
one month.  We expect that DMCAO and TGF-β treatment will similarly increase Methoxy-
X04 labeling of vessels in Tg2576 mice, which will colocalize with intracisternally injected 
FITC-Aβ1-40.  If successful, these experiments could definitively show that stroke is an 
independent risk factor for CAA, and that this acceleration occurs, in part, due to the 
deposition of CSF Aβ1-40.  It could also show that TGF-β alone is sufficient to induce these 
changes, paving the way for subsequent experiments exploring the impact of TGF-β 
inhibition on plaque development. 
 Then, to determine whether inhibiting TGF-β signaling reduces CAA development 
after stroke, we will perform DMCAO in Tg2576 mice and treat them with a TGF-βR1 
antagonist (GW788388) or vehicle control via continuous peripheral and/or central infusion.  
Our previous data in aged wild-type mice found that peripheral treatment with this inhibitor 
reduced perivascular gliosis and fibronectin expression, as well as improved perivascular 
CSF flow.  We expect that TGF-βR1 antagonism will have similar effects on Tg2576 mice, 
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with the added benefit of reducing CAA development and improving long-term cognitive 
function.  If successful, these experiments would indicate that peripheral TGF-βR1 
antagonism can blunt the impact of stroke on accelerating CAA pathology, potentially 
leading to a new therapy for CAA that could be explored in higher-order model systems.  In 
the future, drugs like this could be given prophylactically to patients with stroke or other 
types of acute brain injuries who are at risk of developing CAA. 
 Overall, these experiments represent a critical next step for our research program, and 
we are excited to have secured NIH/NIA R01 grant funding to continue this work over the 
coming years.  While we already have some data suggesting a potential benefit of TGF-βR1 
antagonism on perivascular CSF flow, these experiments could show that these benefits 
extend to histopathological and behavioral improvements in animal models of CAA.  There 
is significantly more work to be done, but following these confirmatory experiments, our 
findings could be rapidly translated to clinical populations, given the ongoing use of 
combinatorial TGF-β antagonists in other diseases, including cancer and pulmonary fibrosis.   
 
7.5: Modulation of basement membrane receptors to improve CSF flow and reduce CAA.   
While previous work has documented that basement membrane changes correlate 
with the severity of CAA pathology, our findings newly demonstrate that aging and stroke 
produce upregulation of fibronectin and its receptor, integrin-α5.  Importantly, these changes 
occurred prior to the development of pathology.  We further found that these changes 
correlated with increased perivascular distribution of CSF Aβ1-40 and reduced CSF flow, 
suggesting a structure/function relationship between these basement membrane changes and 
perivascular transport.  These new findings provide significant insight into the pathogenesis 
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of CAA, as it suggests that these changes could be a cause, not a consequence, of the 
development of amyloid pathology. 
As one future direction, we could continue to develop this pathway as a therapeutic 
target by examining the impact of fibronectin and/or integrin-α5 knockout on the progression 
of CAA.  For example, to test the hypothesis that astrocytic fibronectin accelerates CAA 
pathology, conditional fibronectin knockouts (GFAPcre/wt x FN1flox/flox) could be crossed with 
a rapidly progressing CAA model mouse, such as the TgSwDI strain, and 
pathology/cognitive deficits examined across the lifespan, at 3, 6, 12 and 24 months of age.  
Cognitive impairment could be measured using a battery of tests, including NORT, Barnes 
maze and contextual fear conditioning.  Amyloid pathology could also be quantified 
histologically by staining brain sections with Thioflavin S, Congo Red or anti-amyloid 
antibodies such as 4G8 monoclonal antibody.  I expect that fibronectin knockouts would 
exhibit less CAA pathology and better cognitive function by 12 months of age, and would 
most likely be resistant to other potential amyloidogenic stimuli such as stroke or advanced 
age.  If these experiments are successful, an interesting next step would be to 
pharmacologically target fibronectin using intracisternal administration of antibody-based 
inhibitors, although the precise binding site of Aβ1-40 to fibronectin would need to be 
determined by synthesizing mutant fibronectin type I domain in vitro, followed by repeated 
binding assays with each isoform.  Additionally, integrin-α5 small molecule inhibitors 
already exist (ATN-161), and could be used to reduce the binding of fibronectin to integrin-
α5.  This may also help in a more selective way by preventing the deposition of fibronectin-
Aβ1-40 aggregates, without a need to identifying the exact binding site for Aβ1-40 on 
fibronectin. 
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An additional, ongoing area of study is using unbiased proteomics to discover new 
ECM proteins that may be involved in regulating perivascular flow.  The glia limitans is an 
ECM-rich area that forms a barrier between the meningeal/vascular compartments and the 
brain interstitial fluid.  As such, it may provide a first line of defense against the penetration 
of damaging CSF waste products, or toxic products that could enter from the peripheral 
circulation into the brain.   We previously found that lectin staining strongly increased within 
the glia limitans and basement membrane following DMCAO in aged animals, indicating 
increased expression of glycosylated residues.  This finding suggests that the composition of 
the glia limitans is changing, but, beyond increases in fibronectin and integrin-α5, we do not 
know how many other ECM proteins may be involved.  Therefore, we hypothesized that 
aging and stroke would alter the glia limitans proteome, in large part due to abnormal 
production of ECM proteins.  To test this hypothesis, we performed DMCAO in young and 
aged mice, then sacrificed them at 30 DPI and collected fresh brain tissue, plasma and CSF.  
We then sectioned the brain tissue on a cryostat, mounted it onto a PEN membrane and 
performed H+E staining to visualize the glia limitans.  Next, we performed laser capture 
microdissection to isolate the outer glia limitans from the rest of the brain.  We are currently 
awaiting LC/MS results, but our preliminary findings indicate detection of >1200 unique 
peptides in our test samples.  Upon completion of this project, we expect that it will generate 
a significant amount of new information about the protein composition of the glia limitans at 
baseline, as well as how it changes with aging and stroke.  This could provide new targets, 
which could then be assessed for binding potential to Aβ1-40, using similar techniques as 
described in Chapter 4. 
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7.6: Brain perivascular flow dynamics may have a molecular size sensitivity.   
Our experiments indicate that the perivascular flow rate is size-dependent, and occurs 
in different basement membrane layers.  We found that larger particles (70 – 2000 kD) 
traveled through the outer region of the basement membrane, and cleared slowly from the 
ISF.  In contrast, smaller particles (0.5 – 4.5 kD), including Aβ1-40, were associated with the 
inner basement membrane and cleared more rapidly from brain tissue.  These findings were 
surprising, as previous studies suggested that CSF solutes are transported by bulk flow, 
which dictates that all particles will move at the same rate, regardless of mass.125,199,200  The 
best interpretation of these data is that passive diffusion interacts with bulk flow to produce a 
dynamic process that cannot be described as purely one or the other. 
It is important to recognize that this process of perivascular flow and solute exchange 
is actually dependent on two distinct compartments: the vascular basement membrane 
compartment (between endothelial cells and astrocyte endfeet) and the interstitial 
compartment (between astrocyte endfeet and other cells such as neurons and 
oligodendrocytes).  If one were to track the movement of a single particle, initially, it may be 
rapidly distributed through the perivascular compartment by a process that has been 
historically attributed to bulk flow.  However, our data suggest that this process is modified 
by certain biophysical properties of the basement membrane (collectively termed ‘tortuosity,’ 
reviewed in Section 1.8), which generate a size-exclusion property within the perivascular 
compartment.202  Our data indicate that the certain regions of basement membrane are more 
selective for small particles, while the others permit the transport of very large particles.  
This property could be a function of tortuosity, which largely depends on the conformation of 
the ECM, which itself depends on composition.  This tendency for particles to diffuse at 
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different rates through different regions of tissue is called anisotropy, and is best measured 
by sensitive techniques such as TMA iontophoresis.202  However, even without this 
technique, we can infer from our data that the structure of the outer basement membrane 
must differ from the inner basement membrane to produce this divergent physiology. 
Following this process of perivascular distribution, which is partly driven by bulk 
flow, CSF solutes must then exchange with ISF solutes.  To accomplish this, particles must 
diffuse between the perivascular and interstitial compartments.  We found that large 
molecules (2000 kD dextran) did not travel into the interstitium, while small molecules (3 kD 
dextran) easily traveled into the interstitium.  If this process were solely governed by bulk 
flow, then one would expect that both particles would travel equally far from the PVS.  
Given the fact that this does not occur, and that travel distance is strongly dependent on the 
hydrodynamic radius (or ‘size’) of the diffusing particle, then this process must be governed 
by the forces of passive diffusion (as predicted by the Stokes-Einstein equation).202  In 
addition to molecular size slowing down the process of diffusion, our data also suggest that 
the glial endfeet, which form the border between the perivascular and interstitial 
compartments, could also provide an anisotropic size-exclusion barrier to larger particles. 
This property may also contribute to the much slower clearance of intraparenchymally 
injected albumin, which is a measure of the reverse phenomenon: ISF-CSF exchange.  An 
alternative interpretation is that the entire interstitial compartment excludes large particles, 
not just the glial endfeet.  However, it is not currently possible to discern which interpretation 
is most accurate from the present data, and would require additional, careful studies with 
more sensitive techniques, such as TMA iontophoresis. 
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This size-exclusion barrier between basement membrane sublayers, as well as 
between the perivascular and interstitial compartments, may have important consequences 
for the pathogenesis of CAA.  In CAA, there is initially a selective build-up of Aβ1-40 within 
the outermost layers of basement membrane of the outermost cortical vessels, which then 
moves inward in both directions as pathology advances.94  This suggests that these size-
exclusion properties could safeguard the vessels against this perivascular pathology, but this 
later becomes dysregulated and ultimately fails in CAA (potentially due to fibrosis).  While 
monomeric Aβ1-40 is small enough to travel within the inner basement membrane layer, the 
assembly of these monomeric particles into oligomers and eventually much larger aggregates 
could form mature CAA plaques that are excluded from the inner membrane and exist within 
the less efficient outer membrane.  
Furthermore, the segregation of the perivascular and interstitial compartments may 
explain the propensity of cortical pathology to begin with vessels,317 as these larger 
oligomers may be able to distribute perivascularly through the outer basement membrane, but 
not be able to spread into the interstitial space.  However, when the plaque becomes large 
enough to cause inflammation and damage this barrier, oligomers can spread into the 
interstitium and further spread pathology throughout the surrounding area.  This concept is 
somewhat similar to metastasis of cancer, as amyloid pathology in one region of the brain 
(such as the hippocampus) may eventually disrupt these insulating barriers and allow for 
toxic oligomers to ‘infect’ the CSF and spread to distant sites via perivascular flow. 
The biggest unanswered question from these experiments is: which proteins are 
responsible for generating this size-exclusion property?  Previous studies have shown that 
HSPGs within the glycocalyx support the repulsive properties of the BBB,90,241 but it is not 
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know whether the HSPGs contained within the basement membrane also produce this 
function of size-exclusion of CSF solutes between membrane sublayers.  As a next step, this 
question could be answered by electron microscopy, which would allow us to visualize the 
ultrastructure of these ECM proteins.  Immunogold labeling of specific classes of basement 
membrane proteins (collagens, laminins, fibronectin, glycosaminoglycans) could demonstrate 
potential differences in the composition of these basement membrane sub-layers.  Then, 
knocking out individual proteins that are enriched in these different layers, and examining the 
relative perivascular transport of small and large gold-labeled dextran particles, could begin 
to address the physiological significance of these differences in structure/composition within 
the specific sub-layer.   
For example, if protein A were found to be enriched in the inner basement membrane, 
and knockout of protein A enabled the diffusion of high molecular weight dextran particles 
within the inner basement membrane, then one could conclude that protein A was responsible 
for generating this size-exclusion property of the inner basement membrane.  Alternatively, 
knockout of protein B could completely abolish perivascular flow, indicating that it is 
required for maintaining a structure that permits the flow of CSF and solutes.  Similar 
approaches could be used to compare the structure/function relationship of size-exclusion by 
the glial endfeet and/or intersititial compartment. 
 
7.7: CSF Aβ1-40 levels may increase in aging and after stroke be by multiple mechanisms. 
 Our findings demonstrate that aging and stroke induce the deposition of CSF Aβ1-40 
within the basement membrane.  This difference in deposition occurred even though we 
injected the same amount of fluorescent Aβ1-40 into the CSF of each animal, suggesting that 
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alterations in the intrinsic Aβ1-40 binding capacity may be altered by pathological states.  
However, it is important to consider that the absolute levels of CSF Aβ1-40 may also change 
with aging, stroke and CAA.  Previous work has shown that early increases in CSF Aβ1-40 
occur before the onset of CAA in human patients.149  If aging or stroke were to also increase 
the levels of CSF Aβ1-40 relative to baseline, this could further magnify the perivascular Aβ1-
40 deposition that was seen in our animal studies. As a potential future direction, we could 
examine how aging and stroke alter choroidal permeability and/or meningeal CSF clearance 
pathways, and determine whether blocking these changes could slow CAA development. 
The CP undergoes several major changes with normal aging, which could lead to 
increases in the concentration of CSF Aβ1-40.  Beginning in old age, the barrier between the 
plasma and CSF becomes thinner.318,319 Additionally, basement membrane fibrosis occurs in 
both the epithelial and endothelial layers, potentially contributing to reduced absorptive 
capacity of the basolateral membrane.319 Furthermore, aging causes the epithelial cells to 
become invested with lipofuscin granules and protein inclusions, which may also impair the 
secretory function of the microvilli and reduce CSF production in aging.320  Together, these 
changes contribute to an approximately 30% reduction in CSF secretion with aging, despite 
increases in total CSF volume within the ventricles and subarachnoid space, which often 
occur due to cerebral atrophy.318,319 Furthermore, Alzheimer’s disease is associated with 
more rapid aging of the CP, with amyloid plaque formation occurring within the PVS of CP 
capillaries, reminiscent of CAA.320  These changes are associated with a 50% reduction in 
CSF turnover compared to the normal aged CP.321  The net effects of these changes are 
reduced CSF turnover and higher CSF protein concentration with aging.322  These reductions 
in CSF turnover could lead to increased transit time for Aβ1-40 particles to be cleared from the 
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brain, which would increase the concentration of CSF Aβ1-40 that is recirculated along the 
basement membrane and lead to CAA. 
Brain injury may further reduce the turnover of CSF.  Following stroke, increased 
cellular debris can act to clog meningeal outflow, leading to increased intracranial pressure 
(ICP) and damage to the CP.323–325 Increased ICP further triggers a negative feedback loop 
involving several vasoregulatory hormones, including atrial natiuretic peptide,326 
vasopressin,132 and fibroblast growth factor,327–329 which all act to reduce CSF formation.  
While this does prevent worsening of ICP, this feedback effectively reduces the turnover of 
CSF, and dysregulation of these pathways may contribute to increased CSF Aβ1-40 levels 
following brain injury.   
In addition to slowing the clearance of CSF Aβ1-40, brain injuries can increase the 
permeability of the blood-CSF barrier and expose the brain to systemic waste products such 
as Aβ1-40.  One study found that TBI increased CP peremeability to plasma solutes, leading to 
increased osmotic uptake of water and elevated ICP.330.  Following stroke, the CP 
upregulates lysosome expression and appears highly vacuolated, the width of the intercellular 
spaces increases, and the microvilli become enlarged.331   These morphological changes are 
also associated with increased trafficking of immune cells through the CP, including 
increased numbers of cytotoxic T cells in aged animals.332,333  Similarly, the CP epithelium 
also provides a route for monocyte-derived macrophages to enter the brain and influence 
post-stroke recovery.334 While it is clear that stroke has dramatic effects on the permeability 
of the CP to immune cells, the effects of stroke on permeability to Aβ1-40 are not known.  In 
older individuals, these changes could have an additive effect with baseline impairments in 
CSF turnover/clearance and further increase CSF Aβ1-40 levels. 
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 As one potential new direction, we could test the hypothesis that stroke disrupts the 
blood-CSF barrier, newly exposing the brain to peripheral Aβ1-40.  To test this hypothesis, we 
could first perform DMCAO, and then intravenously inject 125I-Aβ1-40 into the peripheral 
bloodstream.  Then, we could block CSF outflow pathways by intracisternally injecting 
glycerol, and collect freshly filtered CSF by a microdialysis catheter placed in the lateral 
ventricle.  Following this, in a separate group, we could intravenously inject gold-labeled 
Aβ1-40, then section the brain and examine CP morphology by electron microscopy to 
determine whether Aβ1-40 was being taken up transcellularly through receptors like 
lipoprotein receptor protein-1 (LRP1), P-glycoprotein (PGP) or receptor for advanced 
glycation endproducts (RAGE), or whether this uptake was occurring paracellularly.  I 
predict that DMCAO will increase the uptake of 125I-Aβ1-40 into the CSF.  Depending on 
what route Aβ1-40 is taken up by, different treatment strategies such as anti-inflammatory 
drugs to reduce damage to the CP and paracellular uptake could be explored, or utilize 
specific knockouts/inhibitors of the transcellular uptake processes.  If successful, these 
experiments would determine whether stroke increases CP permeability to Aβ1-40, and by 
which route this occurs.  Depending on the outcome, new drugs could be utilized to reduce 
the uptake of Aβ1-40 into the brain after stroke. 
 As an additional future area of research, we could also test the hypothesis that stroke 
releases necrotic debris that reduce the outflow of CSF through the dural lymphatics, 
impairing the removal of CSF Aβ1-40 and worsening vascular amyloid pathology and 
cognitive impairment.  To test this hypothesis, we could place a cranial window over the 
dural lymphatic vessels of Tg2576 x GFP mice, then perform DMCAO.  Following this, we 
could then measure lymphatic outflow by intracisternally injecting fluorescent quantum dots 
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and measuring their flow velocity by two-photon microscopy.   I would predict that DMCAO 
would reduce lymphatic outflow acutely after injury due to the presence of GFP-positive 
cellular debris within the lymphatics.  We could then test whether installing a 
ventriculoperitoneal shunt could help to normalize CSF outflow and allow for the debris to 
clear more rapidly from the brain.  Then, we could determine whether this treatment 
improves post-stroke cognitive function, and whether this impairment is greater in the 
transgenic Tg2576 mice.  If successful, shunting could be used to improve the clearance of 
Aβ1-40 in human CAA patients, particularly after an acute injury like stroke. 
 In conclusion, CSF Aβ1-40 levels fluctuate over the course of CAA, with high levels 
observed in the early stages of disease.  Degradation of the blood-CSF barrier, reduced CSF 
turnover and impaired outflow of through the meninges all likely contribute to early 
increases in Aβ1-40 within the CSF with CAA.  Aging, brain injury and Alzheimer’s disease 
may be associated with alterations in these parameters, which could favor a build-up of CSF 
Aβ1-40, worsening CAA.  Further work must be done to assess how these changes in the CP 
impact that uptake and/or clearance of Aβ1-40 after stroke.  This could provide an additional 
target to reduce CSF Aβ1-40 levels and CAA development. 
 
7.8: Concluding remarks.   
This work represents an early step in developing a new understanding of how CAA 
develops in survivors of ischemic stroke.  CAA may be a late sign of disease within the 
perivascular glymphatic system, which opens up a plethora of potential treatment strategies 
to treat the underlying problems that are driving vascular amyloid pathology in these patients.  
New strategies to detect early reductions in perivascular CSF flow by imaging or serum 
	   200 
biomarkers could expand the treatment window for CAA.  If early disease is detected, then 
reducing the levels of CSF Aβ1-40 by reducing distribution or enhancing clearance may help 
to slow the progression of amyloid pathology in distal perivascular beds.  We have also 
shown that targeting the basement membrane with anti-TGF-β therapies can be an effective 
strategy for reducing perivascular amyloid burden after focal injury, which could one-day be 
translated to the clinic. 
Overall, this work is a testament to the value of collaborative research.  This project 
began as a far-fetched idea, but was shaped into a coherent project with much help from Dr. 
McCullough, Dr. Urayama and my thesis committee.  With the help of other lab members, 
and a great deal of patience, we were able to accomplish what I once believed to be a very 
long shot—to reverse impairment in the perivascular drainage of waste products after stroke.  
Over the course of these experiments, I shared my findings with others in our research group 
and helped to obtain new grants, which have delivered funding that will ensure these new 
projects continue to grow in the coming years.  While this chapter in my life is ending, it also 
provides a new beginning for the next wave of researchers with their own ideas.  Already, 
others in our research group have begun to probe the contributions of diverse other systems 
to CAA pathogenesis, including neuroimmunology, gut microbiology and respiratory 
physiology.  This work will provide even more of the missing pieces to the puzzle of CAA, 
which we can assemble into a new strategy to end dementia in the 21st century.  
 
 
 
 
	   201 
CHAPTER 8 
References 
 
1. Grysiewicz RA, Thomas K, Pandey DK. Epidemiology of ischemic and hemorrhagic 
stroke: incidence, prevalence, mortality, and risk factors. Neurol Clin. 2008;26:871–
95, vii. 
2. Impact of Stroke (Stroke statistics). Available at 
http://www.strokeassociation.org/STROKEORG/AboutStroke/Impact-of-Stroke-
Stroke-statistics_UCM_310728_Article.jsp#.WpM5WBPwZE5. Accessed February 
25, 2018. 
3. Skolarus LE, Burke JF, Brown DL, Freedman VA. Understanding stroke survivorship: 
expanding the concept of poststroke disability. Stroke. 2014;45:224–30. 
4. Hacke W, Schwab S, Horn M, Spranger M, Georgia M De, Kummer R von. 
“Malignant” Middle Cerebral Artery Territory Infarction. Arch Neurol. 1996;53:309. 
5. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, 
Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi 
TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers D V, Tirschwell 
DL, American Heart Association Stroke Council  on behalf of the AHAS. 2018 
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A 
Guideline for Healthcare Professionals From the American Heart 
Association/American Stroke Association. Stroke. 2018;:STR.0000000000000158. 
6. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, 
Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, 
	   202 
Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke 
FW, Seshadri S. Vascular contributions to cognitive impairment and dementia: a 
statement for healthcare professionals from the american heart association/american 
stroke association. Stroke. 2011;42:2672–2713. 
7. Ivan CS, Seshadri S, Beiser A, Au R, Kase CS, Kelly-Hayes M, Wolf PA. Dementia 
after stroke: the Framingham Study. Stroke. 2004;35:1264–8. 
8. Reitz C, Bos MJ, Hofman A, Koudstaal PJ, Breteler MMB. Prestroke Cognitive 
Performance, Incident Stroke, and Risk of Dementia: The Rotterdam Study. Stroke. 
2008;39:36–41. 
9. Mahon S, Parmar P, Barker-Collo S, Krishnamurthi R, Jones K, Theadom A, Feigin 
V. Determinants, Prevalence, and Trajectory of Long-Term Post-Stroke Cognitive 
Impairment: Results from a 4-Year Follow-Up of the ARCOS-IV Study. 
Neuroepidemiology. 2017;49:129–134. 
10. Doyle KP, Buckwalter MS. Does B lymphocyte-mediated autoimmunity contribute to 
post-stroke dementia? Brain Behav Immun. 2017;64:1–8. 
11. Doyle KP, Quach LN, Sole M, Axtell RC, Nguyen T-V V., Soler-Llavina GJ, Jurado 
S, Han J, Steinman L, Longo FM, Schneider JA, Malenka RC, Buckwalter MS. B-
Lymphocyte-Mediated Delayed Cognitive Impairment following Stroke. J Neurosci. 
2015;35:2133–2145. 
12. Ritzel RM, Crapser J, Patel AR, Verma R, Grenier JM, Chauhan A, Jellison ER, 
McCullough LD. Age-Associated Resident Memory CD8 T Cells in the Central 
Nervous System Are Primed To Potentiate Inflammation after Ischemic Brain Injury. J 
Immunol. 2016. doi:10.4049/jimmunol.1502021. 
	   203 
13. Sorrenti V, Contarini G, Sut S, Dall’Acqua S, Confortin F, Pagetta A, Giusti P, Zusso 
M. Curcumin Prevents Acute Neuroinflammation and Long-Term Memory 
Impairment Induced by Systemic Lipopolysaccharide in Mice. Front Pharmacol. 
2018;9:183. 
14. Ye BS, Seo SW, Kim GH, Noh Y, Cho H, Yoon CW, Kim HJ, Chin J, Jeon S, Lee 
JM, Seong J-K, Kim JS, Lee J-H, Choe YS, Lee KH, Sohn YH, Ewers M, Weiner M, 
Na DL. Amyloid burden, cerebrovascular disease, brain atrophy, and cognition in 
cognitively impaired patients. Alzheimer’s Dement. 2015;11:494–503.e3. 
15. Li Q, Lebson L, Lee DC, Nash K, Grimm J, Rosenthal A, Selenica M-LB, Morgan D, 
Gordon MN. Chronological age impacts immunotherapy and monocyte uptake 
independent of amyloid load. J Neuroimmune Pharmacol. 2012;7:202–14. 
16. Ameen-Ali KE, Wharton SB, Simpson JE, Heath PR, Sharp P, Berwick J. Review: 
Neuropathology and behavioural features of transgenic murine models of Alzheimer’s 
disease. Neuropathol Appl Neurobiol. 2017;43:553–570. 
17. Sanabria-Castro A, Alvarado-Echeverría I, Monge-Bonilla C. Molecular Pathogenesis 
of Alzheimer’s Disease: An Update. Ann Neurosci. 2017;24:46–54. 
18. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of 
probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 
2009;66:200–8. 
19. Vonsattel JPG, Myers RH, Tessa Hedley-Whyte E, Ropper AH, Bird ED, Richardson 
EP. Cerebral amyloid angiopathy without and with cerebral hemorrhages: A 
comparative histological study. Ann Neurol. 1991;30:637–649. 
20. Greenberg SM, Vonsattel JP. Diagnosis of cerebral amyloid angiopathy. Sensitivity 
	   204 
and specificity of cortical biopsy. Stroke. 1997;28:1418–22. 
21. Planton M, Raposo N, Albucher J-F, Pariente J. Cerebral amyloid angiopathy-related 
cognitive impairment: The search for a specific neuropsychological pattern. Rev 
Neurol (Paris). 2017;173:562–565. 
22. Kim HJ, Yang JJ, Kwon H, Kim C, Lee JM, Chun P, Kim YJ, Jung N-Y, Chin J, Kim 
S, Woo S, Choe YS, Lee K-H, Kim ST, Kim JS, Lee JH, Weiner MW, Na DL, Seo 
SW. Relative impact of amyloid-β, lacunes, and downstream imaging markers on 
cognitive trajectories. Brain. 2016;139:2516–2527. 
23. Biffi A, Greenberg SM. Cerebral Amyloid Angiopathy: A Systematic Review. J Clin 
Neurol. 2011;7:1. 
24. Schneider JA, Boyle PA, Arvanitakis Z, Bienias JL, Bennett DA. Subcortical infarcts, 
Alzheimer’s disease pathology, and memory function in older persons. Ann Neurol. 
2007;62:59–66. 
25. Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB, Ince P. Epidemiological 
pathology of dementia: attributable-risks at death in the Medical Research Council 
Cognitive Function and Ageing Study. PLoS Med. 2009;6:e1000180. 
26. Dugger BN, Davis K, Malek-Ahmadi M, Hentz JG, Sandhu S, Beach TG, Adler CH, 
Caselli RJ, Johnson TA, Serrano GE, Shill HA, Belden C, Driver-Dunckley E, 
Caviness JN, Sue LI, Jacobson S, Powell J, Sabbagh MN. Neuropathological 
comparisons of amnestic and nonamnestic mild cognitive impairment. BMC Neurol. 
2015;15:146. 
27. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, Smith EE, 
Rosand J, Rentz DM, Klunk WE, Mathis CA, Price JC, DeKosky ST, Fischman AJ, 
	   205 
Greenberg SM. Imaging of amyloid burden and distribution in cerebral amyloid 
angiopathy. Ann Neurol. 2007;62:229–234. 
28. Ly J V., Rowe CC, Villemagne VL, Zavala JA, Ma H, Sahathevan R, O’Keefe G, 
Gong SJ, Gunawan R, Churilov L, Saunder T, Ackerman U, Tochon-Danguy H, 
Donnan GA. Subacute Ischemic Stroke Is Associated With Focal 11C PiB Positron 
Emission Tomography Retention But Not With Global Neocortical A  Deposition. 
Stroke. 2012;43:1341–1346. 
29. Yang J, Wong A, Wang Z, Liu W, Au L, Xiong Y, Chu WWC, Leung EYL, Chen S, 
Lau C, Chan AYY, Lau AYL, Fan F, Ip V, Soo Y, Leung T, Ho CL, Wong LKS, Mok 
VCT. Risk factors for incident dementia after stroke and transient ischemic attack. 
Alzheimer’s Dement. 2015;11:16–23. 
30. Sahathevan R, Linden T, Villemagne VL, Churilov L, Ly J V., Rowe C, Donnan G, 
Brodtmann A. Positron Emission Tomographic Imaging in Stroke. Stroke. 
2016;47:113–119. 
31. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral 
amyloid angiopathy: validation of the Boston criteria. Neurology. 2001;56:537–9. 
32. Charidimou A, Boulouis G, Pasi M, Auriel E, van Etten ES, Haley K, Ayres A, 
Schwab KM, Martinez-Ramirez S, Goldstein JN, Rosand J, Viswanathan A, 
Greenberg SM, Gurol ME. MRI-visible perivascular spaces in cerebral amyloid 
angiopathy and hypertensive arteriopathy. Neurology. 2017;88:1157–1164. 
33. Liang Y, Chen Y-K, Deng M, Mok VCT, Wang D-F, Ungvari GS, Chu CW, Kamiya 
A, Tang W-K. Association of Cerebral Small Vessel Disease Burden and Health-
Related Quality of Life after Acute Ischemic Stroke. Front Aging Neurosci. 
	   206 
2017;9:372. 
34. ZHANG Z, REN W, SHAO B, XU H, CHENG J, WANG Q, GU Y, ZHU B, HE J. 
Leukoaraiosis is Associated with Worse Short-Term Functional and Cognitive 
Recovery after Minor Stroke. Neurol Med Chir (Tokyo). 2017;57:136–143. 
35. Liu Y, Zhang M, Chen Y, Gao P, Yun W, Zhou X. The degree of leukoaraiosis 
predicts clinical outcomes and prognosis in patients with middle cerebral artery 
occlusion after intravenous thrombolysis. Brain Res. 2018;1681:28–33. 
36. Zhang X, Tang Y, Xie Y, Ding C, Xiao J, Jiang X, Shan H, Lin Y, Li C, Hu D, Li T, 
Sheng L. Total magnetic resonance imaging burden of cerebral small-vessel disease is 
associated with post-stroke depression in patients with acute lacunar stroke. Eur J 
Neurol. 2017;24:374–380. 
37. Santos CY, Snyder PJ, Wu W-C, Zhang M, Echeverria A, Alber J. Pathophysiologic 
relationship between Alzheimer’s disease, cerebrovascular disease, and cardiovascular 
risk: A review and synthesis. Alzheimer’s Dement (Amsterdam, Netherlands). 
2017;7:69–87. 
38. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, 
Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele 
and the risk of Alzheimer’s disease in late onset families. Science. 1993;261:921–3. 
39. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP. Moderately elevated 
plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for 
stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke. 
2002;33:2351–6. 
40. Desikan RS, Schork AJ, Wang Y, Thompson WK, Dehghan A, Ridker PM, Chasman 
	   207 
DI, McEvoy LK, Holland D, Chen C-H, Karow DS, Brewer JB, Hess CP, Williams J, 
Sims R, O’Donovan MC, Choi SH, Bis JC, Ikram MA, Gudnason V, DeStefano AL, 
van der Lee SJ, Psaty BM, van Duijn CM, Launer L, Seshadri S, Pericak-Vance MA, 
Mayeux R, Haines JL, Farrer LA, Hardy J, Ulstein ID, Aarsland D, Fladby T, White 
LR, Sando SB, Rongve A, Witoelar A, Djurovic S, Hyman BT, Snaedal J, Steinberg S, 
Stefansson H, Stefansson K, Schellenberg GD, Andreassen OA, Dale AM, 
Inflammation working group, IGAP and DemGene Investigators. Polygenic Overlap 
Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease. Circulation. 
2015;131:2061–2069. 
41. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, 
Odén A, Svanborg A. 15-year longitudinal study of blood pressure and dementia. 
Lancet (London, England). 1996;347:1141–5. 
42. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto 
J, Nissinen A. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and 
Alzheimer’s disease. Neuroepidemiology. 1998;17:14–20. 
43. Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B, 
Sulkava R, Kivipelto M. Diabetes, Alzheimer disease, and vascular dementia: A 
population-based neuropathologic study. Neurology. 2010;75:1195–1202. 
44. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. 
Central obesity and increased risk of dementia more than three decades later. 
Neurology. 2008;71:1057–1064. 
45. Groot C, Hooghiemstra AM, Raijmakers PGHM, van Berckel BNM, Scheltens P, 
Scherder EJA, van der Flier WM, Ossenkoppele R. The effect of physical activity on 
	   208 
cognitive function in patients with dementia: A meta-analysis of randomized control 
trials. Ageing Res Rev. 2016;25:13–23. 
46. Cataldo JK, Prochaska JJ, Glantz SA. Cigarette Smoking is a Risk Factor for 
Alzheimer’s Disease: An Analysis Controlling for Tobacco Industry Affiliation. J 
Alzheimer’s Dis. 2010;19:465–480. 
47. van Groen T, Puurunen K, Maki H-M, Sivenius J, Jolkkonen J. Transformation of 
Diffuse  -Amyloid Precursor Protein and  -Amyloid Deposits to Plaques in the 
Thalamus After Transient Occlusion of the Middle Cerebral Artery in Rats. Stroke. 
2005;36:1551–1556. 
48. Lipsanen A, Hiltunen M, Jolkkonen J. Chronic ibuprofen treatment does not affect the 
secondary pathology in the thalamus or improve behavioral outcome in middle 
cerebral artery occlusion rats. Pharmacol Biochem Behav. 2011;99:468–474. 
49. Sarajärvi T, Lipsanen A, Mäkinen P, Peräniemi S, Soininen H, Haapasalo A, 
Jolkkonen J, Hiltunen M. Bepridil decreases Aβ and calcium levels in the thalamus 
after middle cerebral artery occlusion in rats. J Cell Mol Med. 2012;16:2754–67. 
50. Xing S, Zhang J, Dang C, Liu G, Zhang Y, Li J, Fan Y, Pei Z, Zeng J. Cerebrolysin 
reduces amyloid-β deposits, apoptosis and autophagy in the thalamus and improves 
functional recovery after cortical infarction. J Neurol Sci. 2014;337:104–111. 
51. Mitkari B, Kerkelä E, Nystedt J, Korhonen M, Jolkkonen J. Unexpected complication 
in a rat stroke model: exacerbation of secondary pathology in the thalamus by 
subacute intraarterial administration of human bone marrow-derived mesenchymal 
stem cells. J Cereb Blood Flow Metab. 2015;35:363–6. 
52. Mucke L, Masliah E, Johnson WB, Ruppe MD, Alford M, Rockenstein EM, Forss-
	   209 
Petter S, Pietropaolo M, Mallory M, Abraham CR. Synaptotrophic effects of human 
amyloid beta protein precursors in the cortex of transgenic mice. Brain Res. 
1994;666:151–67. 
53. Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J. Synapse 
Formation and Function Is Modulated by the Amyloid Precursor Protein. J Neurosci. 
2006;26:7212–7221. 
54. Zou C, Crux S, Marinesco S, Montagna E, Sgobio C, Shi Y, Shi S, Zhu K, Dorostkar 
MM, Müller UC, Herms J. Amyloid precursor protein maintains constitutive and 
adaptive plasticity of dendritic spines in adult brain by regulating D‐serine 
homeostasis. EMBO J. 2016;35:2213–2222. 
55. Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K, Leong SL, Perez K, 
Johanssen T, Greenough MA, Cho H-H, Galatis D, Moir RD, Masters CL, McLean C, 
Tanzi RE, Cappai R, Barnham KJ, Ciccotosto GD, Rogers JT, Bush AI. Iron-Export 
Ferroxidase Activity of β-Amyloid Precursor Protein Is Inhibited by Zinc in 
Alzheimer’s Disease. Cell. 2010;142:857–867. 
56. Anderson JP, Chen Y, Kim KS, Robakis NK. An alternative secretase cleavage 
produces soluble Alzheimer amyloid precursor protein containing a potentially 
amyloidogenic sequence. J Neurochem. 1992;59:2328–31. 
57. Kakuda N, Miyasaka T, Iwasaki N, Nirasawa T, Wada-Kakuda S, Takahashi-
Fujigasaki J, Murayama S, Ihara Y, Ikegawa M. Distinct deposition of amyloid-β 
species in brains with Alzheimer’s disease pathology visualized with MALDI imaging 
mass spectrometry. Acta Neuropathol Commun. 2017;5:73. 
58. Zheng W, Tsai M-Y, Wolynes PG. Comparing the Aggregation Free Energy 
	   210 
Landscapes of Amyloid Beta(1–42) and Amyloid Beta(1–40). J Am Chem Soc. 
2017;139:16666–16676. 
59. Head E, Phelan MJ, Doran E, Kim RC, Poon WW, Schmitt FA, Lott IT. 
Cerebrovascular pathology in Down syndrome and Alzheimer disease. Acta 
Neuropathol Commun. 2017;5:93. 
60. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin 
C, Holman K, Tsuda T, Mar L, Sorbi S, Nacmias B, Piacentini S, Amaducci L, 
Chumakov I, Cohen D, Lannfelt L, Fraser PE, Rommens JM, George-Hyslop PHS. 
Familial Alzheimer’s disease in kindreds with missense mutations in a gene on 
chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 1995;376:775–
778. 
61. Shea Y-F, Chu L-W, Chan AO-K, Ha J, Li Y, Song Y-Q. A systematic review of 
familial Alzheimer’s disease: Differences in presentation of clinical features among 
three mutated genes and potential ethnic differences. J Formos Med Assoc. 
2016;115:67–75. 
62. Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC, Yamaguchi H, Ruiz 
A, Martinez A, Madrigal L, Hincapie L, Arango JC, Anthony DC, Koo EH, Goate 
AM, Selkoe DJ, Arango JC. The E280A presenilin 1 Alzheimer mutation produces 
increased A beta 42 deposition and severe cerebellar pathology. Nat Med. 
1996;2:1146–50. 
63. Yasuda M, Maeda K, Ikejiri Y, Kawamata T, Kuroda S, Tanaka C. A novel missense 
mutation in the presenilin-1 gene in a familial Alzheimer’s disease pedigree with 
abundant amyloid angiopathy. Neurosci Lett. 1997;232:29–32. 
	   211 
64. Yamada M, Sodeyama N, Itoh Y, Suematsu N, Otomo E, Matsushita M, Mizusawa H. 
Association of presenilin-1 polymorphism with cerebral amyloid angiopathy in the 
elderly. Stroke. 1997;28:2219–21. 
65. Dermaut B, Kumar-Singh S, De Jonghe C, Cruts M, Löfgren A, Lübke U, Cras P, 
Dom R, De Deyn PP, Martin JJ, Van Broeckhoven C. Cerebral amyloid angiopathy is 
a pathogenic lesion in Alzheimer’s disease due to a novel presenilin 1 mutation. Brain. 
2001;124:2383–92. 
66. Wattendorff AR, Bots GT, Went LN, Endtz LJ. Familial cerebral amyloid angiopathy 
presenting as recurrent cerebral haemorrhage. J Neurol Sci. 1982;55:121–35. 
67. Luyendijk W, Bots GT, Vegter-van der Vlis M, Went LN, Frangione B. Hereditary 
cerebral haemorrhage caused by cortical amyloid angiopathy. J Neurol Sci. 
1988;85:267–80. 
68. Van Broeckhoven C, Haan J, Bakker E, Hardy JA, Van Hul W, Wehnert A, Vegter-
Van der Vlis M, Roos RA. Amyloid beta protein precursor gene and hereditary 
cerebral hemorrhage with amyloidosis (Dutch). Science. 1990;248:1120–2. 
69. Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen SG, 
Bots GT, Luyendijk W, Frangione B. Mutation of the Alzheimer’s disease amyloid 
gene in hereditary cerebral hemorrhage, Dutch type. Science. 1990;248:1124–6. 
70. van Nostrand WE, Wagner SL, Haan J, Bakker E, Roos RAC. Alzheimer’s disease 
and hereditary cerebral hemorrhage with amyloidosis-dutch type share a decrease in 
cerebrospinal fluid levels of amyloid  ?-protein precursor. Ann Neurol. 1992;32:215–
218. 
71. Stenh C, Nilsberth C, Hammarbäck J, Engvall B, Näslund J, Lannfelt L. The Arctic 
	   212 
mutation interferes with processing of the amyloid precursor protein. Neuroreport. 
2002;13:1857–60. 
72. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. 
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. 
Science. 1996;274:99–102. 
73. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun 
ME, Jäggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, Hölscher C, 
Mathews PM, Jucker M. Aβ42-driven cerebral amyloidosis in transgenic mice reveals 
early and robust pathology. EMBO Rep. 2006;7:940–946. 
74. Davis J, Xu F, Deane R, Romanov G, Previti M Lou, Zeigler K, Zlokovic B V, Van 
Nostrand WE. Early-onset and robust cerebral microvascular accumulation of amyloid 
beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa 
mutant form of amyloid beta-protein precursor. J Biol Chem. 2004;279:20296–20306. 
75. Van Nostrand WE, Melchor JP, Cho HS, Greenberg SM, Rebeck GW. Pathogenic 
effects of D23N Iowa mutant amyloid beta -protein. J Biol Chem. 2001;276:32860–6. 
76. Xu F, Grande AM, Robinson JK, Previti ML, Vasek M, Davis J, Van Nostrand WE. 
Early-onset subicular microvascular amyloid and neuroinflammation correlate with 
behavioral deficits in vasculotropic mutant amyloid β-protein precursor transgenic 
mice. Neuroscience. 2007;146:98–107. 
77. Yamada M, Tsukagoshi H, Otomo E, Hayakawa M. Cerebral amyloid angiopathy in 
the aged. J Neurol. 1987;234:371–6. 
78. Yamada M. Risk factors for cerebral amyloid angiopathy in the elderly. Ann N Y Acad 
Sci. 2002;977:37–44. 
	   213 
79. Mackic JB, Weiss MH, Miao W, Kirkman E, Ghiso J, Calero M, Bading J, Frangione 
B, Zlokovic B V. Cerebrovascular accumulation and increased blood-brain barrier 
permeability to circulating Alzheimer’s amyloid beta peptide in aged squirrel monkey 
with cerebral amyloid angiopathy. J Neurochem. 1998;70:210–5. 
80. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, 
Miller CA, Strickland DK, Ghiso J, Zlokovic B V. Clearance of Alzheimer’s amyloid-
β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier. 
J Clin Invest. 2000;106:1489–1499. 
81. Hawkes CA, Härtig W, Kacza J, Schliebs R, Weller RO, Nicoll JA, Carare RO. 
Perivascular drainage of solutes is impaired in the ageing mouse brain and in the 
presence of cerebral amyloid angiopathy. Acta Neuropathol. 2011;121:431–443. 
82. Kress BT, Iliff JJ, Xia M, Wang M, Wei HS, Zeppenfeld D, Xie L, Kang H, Xu Q, 
Liew JA, Plog BA, Ding F, Deane R, Nedergaard M. Impairment of paravascular 
clearance pathways in the aging brain. Ann Neurol. 2014;76:845–861. 
83. Carnevale D, Mascio G, D’Andrea I, Fardella V, Bell RD, Branchi I, Pallante F, 
Zlokovic B, Yan SS, Lembo G. Hypertension Induces Brain  -Amyloid Accumulation, 
Cognitive Impairment, and Memory Deterioration Through Activation of Receptor for 
Advanced Glycation End Products in Brain Vasculature. Hypertension. 2012;60:188–
197. 
84. Hawkes CA, Gentleman SM, Nicoll JA, Carare RO. Prenatal high-fat diet alters the 
cerebrovasculature and clearance of β -amyloid in adult offspring. J Pathol. 
2015;235:619–631. 
85. Vandal M, White PJ, Tremblay C, St-Amour I, Chevrier G, Emond V, Lefrancois D, 
	   214 
Virgili J, Planel E, Giguere Y, Marette A, Calon F. Insulin Reverses the High-Fat 
Diet-Induced Increase in Brain A  and Improves Memory in an Animal Model of 
Alzheimer Disease. Diabetes. 2014;63:4291–4301. 
86. Martel CL, Mackic JB, Matsubara E, Governale S, Miguel C, Miao W, McComb JG, 
Frangione B, Ghiso J, Zlokovic B V. Isoform-specific effects of apolipoproteins E2, 
E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of 
circulating Alzheimer’s amyloid beta. J Neurochem. 1997;69:1995–2004. 
87. He X, Liu D, Zhang Q, Liang F, Dai G, Zeng J, Pei Z, Xu G, Lan Y. Voluntary 
Exercise Promotes Glymphatic Clearance of Amyloid Beta and Reduces the 
Activation of Astrocytes and Microglia in Aged Mice. Front Mol Neurosci. 
2017;10:144. 
88. Jacob M, Chappell D, Becker BF. Regulation of blood flow and volume exchange 
across the microcirculation. Crit Care. 2016;20:319. 
89. Hakim A, Gralla J, Rozeik C, Mordasini P, Leidolt L, Piechowiak E, Ozdoba C, El-
Koussy M. Anomalies and Normal Variants of the Cerebral Arterial Supply: A 
Comprehensive Pictorial Review with a Proposed Workflow for Classification and 
Significance. J Neuroimaging. 2018;28:14–35. 
90. Thomsen MS, Routhe LJ, Moos T. The vascular basement membrane in the healthy 
and pathological brain. J Cereb Blood Flow Metab. 2017;37:3300–3317. 
91. Iadecola C. The Neurovascular Unit Coming of Age: A Journey through 
Neurovascular Coupling in Health and Disease. Neuron. 2017;96:17–42. 
92. Yamada M. Cerebral amyloid angiopathy: emerging concepts. J stroke. 2015;17:17–
30. 
	   215 
93. Thal DR, Ghebremedhin E, Rüb U, Yamaguchi H, Del Tredici K, Braak H. Two types 
of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2002;61:282–93. 
94. Yamaguchi H, Yamazaki T, Lemere CA, Frosch MP, Selkoe DJ. Beta amyloid is 
focally deposited within the outer basement membrane in the amyloid angiopathy of 
Alzheimer’s disease. An immunoelectron microscopic study. Am J Pathol. 
1992;141:249–59. 
95. Maeda A, Yamada M, Itoh Y, Otomo E, Hayakawa M, Miyatake T. Computer-assisted 
three-dimensional image analysis of cerebral amyloid angiopathy. Stroke. 
1993;24:1857–64. 
96. Mandybur TI. Cerebral amyloid angiopathy: the vascular pathology and 
complications. J Neuropathol Exp Neurol. 1986;45:79–90. 
97. Charidimou A, Imaizumi T, Moulin S, Biffi A, Samarasekera N, Yakushiji Y, Peeters 
A, Vandermeeren Y, Laloux P, Baron J-C, Hernandez-Guillamon M, Montaner J, 
Casolla B, Gregoire SM, Kang D-W, Kim JS, Naka H, Smith EE, Viswanathan A, 
Jäger HR, Al-Shahi Salman R, Greenberg SM, Cordonnier C, Werring DJ. Brain 
hemorrhage recurrence, small vessel disease type, and cerebral microbleeds. 
Neurology. 2017;89:820–829. 
98. Gregoire SM, Charidimou A, Gadapa N, Dolan E, Antoun N, Peeters A, 
Vandermeeren Y, Laloux P, Baron J-C, Jäger HR, Werring DJ. Acute ischaemic brain 
lesions in intracerebral haemorrhage: multicentre cross-sectional magnetic resonance 
imaging study. Brain. 2011;134:2376–2386. 
99. Kimberly WT, Gilson A, Rost NS, Rosand J, Viswanathan A, Smith EE, Greenberg 
SM. Silent ischemic infarcts are associated with hemorrhage burden in cerebral 
	   216 
amyloid angiopathy. Neurology. 2009;72:1230–1235. 
100. Tabaton M, Caponnetto C, Mancardi G, Loeb C. Amyloid beta protein deposition in 
brains from elderly subjects with leukoaraiosis. J Neurol Sci. 1991;106:123–7. 
101. Pluta R, Januszewski S, Ułamek M. Ischemic blood-brain barrier and amyloid in white 
matter as etiological factors in leukoaraiosis. Acta Neurochir Suppl. 2008;102:353–6. 
102. Reijmer YD, Fotiadis P, Riley GA, Xiong L, Charidimou A, Boulouis G, Ayres AM, 
Schwab K, Rosand J, Gurol ME, Viswanathan A, Greenberg SM. Progression of Brain 
Network Alterations in Cerebral Amyloid Angiopathy. Stroke. 2016;47:2470–2475. 
103. Reijmer YD, Fotiadis P, Martinez-Ramirez S, Salat DH, Schultz A, Shoamanesh A, 
Ayres AM, Vashkevich A, Rosas D, Schwab K, Leemans A, Biessels G-J, Rosand J, 
Johnson KA, Viswanathan A, Gurol ME, Greenberg SM. Structural network 
alterations and neurological dysfunction in cerebral amyloid angiopathy. Brain. 
2015;138:179–188. 
104. Reijmer YD, Fotiadis P, Charidimou A, van Veluw SJ, Xiong L, Riley GA, Martinez-
Ramirez S, Schwab K, Viswanathan A, Gurol ME, Greenberg SM. Relationship 
between white matter connectivity loss and cortical thinning in cerebral amyloid 
angiopathy. Hum Brain Mapp. 2017. doi:10.1002/hbm.23629. 
105. Fotiadis P, van Rooden S, van der Grond J, Schultz A, Martinez-Ramirez S, Auriel E, 
Reijmer Y, van Opstal AM, Ayres A, Schwab KM, Alzheimer’s Disease 
Neuroimaging Initiative (ADNI), Hedden T, Rosand J, Viswanathan A, Wermer M, 
Terwindt GM, Sperling RA, Polimeni JR, Johnson KA, van Buchem MA, Greenberg 
SM, Gurol ME. Cortical atrophy in patients with cerebral amyloid angiopathy: a case-
control study. Lancet Neurol. 2016;15:811–819. 
	   217 
106. Martucci M, Sarria S, Toledo M, Coscojuela P, Vert C, Siurana S, Auger C, Rovira A. 
Cerebral amyloid angiopathy-related inflammation: imaging findings and clinical 
outcome. Neuroradiology. 2014;56:283–289. 
107. Salvarani C, Hunder GG, Morris JM, Brown RD, Christianson T, Giannini C. A -
related angiitis: Comparison with CAA without inflammation and primary CNS 
vasculitis. Neurology. 2013;81:1596–1603. 
108. Iadecola C. Cerebrovascular effects of amyloid-beta peptides: mechanisms and 
implications for Alzheimer’s dementia. Cell Mol Neurobiol. 2003;23:681–9. 
109. Park L, Zhou P, Pitstick R, Capone C, Anrather J, Norris EH, Younkin L, Younkin S, 
Carlson G, McEwen BS, Iadecola C. Nox2-derived radicals contribute to 
neurovascular and behavioral dysfunction in mice overexpressing the amyloid 
precursor protein. Proc Natl Acad Sci U S A. 2008;105:1347–52. 
110. Goodwin JL, Uemura E, Cunnick JE. Microglial release of nitric oxide by the 
synergistic action of beta-amyloid and IFN-gamma. Brain Res. 1995;692:207–14. 
111. Ueda K, Fukui Y, Kageyama H. Amyloid beta protein-induced neuronal cell death: 
neurotoxic properties of aggregated amyloid beta protein. Brain Res. 1994;639:240–4. 
112. Yagami T, Ueda K, Asakura K, Sakaeda T, Kuroda T, Hata S, Kambayashi Y, 
Fujimoto M. Effects of S-2474, a novel nonsteroidal anti-inflammatory drug, on 
amyloid β protein-induced neuronal cell death. Br J Pharmacol. 2001;134:673–681. 
113. Blaise R, Mateo V, Rouxel C, Zaccarini F, Glorian M, Béréziat G, Golubkov VS, 
Limon I. Wild-type amyloid beta 1-40 peptide induces vascular smooth muscle cell 
death independently from matrix metalloprotease activity. Aging Cell. 2012;11:384–
393. 
	   218 
114. Verbeek MM, de Waal RM, Schipper JJ, Van Nostrand WE. Rapid degeneration of 
cultured human brain pericytes by amyloid beta protein. J Neurochem. 1997;68:1135–
41. 
115. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. β-Amyloid-mediated 
vasoactivity and vascular endothelial damage. Nature. 1996;380:168–171. 
116. Liu H, Yang Y, Xia Y, Zhu W, Leak RK, Wei Z, Wang J, Hu X. Aging of cerebral 
white matter. Ageing Res Rev. 2017;34:64–76. 
117. Miners JS, Palmer JC, Love S. Pathophysiology of Hypoperfusion of the Precuneus in 
Early Alzheimer’s Disease. Brain Pathol. 2016;26:533–541. 
118. Maier FC, Wehrl HF, Schmid AM, Mannheim JG, Wiehr S, Lerdkrai C, Calaminus C, 
Stahlschmidt A, Ye L, Burnet M, Stiller D, Sabri O, Reischl G, Staufenbiel M, 
Garaschuk O, Jucker M, Pichler BJ. Longitudinal PET-MRI reveals β-amyloid 
deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss 
of perfusion. Nat Med. 2014;20:1485–1492. 
119. Carrano A, Hoozemans JJM, van der Vies SM, Rozemuller AJM, van Horssen J, de 
Vries HE. Amyloid Beta Induces Oxidative Stress-Mediated Blood–Brain Barrier 
Changes in Capillary Amyloid Angiopathy. Antioxid Redox Signal. 2011;15:1167–
1178. 
120. Carrano A, Hoozemans JJM, van der Vies SM, van Horssen J, de Vries HE, 
Rozemuller AJM. Neuroinflammation and Blood-Brain Barrier Changes in Capillary 
Amyloid Angiopathy. Neurodegener Dis. 2012;10:329–331. 
121. Hartz AMS, Bauer B, Soldner ELB, Wolf A, Boy S, Backhaus R, Mihaljevic I, 
Bogdahn U, Klunemann HH, Schuierer G, Schlachetzki F. Amyloid-beta contributes 
	   219 
to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and 
in humans with cerebral amyloid angiopathy. Stroke. 2012;43:514–523. 
122. Peca S, McCreary CR, Donaldson E, Kumarpillai G, Shobha N, Sanchez K, Charlton 
A, Steinback CD, Beaudin AE, Fluck D, Pillay N, Fick GH, Poulin MJ, Frayne R, 
Goodyear BG, Smith EE. Neurovascular decoupling is associated with severity of 
cerebral amyloid angiopathy. Neurology. 2013;81:1659–1665. 
123. Maki T, Okamoto Y, Carare RO, Hase Y, Hattori Y, Hawkes CA, Saito S, Yamamoto 
Y, Terasaki Y, Ishibashi-Ueda H, Taguchi A, Takahashi R, Miyakawa T, Kalaria RN, 
Lo EH, Arai K, Ihara M. Phosphodiesterase III inhibitor promotes drainage of 
cerebrovascular β-amyloid. Ann Clin Transl Neurol. 2014;1:519–533. 
124. Williams RJ, Goodyear BG, Peca S, McCreary CR, Frayne R, Smith EE, Pike GB. 
Identification of neurovascular changes associated with cerebral amyloid angiopathy 
from subject-specific hemodynamic response functions. J Cereb Blood Flow Metab. 
2017;:0271678X1769105. 
125. Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, Benveniste H, Vates 
GE, Deane R, Goldman SA, Nagelhus EA, Nedergaard M. A paravascular pathway 
facilitates CSF flow through the brain parenchyma and the clearance of interstitial 
solutes, including amyloid β. Sci Transl Med. 2012;4:147ra111. 
126. Ghersi-Egea J-F, Strazielle N, Catala M, Silva-Vargas V, Doetsch F, Engelhardt B. 
Molecular anatomy and functions of the choroidal blood-cerebrospinal fluid barrier in 
health and disease. Acta Neuropathol. 2018;135:337–361. 
127. MAXWELL DS, PEASE DC. The electron microscopy of the choroid plexus. J 
Biophys Biochem Cytol. 1956;2:467–74. 
	   220 
128. Cserr HF. Physiology of the choroid plexus. Physiol Rev. 1971;51:273–311. 
129. Wright EM. Transport processes in the formation of the cerebrospinal fluid. Rev 
Physiol Biochem Pharmacol. 1978;83:3–34. 
130. Keep RF, Jones HC. A morphometric study on the development of the lateral ventricle 
choroid plexus, choroid plexus capillaries and ventricular ependyma in the rat. Brain 
Res Dev Brain Res. 1990;56:47–53. 
131. Pollay M, Hisey B, Reynolds E, Tomkins P, Stevens FA, Smith R. Choroid plexus 
Na+/K+-activated adenosine triphosphatase and cerebrospinal fluid formation. 
Neurosurgery. 1985;17:768–72. 
132. Davson H, Segal MB. The effects of some inhibitors and accelerators of sodium 
transport on the turnover of 22Na in the cerebrospinal fluid and the brain. J Physiol. 
1970;209:131–53. 
133. Preston GM, Agre P. Isolation of the cDNA for erythrocyte integral membrane protein 
of 28 kilodaltons: member of an ancient channel family. Proc Natl Acad Sci U S A. 
1991;88:11110–4. 
134. Preston GM, Carroll TP, Guggino WB, Agre P. Appearance of water channels in 
Xenopus oocytes expressing red cell CHIP28 protein. Science. 1992;256:385–7. 
135. Nielsen S, Smith BL, Christensen EI, Agre P. Distribution of the aquaporin CHIP in 
secretory and resorptive epithelia and capillary endothelia. Proc Natl Acad Sci U S A. 
1993;90:7275–9. 
136. Speake T, Freeman LJ, Brown PD. Expression of aquaporin 1 and aquaporin 4 water 
channels in rat choroid plexus. Biochim Biophys Acta. 2003;1609:80–6. 
137. Oshio K, Watanabe H, Song Y, Verkman AS, Manley GT. Reduced cerebrospinal 
	   221 
fluid production and intracranial pressure in mice lacking choroid plexus water 
channel Aquaporin-1. FASEB J. 2005;19:76–8. 
138. Wolburg H, Wolburg-Buchholz K, Liebner S, Engelhardt B. Claudin-1, claudin-2 and 
claudin-11 are present in tight junctions of choroid plexus epithelium of the mouse. 
Neurosci Lett. 2001;307:77–80. 
139. Rosenthal R, Milatz S, Krug SM, Oelrich B, Schulzke J-D, Amasheh S, Gunzel D, 
Fromm M. Claudin-2, a component of the tight junction, forms a paracellular water 
channel. J Cell Sci. 2010;123:1913–1921. 
140. Stratchko L, Filatova I, Agarwal A, Kanekar S. The Ventricular System of the Brain: 
Anatomy and Normal Variations. Semin Ultrasound, CT MRI. 2016;37:72–83. 
141. Glimcher SA, Holman DW, Lubow M, Grzybowski DM. Ex vivo model of 
cerebrospinal fluid outflow across human arachnoid granulations. Invest Ophthalmol 
Vis Sci. 2008;49:4721–8. 
142. Upton ML, Weller RO. The morphology of cerebrospinal fluid drainage pathways in 
human arachnoid granulations. J Neurosurg. 1985;63:867–875. 
143. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, 
Castle D, Mandell JW, Lee KS, Harris TH, Kipnis J. Structural and functional features 
of central nervous system lymphatic vessels. Nature. 2015;523:337–341. 
144. Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M, Wiig H, Alitalo 
K. A dural lymphatic vascular system that drains brain interstitial fluid and 
macromolecules. J Exp Med. 2015;212:991–999. 
145. de Leon MJ, Li Y, Okamura N, Tsui WH, Saint-Louis LA, Glodzik L, Osorio RS, 
Fortea J, Butler T, Pirraglia E, Fossati S, Kim H-J, Carare RO, Nedergaard M, 
	   222 
Benveniste H, Rusinek H. Cerebrospinal Fluid Clearance in Alzheimer Disease 
Measured with Dynamic PET. J Nucl Med. 2017;58:1471–1476. 
146. Chen L, Elias G, Yostos MP, Stimec B, Fasel J, Murphy K. Pathways of cerebrospinal 
fluid outflow: a deeper understanding of resorption. Neuroradiology. 2015;57:139–
147. 
147. MATSUMAE M, SATO O, HIRAYAMA A, HAYASHI N, TAKIZAWA K, 
ATSUMI H, SORIMACHI T. Research into the Physiology of Cerebrospinal Fluid 
Reaches a New Horizon: Intimate Exchange between Cerebrospinal Fluid and 
Interstitial Fluid May Contribute to Maintenance of Homeostasis in the Central 
Nervous System. Neurol Med Chir (Tokyo). 2016;56:416–441. 
148. Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, Axel 
L, Rusinek H, Nicholson C, Zlokovic B V., Frangione B, Blennow K, Ménard J, 
Zetterberg H, Wisniewski T, de Leon MJ. Clearance systems in the brain—
implications for Alzheimer disease. Nat Rev Neurol. 2015;11:457–470. 
149. Charidimou A, Friedrich JO, Greenberg SM, Viswanathan A. Core cerebrospinal fluid 
biomarker profile in cerebral amyloid angiopathy. Neurology. 2018;90:e754–e762. 
150. van Etten ES, Verbeek MM, van der Grond J, Zielman R, van Rooden S, van Zwet 
EW, van Opstal AM, Haan J, Greenberg SM, van Buchem MA, Wermer MJH, 
Terwindt GM. β-Amyloid in CSF. Neurology. 2017;88:169–176. 
151. Thomsen MS, Birkelund S, Burkhart A, Stensballe A, Moos T. Synthesis and 
deposition of basement membrane proteins by primary brain capillary endothelial cells 
in a murine model of the blood-brain barrier. J Neurochem. 2017;140:741–754. 
152. Keski-Oja J, Mosher DF, Vaheri A. Dimeric character of fibronectin, a major cell 
	   223 
surface-associated glycoprotein. Biochem Biophys Res Commun. 1977;74:699–706. 
153. Tilling T, Korte D, Hoheisel D, Galla HJ. Basement membrane proteins influence 
brain capillary endothelial barrier function in vitro. J Neurochem. 1998;71:1151–7. 
154. Kose N, Asashima T, Muta M, Iizasa H, Sai Y, Terasaki T, Nakashima E. Altered 
expression of basement membrane-related molecules in rat brain pericyte, endothelial, 
and astrocyte cell lines after transforming growth factor-beta1 treatment. Drug Metab 
Pharmacokinet. 2007;22:255–66. 
155. Krum JM, More NS, Rosenstein JM. Brain angiogenesis: variations in vascular 
basement membrane glycoprotein immunoreactivity. Exp Neurol. 1991;111:152–65. 
156. Schwarzbauer JE, DeSimone DW. Fibronectins, Their Fibrillogenesis, and In Vivo 
Functions. Cold Spring Harb Perspect Biol. 2011;3:a005041–a005041. 
157. Li J-P, Kusche-Gullberg M. Heparan Sulfate: Biosynthesis, Structure, and Function. 
In: International review of cell and molecular biology. ; 2016: 215–273. 
158. Parham CL, Shaw C, Auckland LD, Dickeson SK, Griswold-Prenner I, Bix G. 
Perlecan Domain V Inhibits Amyloid-β Induced Activation of the α2β1 Integrin-
Mediated Neurotoxic Signaling Cascade. J Alzheimer’s Dis. 2016;54:1629–1647. 
159. Verbeek MM, Otte-Höller I, van den Born J, van den Heuvel LPWJ, David G, 
Wesseling P, de Waal RMW. Agrin Is a Major Heparan Sulfate Proteoglycan 
Accumulating in Alzheimer’s Disease Brain. Am J Pathol. 1999;155:2115–2125. 
160. Barber AJ, Lieth E. Agrin accumulates in the brain microvascular basal lamina during 
development of the blood-brain barrier. Dev Dyn. 1997;208:62–74. 
161. Lunde LK, Camassa LMA, Hoddevik EH, Khan FH, Ottersen OP, Boldt HB, Amiry-
Moghaddam M. Postnatal development of the molecular complex underlying astrocyte 
	   224 
polarization. Brain Struct Funct. 2015;220:2087–2101. 
162. Utriainen A, Sormunen R, Kettunen M, Carvalhaes LS, Sajanti E, Eklund L, 
Kauppinen R, Kitten GT, Pihlajaniemi T. Structurally altered basement membranes 
and hydrocephalus in a type XVIII collagen deficient mouse line. Hum Mol Genet. 
2004;13:2089–2099. 
163. Horiguchi K, Kouki T, Fujiwara K, Tsukada T, Ly F, Kikuchi M, Yashiro T. 
Expression of the proteoglycan syndecan-4 and the mechanism by which it mediates 
stress fiber formation in folliculostellate cells in the rat anterior pituitary gland. J 
Endocrinol. 2012;214:199–206. 
164. Woods A, Longley RL, Tumova S, Couchman JR. Syndecan-4 binding to the high 
affinity heparin-binding domain of fibronectin drives focal adhesion formation in 
fibroblasts. Arch Biochem Biophys. 2000;374:66–72. 
165. Lee B, Clarke D, Al Ahmad A, Kahle M, Parham C, Auckland L, Shaw C, Fidanboylu 
M, Orr AW, Ogunshola O, Fertala A, Thomas SA, Bix GJ. Perlecan domain V is 
neuroprotective and proangiogenic following ischemic stroke in rodents. J Clin Invest. 
2011;121:3005–3023. 
166. Engelhardt B. β1-integrin/matrix interactions support blood-brain barrier integrity. J 
Cereb Blood Flow Metab. 2011;31:1969–71. 
167. Paulus W, Baur I, Schuppan D, Roggendorf W. Characterization of integrin receptors 
in normal and neoplastic human brain. Am J Pathol. 1993;143:154–63. 
168. Milner R, Campbell IL. Developmental regulation of beta1 integrins during 
angiogenesis in the central nervous system. Mol Cell Neurosci. 2002;20:616–26. 
169. Milner R, Campbell IL. Increased expression of the beta4 and alpha5 integrin subunits 
	   225 
in cerebral blood vessels of transgenic mice chronically producing the pro-
inflammatory cytokines IL-6 or IFN-alpha in the central nervous system. Mol Cell 
Neurosci. 2006;33:429–40. 
170. Grazioli A, Alves CS, Konstantopoulos K, Yang JT. Defective blood vessel 
development and pericyte/pvSMC distribution in alpha 4 integrin-deficient mouse 
embryos. Dev Biol. 2006;293:165–77. 
171. Huveneers S, Truong H, Fassler R, Sonnenberg A, Danen EHJ. Binding of soluble 
fibronectin to integrin  5 1 - link to focal adhesion redistribution and contractile shape. 
J Cell Sci. 2008;121:2452–2462. 
172. Mahalingam Y, Gallagher JT, Couchman JR. Cellular Adhesion Responses to the 
Heparin-binding (HepII) Domain of Fibronectin Require Heparan Sulfate with 
Specific Properties. J Biol Chem. 2007;282:3221–3230. 
173. Wang Z, Collighan RJ, Gross SR, Danen EHJ, Orend G, Telci D, Griffin M. RGD-
independent Cell Adhesion via a Tissue Transglutaminase-Fibronectin Matrix 
Promotes Fibronectin Fibril Deposition and Requires Syndecan-4/2 and α5β1 Integrin 
Co-signaling. J Biol Chem. 2010;285:40212–40229. 
174. Banères JL, Roquet F, Green M, LeCalvez H, Parello J. The cation-binding domain 
from the alpha subunit of integrin alpha5 beta1 is a minimal domain for fibronectin 
recognition. J Biol Chem. 1998;273:24744–53. 
175. Mould AP, Askari JA, Aota S i, Yamada KM, Irie A, Takada Y, Mardon HJ, 
Humphries MJ. Defining the topology of integrin alpha5beta1-fibronectin interactions 
using inhibitory anti-alpha5 and anti-beta1 monoclonal antibodies. Evidence that the 
synergy sequence of fibronectin is recognized by the amino-terminal repeats of the 
	   226 
alpha5 subunit. J Biol Chem. 1997;272:17283–92. 
176. Nagae M, Re S, Mihara E, Nogi T, Sugita Y, Takagi J. Crystal structure of α5β1 
integrin ectodomain: Atomic details of the fibronectin receptor. J Cell Biol. 
2012;197:131–140. 
177. Su Y, Xia W, Li J, Walz T, Humphries MJ, Vestweber D, Cabañas C, Lu C, Springer 
TA. Relating conformation to function in integrin α 5 β 1. Proc Natl Acad Sci. 
2016;113:E3872–E3881. 
178. Winder SJ. The complexities of dystroglycan. Trends Biochem Sci. 2001;26:118–24. 
179. Zaccaria ML, Di Tommaso F, Brancaccio A, Paggi P, Petrucci TC. Dystroglycan 
distribution in adult mouse brain: a light and electron microscopy study. Neuroscience. 
2001;104:311–24. 
180. Zarow C, Barron E, Chui HC, Perlmutter LS. Vascular basement membrane pathology 
and Alzheimer’s disease. Ann N Y Acad Sci. 1997;826:147–60. 
181. Hawkes CA, Gatherer M, Sharp MM, Dorr A, Yuen HM, Kalaria R, Weller RO, 
Carare RO. Regional differences in the morphological and functional effects of aging 
on cerebral basement membranes and perivascular drainage of amyloid-β from the 
mouse brain. Aging Cell. 2013;12:224–36. 
182. Lepelletier F-X, Mann DMA, Robinson AC, Pinteaux E, Boutin H. Early changes in 
extracellular matrix in Alzheimer’s disease. Neuropathol Appl Neurobiol. 
2017;43:167–182. 
183. Merlini M, Meyer EP, Ulmann-Schuler A, Nitsch RM. Vascular β-amyloid and early 
astrocyte alterations impair cerebrovascular function and cerebral metabolism in 
transgenic arcAβ mice. Acta Neuropathol. 2011;122:293–311. 
	   227 
184. Kiuchi Y, Isobe Y, Fukushima K. Entactin-induced inhibition of human amyloid beta-
protein fibril formation in vitro. Neurosci Lett. 2001;305:119–22. 
185. Kiuchi Y, Isobe Y, Fukushima K, Kimura M. Disassembly of amyloid beta-protein 
fibril by basement membrane components. Life Sci. 2002;70:2421–31. 
186. Hawkes CA, Sullivan PM, Hands S, Weller RO, Nicoll JAR, Carare RO. Disruption of 
Arterial Perivascular Drainage of Amyloid-β from the Brains of Mice Expressing the 
Human APOE ε4 Allele. PLoS One. 2012;7:e41636. 
187. Castillo GM, Ngo C, Cummings J, Wight TN, Snow AD. Perlecan binds to the beta-
amyloid proteins (A beta) of Alzheimer’s disease, accelerates A beta fibril formation, 
and maintains A beta fibril stability. J Neurochem. 1997;69:2452–65. 
188. Fukuda S, Fini CA, Mabuchi T, Koziol JA, Eggleston LL, del Zoppo GJ. Focal 
cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke. 
2004;35:998–1004. 
189. Katsu M, Niizuma K, Yoshioka H, Okami N, Sakata H, Chan PH. Hemoglobin-
Induced Oxidative Stress Contributes to Matrix Metalloproteinase Activation and 
Blood–Brain Barrier Dysfunction in vivo. J Cereb Blood Flow Metab. 2010;30:1939–
1950. 
190. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ. Microvascular basal lamina antigens 
disappear during cerebral ischemia and reperfusion. Stroke. 1995;26:2120–6. 
191. Hamann GF, Liebetrau M, Martens H, Burggraf D, Kloss CUA, Bültemeier G, 
Wunderlich N, Jäger G, Pfefferkorn T. Microvascular basal lamina injury after 
experimental focal cerebral ischemia and reperfusion in the rat. J Cereb Blood Flow 
Metab. 2002;22:526–33. 
	   228 
192. Wasserman JK, Schlichter LC. Minocycline protects the blood-brain barrier and 
reduces edema following intracerebral hemorrhage in the rat. Exp Neurol. 
2007;207:227–37. 
193. Rosell A, Cuadrado E, Ortega-Aznar A, Hernández-Guillamon M, Lo EH, Montaner J. 
MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown 
and basal lamina type IV collagen degradation during hemorrhagic transformation 
after human ischemic stroke. Stroke. 2008;39:1121–6. 
194. Huang Q, Chen B, Wang F, Huang H, Milner R, Li L. The temporal expression 
patterns of fibronectin and its receptors-α5β1 and αvβ3 integrins on blood vessels after 
cerebral ischemia. Restor Neurol Neurosci. 2015;33:493–507. 
195. Nakada T, Kwee IL, Igarashi H, Suzuki Y. Aquaporin-4 Functionality and Virchow-
Robin Space Water Dynamics: Physiological Model for Neurovascular Coupling and 
Glymphatic Flow. Int J Mol Sci. 2017;18. doi:10.3390/ijms18081798. 
196. Morris AWJ, Sharp MM, Albargothy NJ, Fernandes R, Hawkes CA, Verma A, Weller 
RO, Carare RO. Vascular basement membranes as pathways for the passage of fluid 
into and out of the brain. Acta Neuropathol. 2016;131:725–36. 
197. Brøchner CB, Holst CB, Møllgård K. Outer brain barriers in rat and human 
development. Front Neurosci. 2015;9:75. 
198. Cserr HF, Cooper DN, Milhorat TH. Flow of cerebral interstitial fluid as indicated by 
the removal of extracellular markers from rat caudate nucleus. Exp Eye Res. 1977;25 
Suppl:461–73. 
199. Bradbury MW, Cserr HF, Westrop RJ. Drainage of cerebral interstitial fluid into deep 
cervical lymph of the rabbit. Am J Physiol Physiol. 1981;240:F329–F336. 
	   229 
200. Cserr HF, Cooper DN, Suri PK, Patlak CS. Efflux of radiolabeled polyethylene 
glycols and albumin from rat brain. Am J Physiol Physiol. 1981;240:F319–F328. 
201. Szentistványi I, Patlak CS, Ellis RA, Cserr HF. Drainage of interstitial fluid from 
different regions of rat brain. Am J Physiol. 1984;246:F835–44. 
202. Syková E, Nicholson C. Diffusion in brain extracellular space. Physiol Rev. 
2008;88:1277–340. 
203. Rosenberg GA, Kyner WT, Estrada E. Bulk flow of brain interstitial fluid under 
normal and hyperosmolar conditions. Am J Physiol. 1980;238:F42–9. 
204. Rennels ML, Gregory TF, Blaumanis OR, Fujimoto K, Grady PA. Evidence for a 
“paravascular” fluid circulation in the mammalian central nervous system, provided by 
the rapid distribution of tracer protein throughout the brain from the subarachnoid 
space. Brain Res. 1985;326:47–63. 
205. Iliff JJ, Chen MJ, Plog BA, Zeppenfeld DM, Soltero M, Yang L, Singh I, Deane R, 
Nedergaard M. Impairment of Glymphatic Pathway Function Promotes Tau Pathology 
after Traumatic Brain Injury. J Neurosci. 2014;34:16180–16193. 
206. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, O’Donnell J, Christensen 
DJ, Nicholson C, Iliff JJ, Takano T, Deane R, Nedergaard M. Sleep drives metabolite 
clearance from the adult brain. Science. 2013;342:373–7. 
207. Iliff JJ, Lee H, Yu M, Feng T, Logan J, Nedergaard M, Benveniste H. Brain-wide 
pathway for waste clearance captured by contrast-enhanced MRI. J Clin Invest. 
2013;123:1299–1309. 
208. Wang M, Ding F, Deng S, Guo X, Wang W, Iliff JJ, Nedergaard M. Focal Solute 
Trapping and Global Glymphatic Pathway Impairment in a Murine Model of Multiple 
	   230 
Microinfarcts. J Neurosci. 2017;37:2870–2877. 
209. Peng W, Achariyar TM, Li B, Liao Y, Mestre H, Hitomi E, Regan S, Kasper T, Peng 
S, Ding F, Benveniste H, Nedergaard M, Deane R. Suppression of glymphatic fluid 
transport in a mouse model of Alzheimer’s disease. Neurobiol Dis. 2016;93:215–225. 
210. Syková E, Vorísek I, Mazel T, Antonova T, Schachner M. Reduced extracellular space 
in the brain of tenascin-R- and HNK-1-sulphotransferase deficient mice. Eur J 
Neurosci. 2005;22:1873–80. 
211. Syková E, Vorísek I, Antonova T, Mazel T, Meyer-Luehmann M, Jucker M, Hájek M, 
Ort M, Or M, Bures J. Changes in extracellular space size and geometry in APP23 
transgenic mice: a model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 
2005;102:479–84. 
212. Vargová L, Homola A, Zámecník J, Tichý M, Benes V, Syková E. Diffusion 
parameters of the extracellular space in human gliomas. Glia. 2003;42:77–88. 
213. Rees S, Cragg BG, Everitt A V. Comparison of extracellular space in the mature and 
aging rat brain using a new technique. J Neurol Sci. 1982;53:347–57. 
214. Bondareff W, Narotzky R. Age changes in the neuronal microenvironment. Science. 
1972;176:1135–6. 
215. Homola A, Zoremba N, Slais K, Kuhlen R, Syková E. Changes in diffusion 
parameters, energy-related metabolites and glutamate in the rat cortex after transient 
hypoxia/ischemia. Neurosci Lett. 2006;404:137–42. 
216. Zoremba N, Homola A, Rossaint R, Syková E. Brain metabolism and extracellular 
space diffusion parameters during and after transient global hypoxia in the rat cortex. 
Exp Neurol. 2007;203:34–41. 
	   231 
217. Maas C, Schiks B, Strangi RD, Hackeng TM, Bouma BN, Gebbink MFBG, Bouma B. 
Identification of fibronectin type I domains as amyloid-binding modules on tissue-type 
plasminogen activator and three homologs. Amyloid. 2008;15:166–180. 
218. Grand Moursel L, Munting LP, van der Graaf LM, van Duinen SG, Goumans M-JTH, 
Ueberham U, Natté R, van Buchem MA, van Roon-Mom WMC, van der Weerd L. 
TGFβ pathway deregulation and abnormal phospho-SMAD2/3 staining in hereditary 
cerebral hemorrhage with amyloidosis-Dutch type. Brain Pathol. 2017. 
doi:10.1111/bpa.12533. 
219. Wyss-Coray T, Feng L, Masliah E, Ruppe MD, Lee HS, Toggas SM, Rockenstein 
EM, Mucke L. Increased central nervous system production of extracellular matrix 
components and development of hydrocephalus in transgenic mice overexpressing 
transforming growth factor-beta 1. Am J Pathol. 1995;147:53–67. 
220. Wyss-Coray T, Lin C, Sanan DA, Mucke L, Masliah E. Chronic overproduction of 
transforming growth factor-beta1 by astrocytes promotes Alzheimer’s disease-like 
microvascular degeneration in transgenic mice. Am J Pathol. 2000;156:139–50. 
221. Zhang X, Huang W-J, Chen W-W. TGF-β1 factor in the cerebrovascular diseases of 
Alzheimer’s disease. Eur Rev Med Pharmacol Sci. 2016;20:5178–5185. 
222. Mecha M, Rabadán MA, Peña-Melián A, Valencia M, Mondéjar T, Blanco MJ. 
Expression of TGF-βs in the embryonic nervous system: Analysis of interbalance 
between isoforms. Dev Dyn. 2008;237:1709–1717. 
223. Doyle KP, Cekanaviciute E, Mamer LE, Buckwalter MS. TGFβ signaling in the brain 
increases with aging and signals to astrocytes and innate immune cells in the weeks 
after stroke. J Neuroinflammation. 2010;7:62. 
	   232 
224. Letourneur O, Goetschy J-F, Horisberger M, Grütter MG. Ligand-Induced 
Dimerization of the Extracellular Domain of the TGF-β Receptor Type II. Biochem 
Biophys Res Commun. 1996;224:709–716. 
225. Nickel J, ten Dijke P, Mueller TD. TGF-β family co-receptor function and signaling. 
Acta Biochim Biophys Sin (Shanghai). 2018;50:12–36. 
226. Bai J, Xi Q. Crosstalk between TGF-β signaling and epigenome. Acta Biochim 
Biophys Sin (Shanghai). 2018;50:60–67. 
227. Zhu H, Gui Q, Hui X, Wang X, Jiang J, Ding L, Sun X, Wang Y, Chen H. TGF-
β1/Smad3 Signaling Pathway Suppresses Cell Apoptosis in Cerebral Ischemic Stroke 
Rats. Med Sci Monit. 2017;23:366–376. 
228. Taylor RA, Chang C-F, Goods BA, Hammond MD, Mac Grory B, Ai Y, 
Steinschneider AF, Renfroe SC, Askenase MH, McCullough LD, Kasner SE, Mullen 
MT, Hafler DA, Love JC, Sansing LH. TGF-β1 modulates microglial phenotype and 
promotes recovery after intracerebral hemorrhage. J Clin Invest. 2017;127:280–292. 
229. Cekanaviciute E, Fathali N, Doyle KP, Williams AM, Han J, Buckwalter MS. 
Astrocytic transforming growth factor-beta signaling reduces subacute 
neuroinflammation after stroke in mice. Glia. 2014;62:1227–40. 
230. Graham JB, Muir D. Chondroitinase C Selectively Degrades Chondroitin Sulfate 
Glycosaminoglycans that Inhibit Axonal Growth within the Endoneurium of 
Peripheral Nerve. PLoS One. 2016;11:e0167682. 
231. Starkey ML, Bartus K, Barritt AW, Bradbury EJ. Chondroitinase ABC promotes 
compensatory sprouting of the intact corticospinal tract and recovery of forelimb 
function following unilateral pyramidotomy in adult mice. Eur J Neurosci. 
	   233 
2012;36:3665–3678. 
232. Kobayashi T, Kakizaki I, Nozaka H, Nakamura T. Chondroitin sulfate proteoglycans 
from salmon nasal cartilage inhibit angiogenesis. Biochem Biophys Reports. 
2017;9:72–78. 
233. Manwani B, Liu F, Xu Y, Persky R, Li J, McCullough LD. Functional recovery in 
aging mice after experimental stroke. Brain Behav Immun. 2011;25:1689–700. 
234. Jha MK, Kim J-H, Song GJ, Lee W-H, Lee I-K, Lee H-W, An SSA, Kim S, Suk K. 
Functional dissection of astrocyte-secreted proteins: Implications in brain health and 
diseases. Prog Neurobiol. 2017. doi:10.1016/j.pneurobio.2017.12.003. 
235. Kress BT, Iliff JJ, Xia M, Wang M, Wei HS, Zeppenfeld D, Xie L, Kang H, Xu Q, 
Liew JA, Plog BA, Ding F, Deane R, Nedergaard M. Impairment of paravascular 
clearance pathways in the aging brain. Ann Neurol. 2014;76:845–61. 
236. Venkat P, Chopp M, Zacharek A, Cui C, Zhang L, Li Q, Lu M, Zhang T, Liu A, Chen 
J. White matter damage and glymphatic dysfunction in a model of vascular dementia 
in rats with no prior vascular pathologies. Neurobiol Aging. 2017;50:96–106. 
237. Wang M, Ding F, Deng S, Guo X, Wang W, Iliff JJ, Nedergaard M. Focal Solute 
Trapping and Global Glymphatic Pathway Impairment in a Murine Model of Multiple 
Microinfarcts. J Neurosci. 2017;37:2870–2877. 
238. Gomez-Arboledas A, Davila JC, Sanchez-Mejias E, Navarro V, Nuñez-Diaz C, 
Sanchez-Varo R, Sanchez-Mico MV, Trujillo-Estrada L, Fernandez-Valenzuela JJ, 
Vizuete M, Comella JX, Galea E, Vitorica J, Gutierrez A. Phagocytic clearance of 
presynaptic dystrophies by reactive astrocytes in Alzheimer’s disease. Glia. 
2018;66:637–653. 
	   234 
239. Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, Barres BA. Genomic 
analysis of reactive astrogliosis. J Neurosci. 2012;32:6391–410. 
240. Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, 
Bennett ML, Münch AE, Chung W-S, Peterson TC, Wilton DK, Frouin A, Napier BA, 
Panicker N, Kumar M, Buckwalter MS, Rowitch DH, Dawson VL, Dawson TM, 
Stevens B, Barres BA. Neurotoxic reactive astrocytes are induced by activated 
microglia. Nature. 2017;541:481–487. 
241. Li G, Fu BM. An Electrodiffusion Model for the Blood-Brain Barrier Permeability to 
Charged Molecules. J Biomech Eng. 2011;133:021002. 
242. Urayama A, Grubb JH, Sly WS, Banks WA. Mannose 6-Phosphate Receptor–
mediated Transport of Sulfamidase Across the Blood–brain Barrier in the Newborn 
Mouse. Mol Ther. 2008;16:1261–1266. 
243. Jin B-J, Smith AJ, Verkman AS. Spatial model of convective solute transport in brain 
extracellular space does not support a “glymphatic” mechanism. J Gen Physiol. 
2016;148:489–501. 
244. Asgari M, de Zélicourt D, Kurtcuoglu V. Glymphatic solute transport does not require 
bulk flow. Sci Rep. 2016;6:38635. 
245. Barrow CJ, Zagorski MG. Solution structures of beta peptide and its constituent 
fragments: relation to amyloid deposition. Science. 1991;253:179–82. 
246. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, 
Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, 
Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, 
Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain 
	   235 
barrier and accumulation in brain. Nat Med. 2003;9:907–913. 
247. Osgood D, Miller MC, Messier AA, Gonzalez L, Silverberg GD. Aging alters mRNA 
expression of amyloid transporter genes at the blood-brain barrier. Neurobiol Aging. 
2017;57:178–185. 
248. Iliff JJ, Wang M, Zeppenfeld DM, Venkataraman A, Plog BA, Liao Y, Deane R, 
Nedergaard M. Cerebral arterial pulsation drives paravascular CSF-interstitial fluid 
exchange in the murine brain. J Neurosci. 2013;33:18190–9. 
249. Hawkes CA, Härtig W, Kacza J, Schliebs R, Weller RO, Nicoll JA, Carare RO. 
Perivascular drainage of solutes is impaired in the ageing mouse brain and in the 
presence of cerebral amyloid angiopathy. Acta Neuropathol. 2011;121:431–43. 
250. Shoji M, Kanai M. Cerebrospinal fluid Aβ40 and Aβ42: Natural course and clinical 
usefulness. J Alzheimers Dis. 2001;3:313–21. 
251. Wyss-Coray T, Lin C, Sanan DA, Mucke L, Masliah E. Chronic overproduction of 
transforming growth factor-beta1 by astrocytes promotes Alzheimer’s disease-like 
microvascular degeneration in transgenic mice. Am J Pathol. 2000;156:139–50. 
252. Briknarová K, Akerman ME, Hoyt DW, Ruoslahti E, Ely KR. Anastellin, an FN3 
fragment with fibronectin polymerization activity, resembles amyloid fibril precursors. 
J Mol Biol. 2003;332:205–15. 
253. Doyle KP, Buckwalter MS. A mouse model of permanent focal ischemia: distal 
middle cerebral artery occlusion. Methods Mol Biol. 2014;1135:103–10. 
254. Attar A, Liu T, Chan W-TC, Hayes J, Nejad M, Lei K, Bitan G. A Shortened Barnes 
Maze Protocol Reveals Memory Deficits at 4-Months of Age in the Triple-Transgenic 
Mouse Model of Alzheimer’s Disease. PLoS One. 2013;8:e80355. 
	   236 
255. Harris NM, Ritzel R, Mancini NS, Jiang Y, Yi X, Manickam DS, Banks WA, 
Kabanov A V., McCullough LD, Verma R. Nano-particle delivery of brain derived 
neurotrophic factor after focal cerebral ischemia reduces tissue injury and enhances 
behavioral recovery. Pharmacol Biochem Behav. 2016;150-151:48–56. 
256. Verma R, Friedler BD, Harris NM, McCullough LD. Pair housing reverses post-stroke 
depressive behavior in mice. Behav Brain Res. 2014;269:155–63. 
257. Milner R, Hung S, Wang X, Berg GI, Spatz M, del Zoppo GJ. Responses of 
endothelial cell and astrocyte matrix-integrin receptors to ischemia mimic those 
observed in the neurovascular unit. Stroke. 2008;39:191–7. 
258. Huang Q, Chen B, Wang F, Huang H, Milner R, Li L. The temporal expression 
patterns of fibronectin and its receptors-α5β1 and αvβ3 integrins on blood vessels after 
cerebral ischemia. Restor Neurol Neurosci. 2015;33:493–507. 
259. Benito-Jardón M, Klapproth S, Gimeno-LLuch I, Petzold T, Bharadwaj M, Müller DJ, 
Zuchtriegel G, Reichel CA, Costell M. The fibronectin synergy site re-enforces cell 
adhesion and mediates a crosstalk between integrin classes. Elife. 2017;6. 
doi:10.7554/eLife.22264. 
260. Jullienne A, Roberts JM, Pop V, Paul Murphy M, Head E, Bix GJ, Badaut J. Juvenile 
traumatic brain injury induces long-term perivascular matrix changes alongside 
amyloid-beta accumulation. J Cereb Blood Flow Metab. 2014;34:1637–45. 
261. Iliff JJ, Chen MJ, Plog BA, Zeppenfeld DM, Soltero M, Yang L, Singh I, Deane R, 
Nedergaard M. Impairment of glymphatic pathway function promotes tau pathology 
after traumatic brain injury. J Neurosci. 2014;34:16180–93. 
262. Zámecník J, Vargová L, Homola A, Kodet R, Syková E. Extracellular matrix 
	   237 
glycoproteins and diffusion barriers in human astrocytic tumours. Neuropathol Appl 
Neurobiol. 2004;30:338–50. 
263. Anderová M, Kubinová S, Mazel T, Chvátal A, Eliasson C, Pekny M, Syková E. 
Effect of elevated K(+), hypotonic stress, and cortical spreading depression on 
astrocyte swelling in GFAP-deficient mice. Glia. 2001;35:189–203. 
264. Roitbak T, Syková E. Diffusion barriers evoked in the rat cortex by reactive 
astrogliosis. Glia. 1999;28:40–8. 
265. Li B, Lin Z, Mitsi M, Zhang Y, Vogel V. Heparin-induced conformational changes of 
fibronectin within the extracellular matrix promote hMSC osteogenic differentiation. 
Biomater Sci. 2015;3:73–84. 
266. Agulhon C, Petravicz J, McMullen AB, Sweger EJ, Minton SK, Taves SR, Casper 
KB, Fiacco TA, McCarthy KD. What is the role of astrocyte calcium in 
neurophysiology? Neuron. 2008;59:932–46. 
267. Papouin T, Dunphy J, Tolman M, Foley JC, Haydon PG. Astrocytic control of 
synaptic function. Philos Trans R Soc B Biol Sci. 2017;372:20160154. 
268. Magaki SD, Williams CK, Vinters H V. Glial function (and dysfunction) in the normal 
&amp; ischemic brain. Neuropharmacology. 2017. 
doi:10.1016/j.neuropharm.2017.11.009. 
269. Hu X, Yuan Y, Wang D, Su Z. Heterogeneous astrocytes: Active players in CNS. 
Brain Res Bull. 2016;125:1–18. 
270. Adams KL, Gallo V. The diversity and disparity of the glial scar. Nat Neurosci. 
2018;21:9–15. 
271. Clarke LE, Liddelow SA, Chakraborty C, Münch AE, Heiman M, Barres BA. Normal 
	   238 
aging induces A1-like astrocyte reactivity. Proc Natl Acad Sci. 2018;115:E1896–
E1905. 
272. Ueberham U, Lange P, Ueberham E, Brückner MK, Hartlage-Rübsamen M, Pannicke 
T, Rohn S, Cross M, Arendt T. Smad2 isoforms are differentially expressed during 
mouse brain development and aging. Int J Dev Neurosci. 2009;27:501–510. 
273. Wyman AE, Noor Z, Fishelevich R, Lockatell V, Shah NG, Todd NW, Atamas SP. 
Sirtuin 7 is decreased in pulmonary fibrosis and regulates the fibrotic phenotype of 
lung fibroblasts. Am J Physiol Cell Mol Physiol. 2017;312:L945–L958. 
274. Ito T, Yamamoto N, Nakajima S, Schaffer SW. Beta-Catenin and SMAD3 Are 
Associated with Skeletal Muscle Aging in the Taurine Transpoeter Knockout Mouse. 
In: Advances in experimental medicine and biology. ; 2017: 497–502. 
275. Kashyap S, Warner G, Hu Z, Gao F, Osman M, Al Saiegh Y, Lien KR, Nath K, 
Grande JP. Cardiovascular phenotype in Smad3 deficient mice with renovascular 
hypertension. PLoS One. 2017;12:e0187062. 
276. Latella G, Vetuschi A, Sferra R, Catitti V, D’Angelo A, Zanninelli G, Flanders KC, 
Gaudio E. Targeted disruption of Smad3 confers resistance to the development of 
dimethylnitrosamine-induced hepatic fibrosis in mice. Liver Int. 2009;29:997–1009. 
277. Burton T, Liang B, Dibrov A, Amara F. Transforming growth factor-beta-induced 
transcription of the Alzheimer beta-amyloid precursor protein gene involves 
interaction between the CTCF-complex and Smads. Biochem Biophys Res Commun. 
2002;295:713–23. 
278. Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA. 
Blocking TGF-β–Smad2/3 innate immune signaling mitigates Alzheimer-like 
	   239 
pathology. Nat Med. 2008;14:681–687. 
279. Hamby ME, Uliasz TF, Hewett SJ, Hewett JA. Characterization of an improved 
procedure for the removal of microglia from confluent monolayers of primary 
astrocytes. J Neurosci Methods. 2006;150:128–137. 
280. Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Lin C, 
Mucke L. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in 
Alzheimer’s disease. Nature. 1997;389:603–606. 
281. Mukherjee D, Patil CG. Epidemiology and the global burden of stroke. World 
Neurosurg. 2011;76:S85–90. 
282. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral 
amyloid angiopathy: validation of the Boston criteria. Neurology. 2001;56:537–9. 
283. Lee J-M, Yin K, Hsin I, Chen S, Fryer JD, Holtzman DM, Hsu CY, Xu J. Matrix 
metalloproteinase-9 in cerebral-amyloid-angiopathy-related hemorrhage. J Neurol Sci. 
2005;229-230:249–54. 
284. Machida T, Takata F, Matsumoto J, Takenoshita H, Kimura I, Yamauchi A, Dohgu S, 
Kataoka Y. Brain pericytes are the most thrombin-sensitive matrix metalloproteinase-
9-releasing cell type constituting the blood–brain barrier in vitro. Neurosci Lett. 
2015;599:109–114. 
285. Kawakita K, Kawai N, Kuroda Y, Yasashita S, Nagao S. Expression of Matrix 
Metalloproteinse-9 in Thrombin-Induced Brain Edema Formation in Rats. J Stroke 
Cerebrovasc Dis. 2006;15:88–95. 
286. Kurogi R, Kikkawa Y, Matsuo S, Nakamizo A, Mizoguchi M, Sasaki T. Upregulation 
of tissue inhibitor of metalloproteinase-1 contributes to restoration of the extracellular 
	   240 
matrix in the rabbit basilar artery during cerebral vasospasm after subarachnoid 
hemorrhage. Brain Res. 2015;1616:26–36. 
287. Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y. Degradation of 
decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic 
analyses and transforming growth factor-beta1 release. Biochem J. 1997;322 ( Pt 
3):809–14. 
288. Carmichael ST, Vespa PM, Saver JL, Coppola G, Geschwind DH, Starkman S, Miller 
CM, Kidwell CS, Liebeskind DS, Martin NA. Genomic Profiles of Damage and 
Protection in Human Intracerebral Hemorrhage. J Cereb Blood Flow Metab. 
2008;28:1860–1875. 
289. Florczak-Rzepka M, Grond-Ginsbach C, Montaner J, Steiner T. Matrix 
Metalloproteinases in Human Spontaneous Intracerebral Hemorrhage: An Update. 
Cerebrovasc Dis. 2012;34:249–262. 
290. Amantea D, Micieli G, Tassorelli C, Cuartero MI, Ballesteros I, Certo M, Moro MA, 
Lizasoain I, Bagetta G. Rational modulation of the innate immune system for 
neuroprotection in ischemic stroke. Front Neurosci. 2015;9:147. 
291. Hemphill JC, Bonovich DC, Besmertis L, Manley GT, Johnston SC. The ICH score: a 
simple, reliable grading scale for intracerebral hemorrhage. Stroke. 2001;32:891–7. 
292. Spilker J, Kongable G, Barch C, Braimah J, Brattina P, Daley S, Donnarumma R, 
Rapp K, Sailor S. Using the NIH Stroke Scale to assess stroke patients. The NINDS rt-
PA Stroke Study Group. J Neurosci Nurs. 1997;29:384–92. 
293. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical 
scale. Lancet (London, England). 1974;2:81–4. 
	   241 
294. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver 
agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604–7. 
295. Hallevi H, Dar NS, Barreto AD, Morales MM, Martin-Schild S, Abraham AT, Walker 
KC, Gonzales NR, Illoh K, Grotta JC, Savitz SI. The IVH score: a novel tool for 
estimating intraventricular hemorrhage volume: clinical and research implications. 
Crit Care Med. 2009;37:969–74, e1. 
296. Weiss R, Lifshitz V, Frenkel D. TGF-β1 affects endothelial cell interaction with 
macrophages and T cells leading to the development of cerebrovascular amyloidosis. 
Brain Behav Immun. 2011;25:1017–1024. 
297. Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Lin C, 
Mucke L. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in 
Alzheimer’s disease. Nature. 1997;389:603–6. 
298. Zhao L, Arbel-Ornath M, Wang X, Betensky RA, Greenberg SM, Frosch MP, Bacskai 
BJ. Matrix metalloproteinase 9-mediated intracerebral hemorrhage induced by 
cerebral  amyloid angiopathy. Neurobiol Aging. 2015;36:2963–2971. 
299. Hernandez-Guillamon M, Martinez-Saez E, Delgado P, Domingues-Montanari S, 
Boada C, Penalba A, Boada M, Pagola J, Maisterra O, Rodriguez-Luna D, Molina CA, 
Rovira A, Alvarez-Sabin J, Ortega-Aznar A, Montaner J. MMP-2/MMP-9 Plasma 
Level and Brain Expression in Cerebral Amyloid Angiopathy-Associated 
Hemorrhagic Stroke. Brain Pathol. 2012;22:133–141. 
300. Greenberg SM, Cho HS, O’Donnell HC, Rosand J, Segal AZ, Younkin LH, Younkin 
SG, Rebeck GW. Plasma beta-amyloid peptide, transforming growth factor-beta 1, and 
risk for cerebral amyloid angiopathy. Ann N Y Acad Sci. 2000;903:144–9. 
	   242 
301. Chang JJ, Emanuel BA, Mack WJ, Tsivgoulis G, Alexandrov A V. Matrix 
Metalloproteinase-9: Dual Role and Temporal Profile in Intracerebral Hemorrhage. J 
Stroke Cerebrovasc Dis. 2014;23:2498–2505. 
302. Silva Y, Leira R, Tejada J, Lainez JM, Castillo J, Davalos A. Molecular Signatures of 
Vascular Injury Are Associated With Early Growth of Intracerebral Hemorrhage. 
Stroke. 2005;36:86–91. 
303. Li N, Liu YF, Ma L, Worthmann H, Wang YL, Wang YJ, Gao YP, Raab P, Dengler 
R, Weissenborn K, Zhao XQ. Association of molecular markers with perihematomal 
edema and clinical outcome in intracerebral hemorrhage. Stroke. 2013;44:658–63. 
304. Buckwalter M, Pepper J-P, Gaertner RF, Von Euw D, Lacombe P, Wyss-Coray T. 
Molecular and functional dissection of TGF-beta1-induced cerebrovascular 
abnormalities in transgenic mice. Ann N Y Acad Sci. 2002;977:87–95. 
305. Smith GM, Strunz C. Growth factor and cytokine regulation of chondroitin sulfate 
proteoglycans by astrocytes. Glia. 2005;52:209–18. 
306. Chio C-C, Lin M-T, Chang C-P, Lin H-J. A positive correlation exists between 
neurotrauma and TGF-β1-containing microglia in rats. Eur J Clin Invest. 
2016;46:1063–1069. 
307. Hippius H, Neundörfer G. The discovery of Alzheimer’s disease. Dialogues Clin 
Neurosci. 2003;5:101–8. 
308. Okazaki H, Reagan TJ, Campbell RJ. Clinicopathologic studies of primary cerebral 
amyloid angiopathy. Mayo Clin Proc. 1979;54:22–31. 
309. Mountjoy CQ, Tomlinson BE, Gibson PH. Amyloid and senile plaques and cerebral 
blood vessels. A semi-quantitative investigation of a possible relationship. J Neurol 
	   243 
Sci.;57:89–103. 
310. Olichney JM, Hansen LA, Hofstetter CR, Grundman M, Katzman R, Thal LJ. Cerebral 
infarction in Alzheimer’s disease is associated with severe amyloid angiopathy and 
hypertension. Arch Neurol. 1995;52:702–8. 
311. Xiong L, Boulouis G, Charidimou A, Roongpiboonsopit D, Jessel MJ, Pasi M, 
Reijmer YD, Fotiadis P, Ayres A, Merrill E, Schwab K, Blacker D, Gurol ME, 
Greenberg SM, Viswanathan A. Dementia incidence and predictors in cerebral 
amyloid angiopathy patients without intracerebral hemorrhage. J Cereb Blood Flow 
Metab. 2017;:0271678X1770043. 
312. Charidimou A, Farid K, Tsai H-H, Tsai L-K, Yen R-F, Baron J-C. Amyloid-PET 
burden and regional distribution in cerebral amyloid angiopathy: a systematic review 
and meta-analysis of biomarker performance. J Neurol Neurosurg Psychiatry. 
2017;:jnnp–2017–316851. 
313. Brkic M, Balusu S, Van Wonterghem E, Gorle N, Benilova I, Kremer A, Van Hove I, 
Moons L, De Strooper B, Kanazir S, Libert C, Vandenbroucke RE. 
Amyloid   Oligomers Disrupt Blood-CSF Barrier Integrity by Activating Matrix 
Metalloproteinases. J Neurosci. 2015;35:12766–12778. 
314. Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP. 
Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative 
histological study. Ann Neurol. 1991;30:637–49. 
315. Senn R, Elkind MS V, Montaner J, Christ-Crain M, Katan M. Potential role of blood 
biomarkers in the management of nontraumatic intracerebral hemorrhage. 
Cerebrovasc Dis. 2014;38:395–409. 
	   244 
316. Wu M-Y, Li C-J, Hou M-F, Chu P-Y. New Insights into the Role of Inflammation in 
the Pathogenesis of Atherosclerosis. Int J Mol Sci. 2017;18:2034. 
317. Yamada M, Tsukagoshi H, Otomo E, Hayakawa M. Cerebral amyloid angiopathy in 
the aged. J Neurol. 1987;234:371–6. 
318. Cutler RW, Page L, Galicich J, Watters G V. Formation and absorption of 
cerebrospinal fluid in man. Brain. 1968;91:707–20. 
319. Serot JM, Foliguet B, Béné MC, Faure GC. Choroid plexus and ageing in rats: a 
morphometric and ultrastructural study. Eur J Neurosci. 2001;14:794–8. 
320. Wen GY, Wisniewski HM, Kascsak RJ. Biondi ring tangles in the choroid plexus of 
Alzheimer’s disease and normal aging brains: a quantitative study. Brain Res. 
1999;832:40–6. 
321. Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D. Alzheimer’s disease, 
normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: 
a hypothesis. Lancet Neurol. 2003;2:506–11. 
322. Garton MJ, Keir G, Lakshmi M V, Thompson EJ. Age-related changes in 
cerebrospinal fluid protein concentrations. J Neurol Sci. 1991;104:74–80. 
323. Wester P, Puu G, Reiz S, Winblad B, Wester PO. Increased monoamine metabolite 
concentrations and cholinesterase activities in cerebrospinal fluid of patients with 
acute stroke. Acta Neurol Scand. 1987;76:473–9. 
324. Massicotte EM, Del Bigio MR. Human arachnoid villi response to subarachnoid 
hemorrhage: possible relationship to chronic hydrocephalus. J Neurosurg. 
1999;91:80–84. 
325. Grzybowski DM, Holman DW, Katz SE, Lubow M. In vitro model of cerebrospinal 
	   245 
fluid outflow through human arachnoid granulations. Invest Ophthalmol Vis Sci. 
2006;47:3664–72. 
326. Steardo L, Nathanson JA. Brain barrier tissues: end organs for atriopeptins. Science. 
1987;235:470–3. 
327. Cuevas P, Carceller F, Reimers D, Fu X, Giménez-Gallego G. Immunohistochemical 
localization of basic fibroblast growth factor in choroid plexus of the rat. Neurol Res. 
1994;16:310–2. 
328. Kataoka H, Yamada E, Hazama F. Increased basic fibroblast growth factor 
immunoreactivity in the brain of stroke-prone spontaneously hypertensive rats. Acta 
Neuropathol. 1994;88:7–13. 
329. Greenwood S, Swetloff A, Wade AM, Terasaki T, Ferretti P. Fgf2 is expressed in 
human and murine embryonic choroid plexus and affects choroid plexus epithelial cell 
behaviour. Cerebrospinal Fluid Res. 2008;5:20. 
330. Kaur C, Singh J, Lim MK, Ng BL, Yap EP, Ling EA. Studies of the choroid plexus 
and its associated epiplexus cells in the lateral ventricles of rats following an exposure 
to a single non-penetrative blast. Arch Histol Cytol. 1996;59:239–48. 
331. Palm D, Knuckey N, Guglielmo M, Watson P, Primiano M, Johanson C. Choroid 
plexus electrolytes and ultrastructure following transient forebrain ischemia. Am J 
Physiol. 1995;269:R73–9. 
332. Ritzel RM, Crapser J, Patel AR, Verma R, Grenier JM, Chauhan A, Jellison ER, 
McCullough LD. Age-Associated Resident Memory CD8 T Cells in the Central 
Nervous System Are Primed To Potentiate Inflammation after Ischemic Brain Injury. J 
Immunol. 2016;196:3318–3330. 
	   246 
333. Llovera G, Benakis C, Enzmann G, Cai R, Arzberger T, Ghasemigharagoz A, Mao X, 
Malik R, Lazarevic I, Liebscher S, Ertürk A, Meissner L, Vivien D, Haffner C, 
Plesnila N, Montaner J, Engelhardt B, Liesz A. The choroid plexus is a key cerebral 
invasion route for T cells after stroke. Acta Neuropathol. 2017;134:851–868. 
334. Ge R, Tornero D, Hirota M, Monni E, Laterza C, Lindvall O, Kokaia Z. Choroid 
plexus-cerebrospinal fluid route for monocyte-derived macrophages after stroke. J 
Neuroinflammation. 2017;14:153. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   247 
CHAPTER 9 
Vita 
 
Matthew David Howe was born in Providence, Rhode Island, the son of Susan Elizabeth 
Howe and Kevin Charles Howe.  After graduating from Barrington High School, in 
Barrington, Rhode Island, in 2008, he entered the University of Connecticut in Storrs, 
Connecticut.  He graduated from UConn in 2012, receiving the degree of Bachelor of 
Science with a double major in Physiology and Psychology, and a minor in Neuroscience.  In 
June of 2012, he entered into the MD/PhD dual degree program at the UConn School of 
Medicine, then transferred with his thesis advisor in August of 2015 to the University of 
Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences to 
complete his graduate research and degrees. 
 
Permanent Address: 
2718 S Belgravia Drive 
Pearland, TX 77584 
 
 
